CONFIDENTIAL  
222253  (RSV OA=ADJ -025) 
Protocol  Amendment 1  Final  
03 May 2024  1  CLINICAL STUDY PROTOCOL  
Primary Study Intervention  GSK’s investigational respiratory syncytial virus 
(RSV) vaccine BIO RSV OA=ADJ (GSK3844766A)  
Study Identifier  222253  (RSV OA=ADJ -025)  
EU CT Number   2023 -510190 -34-00 
Approval Date 03 May 2024  
Title  A Phase 3b, open -label study to evaluate the non -
inferiority of the immune response and to evaluate 
the safety of the RSVPreF3 OA investigational 
vaccine in adults 18 -49 years of age at increased risk 
for respiratory syncytial virus disease, compared to 
older adults ≥60 years of age.  
Brief Title A study on the  immun e response  and safety  of 
vaccine against respiratory syncytial virus given to  
adults 18  to 49 years of age  at increased risk f or 
respiratory syncytial virus  disease , compared to  older 
adults 60 years of age  and above . 
Sponsor  GlaxoSmithKline Biologicals S.A.  
Rue De L' Institut 89  
1330 Rixensart  
Belgium  
Sponsor signatory  Veronica Hulstrøm, MD , PhD  
Clinical Project Lead  
RSV Older Adults  
Medical monitor name and contact can be found in local study contact 
information document  
©2024 GSK group of companies or its licensor.  
CONFIDENTIAL  
222253  (RSV OA=ADJ -025) 
Protocol  Amendment 1  Final  
03 May 2024  2 Protocol  Amendment 1  Investigator Agreement  
I agree:  
• To conduct the study in compliance with this protocol, any future protocol  
amendments , with the terms of the clinical trial agreement and with any other study 
conduct procedures and/or study conduct documents provided by GSK.  
• To assume responsibility for the proper conduct of the  study at this site.  
• That I am aware of and  will comply with GCP and all applicable regulatory 
requirements.  
• That I will comply with the terms of the site agreement.  
• To comply with local bio -safety legislation.  
• To ensure that all persons assisting me with  the study are adequately informed about 
the GSK  study intervention and other study -related duties and functions as described 
in the protocol.  
• To supervise any individual or party to whom I have delegated study -related duties 
and functions conducted at the study site.  
• To ensure that any individual or party to whom I have delegated study -related duties 
and functions conducted at the study site are qualified to perform those study -related 
duties and functions.  
• To acquire the reference ranges f or laboratory tests performed locally and, if required 
by local regulations, obtain the laboratory’s current certification or Quality 
Assurance procedure manual.  
• To ensure that no clinical samples (including serum samples) are retained on -site or 
elsewhere  without the approval of GSK  and the express  physical  informed consent of 
the participant and/or the participant’s LAR .  
• To perform no biological assays on the clinical samples other than those described in 
the protocol or its amendment(s).  
• To co -operate w ith representative(s) of GSK in the monitoring  and data management 
processes of the study with respect to data entry and resolution of queries about the 
data.  
• To have control of all essential documents and records generated under my 
responsibility before, during, and after the study.  
• That I have been informed that certain regulatory authorities require the sponsor to 
obtain and supply, as necessary, details about the investigator(s)’ ownership interest 
in the sponsor or the study intervention(s), and more generally about their financia l 
ties with the sponsor. GSK will use and disclose the information solely for the 
purpose of complying with regulatory requirements.  
CONFIDENTIAL  
222253  (RSV OA=ADJ -025) 
Protocol  Amendment 1  Final  
03 May 2024  3 Hence, I:  
• Agree to supply  GSK  with any necessary information regarding ownership interest 
and financial ties (including those of my spouse and dependent children).  
• Agree to promptly update this information if any relevant changes occur during the 
study and for 1 year following completion of the study.  
• Agree that GSK may disclose any information about such ownersh ip interests and 
financial ties to regulatory authorities.  
• Agree to provide GSK  with an updated Curriculum Vitae and all other documents 
required by regulatory agencies for this study.  
CONFIDENTIAL  
222253  (RSV OA=ADJ -025) 
Protocol  Amendment 1  Final  
03 May 2024  4 Study identifier  222253  (RSV OA=ADJ -025) 
EU CT number  2023 -510190 -34-00 
Approval date  03 May 2024  
Title  A Phase 3b, open -label study to evaluate the non -
inferiority of the immune response and to evaluate 
the safety of the RSVPreF3 OA investigational 
vaccine in adults 18 -49 years of age at increased risk 
for respiratory syncytial virus disease, compared to 
older adults ≥60 years of age.  
Investigator name   
  
Signature   
  
Date  of signature  
(DD Month Y YYY )  
  
CONFIDENTIAL  
222253  (RSV OA=ADJ -025) 
Protocol  Amendment 1  Final  
03 May 2024  5 PROTOCOL AMENDMENT SUMMARY OF CHANGES TABLE  
DOCUMENT HISTORY  
Document  Date of Issue  
Amendment 1  03 May 2024  
Original Protocol  18 December 2023  
Amendment 1 (03 May 2024 ) 
Overall rationale for the current Amendment:  
The purpose of  this amendment is to implement  a new Cohort 3 as a Part B of this study  
to collect safety information in an extended sample size  to better characterize the safety 
profile of the RSVPreF3 OA investigational vaccine in a population of individuals at 
increased risk for RSV disease 18-49 years of age . It is planned to include  an extra  
~600 adults 1 8-49 years of age at increased risk for RSV  disease, who will be monitored  
for reactogenicity and safety for a period of 6 months following the administration of one 
dose of  RSVPreF3 OA investigational vaccine  at Visit 1. The same in clusion  and 
exclusion c riteria as well as enrolment rules as for participants of Cohort 1 will apply for 
Cohort 3.   
Minor editorial changes for consistency and clarity have also been made and 
typographical errors have been corrected.  
Other updates made to the protocol are descri bed in the table below.  
CONFIDENTIAL  
222253  (RSV OA=ADJ -025) 
Protocol  Amendment 1  Final  
03 May 2024  6 LIST OF MAIN CHANGES IN THE PROTOCOL AND THEIR RATIONALE:  
Section # and 
title Description of change  Brief rationale  
1.2 Schema  Included the study design overview for Part B  The study population has been 
extended to include a cohort of 
AIR participants 18 -49 YOA  to 
better characterize the safety 
profile of the RSVPreF3 OA 
investigational vaccine in this 
population.  
 1.3 Schedule of 
activities  A separate table for Part B sched ule of activities 
and intervals between study visits  has been added.  
3 Objectives, 
endpoints and 
estimands  Differentiated the objectives, endpoints and 
estimands that are specific to Part A and Part B  
4.1 Overall design  Study design details for Part B (Cohort 3) ha ve 
been i ncluded . 
5.1 Inclusion criteria  Numbering has been added for each inclusion 
criterion.  This change has been made to 
align with latest protocol template  
5.2 Exclusion criteria  Numbering has been added for each exclusion 
criterion.  This change has been made to 
align with latest protocol template  
6.3.3 Intervention 
allocation to the 
participant  Participants enrolment in Part B has been included  The study population has been 
extended to include a cohort of 
AIR participants 18 -49 YOA  to 
better characterize the safety 
profile of the RSVPreF3 OA 
investigational vaccine in this 
population . 9 Statistical 
considerations  Additional details for Cohort 3 has been provided 
where applicable.  
10.5.  Appendix 5: 
Country -specific 
requirements  Added South Africa specific requirements for HIV 
participants  This change has been made to 
align with local requirements . 
10.6 Appendix 6: 
Grading scaled for 
chronic diseases in 
scope of the AIR 
population  Added Appendix 6: Grading scale s for chronic 
diseases in scope of the AIR population  This was added to clarify the 
grading of medical conditions 
mentioned in Section 5.1.1 . 
Throughout protocol  Administrative  and editorial changes were made to 
align table numbers, formatting, and cross 
references . To maintain consistency with 
template guidance.  
 
CONFIDENTIAL  
222253  (RSV OA=ADJ -025) 
Protocol  Amendment 1  Final  
03 May 2024  7 TABLE OF CONTENTS  
PAGE  
PROTOCOL AMENDMENT SUMMARY OF CHANGES TABLE  ................................ ..... 5 
List of main changes in the protocol and their rationale:  ................................ ...........  6 
LIST OF ABBREVIATIONS AND DEFINITI ONS OF TERMS  ................................ ........  14 
1. PROTOCOL SUMMARY  ................................ ................................ ........................  24 
1.1. Synopsis  ................................ ................................ ................................ ..... 24 
1.2. Schema  ................................ ................................ ................................ ...... 24 
1.3. Schedule of activities (SoA)  ................................ ................................ ........  27 
2. INTRODUCTION  ................................ ................................ ................................ .... 33 
2.1. Study r ationale  ................................ ................................ ............................  33 
2.2. Background  ................................ ................................ ................................  33 
2.3. Benefit/risk assessment  ................................ ................................ ..............  34 
2.3.1.  Risk assessment  ................................ ................................ ..........  34 
2.3.2.  Benefit assessment  ................................ ................................ ..... 37 
2.3.3.  Overall benefit -risk conclusion  ................................ .....................  37 
3. OBJECTIVES, ENDPOINTS AND ESTIMANDS  ................................ ....................  37 
4. STUDY DESIGN  ................................ ................................ ................................ .... 41 
4.1. Overall design  ................................ ................................ .............................  41 
4.2. Scientific rationale for study design  ................................ .............................  42 
4.2.1.  Participant input into design  ................................ .........................  43 
4.3. Justification for dose  ................................ ................................ ...................  43 
4.4. End-of-study definition  ................................ ................................ ................  43 
5. STUDY POPULATION  ................................ ................................ ...........................  43 
5.1. Inclusion criteria  ................................ ................................ ..........................  43 
5.1.1.  Specific inclusion criteria for all participants in Cohort 1 
and Cohort 3  ................................ ................................ ................  44 
5.1.2.  Specific inclusion criteria for all participants in Cohort 2  ...............  45 
5.2. Exclusion criteria  ................................ ................................ .........................  46 
5.2.1.  Medical conditions  ................................ ................................ ....... 46 
5.2.2.  Prior/Concomitant therapy  ................................ ...........................  47 
5.2.3.  Prior/Concurrent clinical study experience  ................................ ... 47 
5.2.4.  Other exclusions  ................................ ................................ ..........  47 
5.2.4.1.  Other exclusions for all participants  ............................  47 
5.2.4.2.  Other exclusions for Cohort 1 and Cohort 3  ................  48 
5.3. Lifestyle considerations  ................................ ................................ ...............  48 
5.4. Screen failures  ................................ ................................ ............................  48 
5.5. Criteria for temporarily delaying enrollment/ administration of study 
intervention  ................................ ................................ ................................ . 48 
6. STUDY INTERVENTION AND CONCOMITANT THERAPY  ................................ .. 49 
6.1. Study intervention(s) administered  ................................ ..............................  49 
6.1.1.  Medical devices  ................................ ................................ ...........  50 
6.2. Preparation, handling, storage, and accountability  ................................ ...... 50 
6.3. Assignment to study intervention  ................................ ................................  51 
CONFIDENTIAL  
222253  (RSV OA=ADJ -025) 
Protocol  Amendment 1  Final  
03 May 2024  8 6.3.1.  Participant identification  ................................ ...............................  51 
6.3.2.  Randomization to study intervention  ................................ ............  51 
6.3.3.  Intervention allocation to the participant  ................................ ....... 51 
6.3.4.  Allocation of participants to  in Part A  .............  52 
6.4. Blinding  ................................ ................................ ................................ ....... 52 
6.5. Study intervention compliance  ................................ ................................ .... 52 
6.6. Dose modification  ................................ ................................ .......................  52 
6.7. Continued access to study intervention after the end of the study  ...............  52 
6.8. Treatment of overdose  ................................ ................................ ................  53 
6.9. Prior and concomitant therapy  ................................ ................................ .... 53 
7. DISCONTINUATION OF STUDY INTERVENTION AND PARTICIPANT 
DISCONTINUATION/WITHDRAWAL  ................................ ................................ ..... 55 
7.1. Discontinuation of study intervention  ................................ ...........................  55 
7.2. Participant discontinuation/withdrawal from the study  ................................ . 55 
7.3. Lost to follow -up................................ ................................ ..........................  56 
8. STUDY ASSESSMENTS AND PROCEDURES  ................................ .....................  57 
8.1. Administrative baseline procedures  ................................ ............................  58 
8.1.1.  Collection of demographic data  ................................ ....................  58 
8.1.2.  Medical/vaccination history  ................................ ..........................  58 
8.1.3.  Measure height and weight  ................................ ..........................  59 
8.1.4.  Smoking status and smoking exposure history  ............................  59 
8.2. Immunogenicity assessments  ................................ ................................ ..... 59 
8.2.1.  Biological samples  ................................ ................................ ....... 59 
8.2.2.  Laboratory assays  ................................ ................................ ....... 60 
8.2.3. Immunological read -outs ................................ ..............................  61 
8.2.4.  Immunological correlates of protection  ................................ .........  61 
8.3. Safety assessments  ................................ ................................ ....................  61 
8.3.1.  Pre-study intervention administration procedures  ........................  61 
8.3.1.1.  Physical examination  ................................ ..................  61 
8.3.1.2.  Vital signs  ................................ ................................ ... 62 
8.3.1.3.  Pregnancy testing  ................................ .......................  62 
8.3.2.  Post-study intervention administration procedures  .......................  62 
8.3.2.1.  Physical examination  ................................ ..................  62 
8.3.3.  Warnings and precautions to administration of study 
intervent ion ................................ ................................ ..................  62 
8.3.4.  Safety monitoring and Committee  ................................ ................  63 
8.4. Adverse Events (AEs), serious adverse events (SAEs), and other 
safety reporting  ................................ ................................ ...........................  63 
8.4.1.  Time period and frequency for collecting AE, SAE, and 
other safety information  ................................ ...............................  63 
8.4.2.  Method of detecting AEs and SAEs  ................................ .............  65 
8.4.3.  Follow -up of AEs and SAEs  ................................ .........................  65 
8.4.4.  AESIs  ................................ ................................ ..........................  65 
8.4.4.1.  Potential immune -mediated diseases  .........................  65 
8.4.4.2.  Atrial fibrillation (AF)  ................................ ...................  70 
8.4.5.  Regulatory reporting requirements for 
SAEs/pregnancies/ AESIs  ................................ ............................  70 
8.4.6.  Pregnancy  ................................ ................................ ...................  71 
8.4.7.  Contact information for reporting SAEs, AESIs and 
pregnancies.  ................................ ................................ ................  72 
CCI
CONFIDENTIAL  
222253  (RSV OA=ADJ -025) 
Protocol  Amendment 1  Final  
03 May 2024  9 8.4.8.  Participant card  ................................ ................................ ............  72 
8.5. Pharmacokinetics  ................................ ................................ .......................  72 
8.6. Pharmacodynamics  ................................ ................................ ....................  72 
8.7. Genetics  ................................ ................................ ................................ ..... 72 
8.8. Biomarkers  ................................ ................................ ................................ . 72 
8.9. Immunogenicity assessments  ................................ ................................ ..... 72 
8.10.  Health economics or medical resource utilization and health 
economics  ................................ ................................ ................................ .. 72 
9. STATISTICAL CONSIDERATIONS  ................................ ................................ ........  73 
9.1. Statistical hypotheses  ................................ ................................ .................  73 
9.2. Analysis sets  ................................ ................................ ...............................  73 
9.2.1.  Criteria for elimination from analyses  ................................ ...........  74 
9.3. Statistical analyses  ................................ ................................ .....................  74 
9.3.1. Primary endpoints/estimands analysis (Part A)  ............................  74 
9.3.1.1.  Success criteria for non -inferiority and testing 
sequence  ................................ ................................ .... 74 
9.3.2.  Secondary endpoints/estimands analyses  ................................ ... 75 
9.4. Interim analyses  ................................ ................................ ..........................  76 
9.4.1.  Sequence of analysis  ................................ ................................ ... 76 
9.5. Pre-dose sample size determination  ................................ ...........................  76 
10. SUPPORTING DOCUMENTATION AND OPERATIONAL 
CONSIDERATIONS  ................................ ................................ ...............................  77 
10.1.  Appendix 1: Regulatory, ethical, and study oversight considerations  ..........  77 
10.1.1.  Regulatory a nd ethical considerations  ................................ .........  77 
10.1.2.  Financial disclosure  ................................ ................................ ..... 78 
10.1.3.  Informed consent process  ................................ ............................  78 
10.1.4.  Recruitment strategy  ................................ ................................ .... 79 
10.1.5.  Data protection  ................................ ................................ ............  80 
10.1.6.  Committees structure  ................................ ................................ ... 80 
10.1.7.  Dissemination of Clinical Study Data  ................................ ...........  80 
10.1.8.  Data quality assurance  ................................ ................................  81 
10.1.9.  Source documents  ................................ ................................ ....... 82 
10.1.10.  Study and site start and closure  ................................ ...................  83 
10.1.11.  Publication policy  ................................ ................................ .........  83 
10.2.  Appendix 2: Clinical laboratory tests  ................................ ...........................  84 
10.2.1.  RSV-A and RSV -B neutralization assays  ................................ ..... 84 
10.3.  Appendix 3: AEs and SAEs: Definitions and procedures for 
recording, evaluating, follow -up, and reporting  ................................ ............  85 
10.3.1.  Definition of AE  ................................ ................................ ............  85 
10.3.2.  Definition of SAE  ................................ ................................ ..........  86 
10.3.3.  Solicited events ................................ ................................ ............  87 
10.3.4.  Unsolicited AE  ................................ ................................ .............  88 
10.3.5.  Recording, assessment and follow -up of AE, SAE, AESIs 
and pregnancies  ................................ ................................ ..........  88 
10.3.5.1.  AE and SAE recording  ................................ ................  88 
10.3.5.2.  Assessment of intensity  ................................ ..............  90 
10.3.5.3.  Assessment of causality  ................................ .............  91 
10.3.5.4.  Assessment of outcomes ................................ ............  92 
CCI
CONFIDENTIAL  
222253  (RSV OA=ADJ -025) 
Protocol  Amendment 1  Final  
03 May 2024  10 10.3.5.5.  Follow -up of AEs, SAEs, AESIs, pregnancies 
or any other events of interest  ................................ .... 92 
10.3.5.6.  Updating of SAE, AESI and pr egnancy 
information after removal of write access to the 
participant’s eCRF  ................................ ......................  93 
10.3.5.7.  Reporting of SAEs, AESIs and pregnancies  ...............  93 
10.4.  Appendix 4: Contraceptive and barrier guidance  ................................ .........  94 
10.4.1.  Definitions  ................................ ................................ ....................  94 
10.4.1.1.  WOCBP Definition  ................................ ......................  94 
10.4.1.2.  Woman of Nonchildbearing Potential 
(WONCBP)  ................................ ................................ . 95 
10.4.2.  Contraception guidance  ................................ ...............................  95 
10.5.  Appendix 5: Country -specific requirements  ................................ .................  97 
10.5.1.  Germany  ................................ ................................ ......................  97 
10.5.2.  Japan  ................................ ................................ ...........................  97 
10.5.3.  South Africa  ................................ ................................ .................  97 
10.6.  Appendix 6: Grading scales for chronic diseases in scope of the AIR 
population  ................................ ................................ ................................ ... 98 
10.6.1.  GOLD classification  ................................ ................................ ..... 98 
10.6.2.  New York Heart Association Classification of heart failure  ...........  98 
10.6.3.  Chronic kidney disease classification  ................................ ...........  99 
11. REFERENCES  ................................ ................................ ................................ ..... 100 
 
CONFIDENTIAL  
222253  (RSV OA=ADJ -025) 
Protocol  Amendment 1  Final  
03 May 2024  11 LIST OF TABLES  
PAGE  
Table 1  Schedule of Activities (Part A)  ................................ ................................  27 
Table 2  Schedule of Activities (Part B)  ................................ ................................  30 
Table 3  Intervals between study visits (Part A)  ................................ ....................  33 
Table 4  Intervals between study visits (Part B)  ................................ ....................  33 
Table 5  Risk Assessment  ................................ ................................ ....................  35 
Table 6  Objectives and Endpoints  ................................ ................................ ....... 37 
Table 7  Primary estimands (Part A)  ................................ ................................ .... 39 
Table 8  Secondary estimands for safety (Part A and Part B)  ..............................  40 
Table 9  Study Intervention administered  ................................ .............................  49 
Table 10  Prohibited medications and washout period  ................................ ...........  54 
Table 11  Timing of collection of concomitant medication to be recorded  ...............  54 
Table 12  Biological samples (Part A) ................................ ................................ .... 60 
Table 13  Laboratory assays (Part A)  ................................ ................................ ..... 60 
Table 14  Immunological read -outs (Part A)  ................................ ...........................  61 
Table 15  Collection and reporting of safety information  ................................ .........  64 
Table 16  List of potential immune -mediated diseases (pIM Ds) .............................  66 
Table 17  Timeframes for submitting SAE, pregnancy and pIMDs to GSK  .............  71 
Table 18  Study objectives and null hypothesis  ................................ ......................  73 
Table 19  Analysis sets  ................................ ................................ ..........................  73 
Table 20  Power for primary objectives of non -inferiority of the humoral 
immune respons e after RSVPreF3 OA vaccine between the 
RSV-A-AIR (18 -49 YOA) Cohort 1 to RSV -OA (≥ 60 YOA) Cohort 
2 for 361  evaluable participants per group ................................ ..............  77 
Table 21  Solicited administration site  ................................ ................................ .... 87 
Table 22  Solicited systemic events  ................................ ................................ ....... 87 
Table 23  Intensity scale for solicited events  ................................ ..........................  90 
CONFIDENTIAL  
222253  (RSV OA=ADJ -025) 
Protocol  Amendment 1  Final  
03 May 2024  12 Table 24  Intensity scale of administration site redness 
(Erythema)/swelling, and fever  ................................ ...............................  91 
Table 25  Highly effective contraceptive methods  ................................ ..................  95 
 
CONFIDENTIAL  
222253  (RSV OA=ADJ -025) 
Protocol  Amendment 1  Final  
03 May 2024  13 LIST OF F IGURES  
PAGE  
Figure 1  Study design overview (Part A)  ................................ ..............................  25 
Figure 2  Study design overview (Part B)  ................................ ..............................  26 
 
CONFIDENTIAL  
222253  (RSV OA=ADJ -025) 
Protocol  Amendment 1  Final  
03 May 2024  14 LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS  
Abbreviation  Definition  
AAION  Arteritic Anterior Ischemic Optic Neuropathy  
ACTM  Acute Complete Transverse Myelitis  
ADE  Adverse device effect  
AE Adverse event  
AESI  Adverse event of special interest  
AF Atrial fibrillation  
AHEI  Acute Hemorrhagic Edema of Infancy  
AIR At Increased Risk  
AMSAN  Acute Motor and Sensory Axonal Neuropathy  
ANCA  Anti-Neutrophil Cytoplasmic Antibody  
APTM  Acute Partial Transverse Myelitis  
AS01  Adjuvant System 01  
ATCC  American Type Culture Collection  
BYOD  Bring Your Own e -Device  
CA Competent authority  
CAD  Coronary Artery Disease  
CHF  Congestive Heart Failure  
CI Confidence Interval  
CIAP  Chronic Idiopathic Axonal Polyneuropathy  
CIDP  Chronic Inflammatory Demyelinating Polyradiculoneuropathy  
CIOMS  Council for International Organizations of Medical Sciences  
CIS Clinically Isolated Syndrome  
CCI
CONFIDENTIAL  
222253  (RSV OA=ADJ -025) 
Protocol  Amendment 1  Final  
03 May 2024  15 Abbreviation  Definition  
CONSORT  Consolidated Standards of Reporting Trials  
COPD  Chronic obstructive pulmonary disease  
COVID -19 Coronavirus Disease 2019  
CREST  Calcinosis, Raynaud’s phenomenon, Esophageal dysmotility, 
Sclerodactyly, and Telangiectasia  
CRO  Clinical Research Organization  
CSR  Clinical study report  
DLP  Data lock point  
DRE  Disease -related event  
ECG  Electrocardiogram  
eCRF  Electronic case report form  
eDiary  Electronic Diary  
EOS  End-of-study  
ERD  Enhanced Respiratory Disease  
ES Exposed Set  
EU European Union  
EUA  Emergency use authorization  
FSFV  First subject first visit 
FSH Follicle Stimulating Hormone  
GCP  Good clinical practices  
GMT  Geometric Mean Titer  
GOLD  Global Initiative for Chronic Disease Obstructive Lung Disease  
GSK  GlaxoSmithKline Biologicals SA  
HHS  Home healthcare services  
CONFIDENTIAL  
222253  (RSV OA=ADJ -025) 
Protocol  Amendment 1  Final  
03 May 2024  16 Abbreviation  Definition  
HIPAA  Health Insurance Portability and Accountability Act  
HLT  High Level Term  
HRT  Hormonal Replacement Therapy  
IAF Informed assent form  
IB  Investigator Brochure  
IB Investigator’s brochure  
ICF Informed consent form  
ICH International Council on Harmonisation  
ICMJE  International Committee of Medical Journal Editors  
ICSR  Individual case safety reports  
IDMC  Independent data monitoring committee  
IEC Independent ethics committee  
IgG Immunoglobulin  
IM Intramuscular  
IMP Investigational medicinal product  
IRB Institutional review board  
ITP Idiopathic thrombocytopenic purpura  
LABD  Linear IgA -mediated Bullous Dermatosis  
LAR  Legally acceptable representative  
LRTD  Lower Respiratory Tract Disease  
LSLV  Last Subject Last Visit  
MART  Maintenance and Reliever Therapy  
MGI  Mean Geometric Increase  
MIS-A Multisystem Inflammatory Syndrome in Adults  
CONFIDENTIAL  
222253  (RSV OA=ADJ -025) 
Protocol  Amendment 1  Final  
03 May 2024  17 Abbreviation  Definition  
MIS-C Multisystem Inflammatory Syndrome in Children  
MMN  Multifocal Motor Neuropathy  
MS Multiple Sclerosis  
NI Non-inferiority  
OA Older Adults  
PI Principal Investigator  
pIMD  Potential immune -mediated disease  
PPFE  Pleuroparenchymal fibroelastosis  
PPS Per-Protocol Set  
QS-21 Quillaja saponaria  Molina, fraction 21  
QTL  Quality tolerance limit  
RS Reynolds Syndrome  
RSV  Respiratory Syncytial Virus  
RTI Respiratory Tract Infections  
RTSM  Randomization and Trial Supply Management  
SADE  Serious adverse device effect  
SAE  Serious adverse event  
SAP Statistical analysis plan  
SAR  Serious adverse reaction  
SJS Stevens -Johnson Syndrome  
SLS Shrinking Lung Syndrome  
SmPC  Summary of product characteristics  
SoA Schedule of activities  
SOC  System Organ Class  
CONFIDENTIAL  
222253  (RSV OA=ADJ -025) 
Protocol  Amendment 1  Final  
03 May 2024  18 Abbreviation  Definition  
SRR  Seroresponse rate  
SRT Safety Review Team  
SUSAR  Suspected unexpected serious adverse reaction  
TED  Thyroid Eye Disease  
TEN  Toxic Epidermal Necrolysis  
TNF  Tumor Necrosis Factor  
TTS Thrombosis with thrombocytopenia syndrome  
UK United Kingdom  
US/USA  United States of America  
USADE  Unanticipated serious adverse device effect  
VAED  Vaccine Associated Enhanced Disease  
VAERD  Vaccine Associated Enhanced Respiratory Disease  
VMED  Vaccine -Mediated Enhanced Disease  
Vx CL&AP  Vaccines Clinical Laboratory and Assay Portfolio  
WOCBP  Woman of childbearing potential  
WONCBP  Woman of nonchildbearing potential  
YOA  Years of Age  
Definition of Terms   
Term  Definition  
Adverse event  Any untoward medical occurrence in a patient or clinical 
investigation participant, temporally associated with the 
use of a medicinal product, whether or not considered 
related to the medicinal product.  
An AE can therefore be any unfavorable and unintended 
sign (including an abnormal laboratory finding), 
symptom, or disease (new or exacerbated) temporally 
associated with the use of a medicinal product. For 
CONFIDENTIAL  
222253  (RSV OA=ADJ -025) 
Protocol  Amendment 1  Final  
03 May 2024  19 Term  Definition  
marketed medicinal products, this also includes failure 
to produce expected benefits (i.e., lack of efficacy), 
abuse or misuse.  
Adverse event of special 
interest  An adverse event of special interest (serious or non -
serious) is one of scientific and medical concern specific 
to the sponsor’s product or program, for which ongoing 
monitoring and rapid communication by the investigator 
to the sponsor can be appropriate. Such an event might 
warrant further investigation in order to characterize and 
underst and it. Depending on the nature of the event, 
rapid communication by the trial sponsor to other parties 
(e.g., regulators) might also be warranted.  
Blinding:  A procedure in which 1 or more parties to the study are 
kept unaware of the intervention assignme nt in order to 
reduce the risk of biased study outcomes. The level of 
blinding is maintained throughout the conduct of the 
study, and only when the data are cleaned to an 
acceptable level of quality will appropriate personnel be 
unblinded or when required in case of a SAE.  
In an open -label study, no blind is used. Both the 
investigator and the participant know the identity of the 
intervention assigned.  
Caregiver  A ‘caregiver’ is someone who  
− lives in the close surroundings of a participant 
and has a continuous caring role or  
− has substantial periods of contact with a 
participant and is engaged in their daily health 
care (e.g., a relative of the participant, a nurse 
who helps with daily activities in case of 
residence in a nursing home).  
In the context  of a clinical study, a caregiver could 
include an individual appointed to oversee and support 
the participant's compliance with protocol -specified 
procedures.  
Certified copy  A copy (irrespective of the type of media used) of the 
original record that has been verified (i.e. by a dated 
signature or by generation through a validated process) 
to have the same information, including data that 
describe the context, content, and structure, as the 
original.  
CONFIDENTIAL  
222253  (RSV OA=ADJ -025) 
Protocol  Amendment 1  Final  
03 May 2024  20 Term  Definition  
Co-administered 
(concomitant) products  A product given to clinical trial participants as required 
in the protocol as part of their standard care for a 
condition which is not the indication for which the IMP 
is being tested and is therefore not part of the objective 
of the study.  
Current smoker  A person who is currently smoking or who has stopped 
smoking within 6 months before study start.  
eDiary  Electronically registered patient data and automated data 
entries on, for example, a handheld mobile device, tablet 
or computer.  
Eligible  Qualified for enrollment into the study based upon strict 
adherence to inclusion/exclusion criteria.  
Enrolled participant  All participants who entered the study (who received 
study intervention administration or underwent a post -
screening study procedure).  
Note: screen ing failures (who never passed screening) 
and participants screened (met eligibility) but never 
enrolled into the study are excluded from the Enrolled 
analysis set as they did not enter the study.  
Refer to the Section 9.2 for the definition of ‘Enrolled 
Set’ applicable to the study.  
Essential documents  Documents which individually and collectively permit 
evaluation of the conduct of a study and the quality of 
the d ata produced.  
Evaluable  Meeting all eligibility criteria, complying with the 
procedures defined in the protocol, and, therefore, 
included in the per -protocol analysis.  
Former smoker  A person who stopped smoking for at least 6 months at 
the time of study start.  
Home Healthcare Services  Deployment of mobile health care professional(s) 
(nurses or phlebotomists) to perform study activities 
remotely.  
Intercurrent medical 
condition  A condition that has the capability of altering the 
immune response to the study vaccine or is confirmed to 
have an alteration of the participant’s initial immune 
status.  
CONFIDENTIAL  
222253  (RSV OA=ADJ -025) 
Protocol  Amendment 1  Final  
03 May 2024  21 Term  Definition  
Intervention number  A number identifying an intervention to a participant,  
according to intervention allocation.  
Investigational product  A pharmaceutical form of an active substance or placebo 
being tested or used as a reference in a clinical trial, 
including products already with a marketing 
authorization but used or assembled (formulated or 
packaged) in a way different from the authorised form, 
or when used for an unauthorised indication, or when 
used to gain further information about the authorised 
form.  
Investigator  A person responsible for the conduct of the clinical 
study at a study site. If a study is conducted by a team of 
individuals at a study site, the investigator is the 
responsible leader of the team and may be called the 
principal investigator.   
The investigator can delegate study -related duties and 
functions conducted at the study site to qualified 
individual or party to perform those study -related duties 
and functions.  
Legally acceptable 
representative  An individual, judicial or other body authorized under 
applicable law to consent on behalf of a pr ospective 
participant to the participant's participation in the 
clinical study.  
The terms legal representative or legally authorized 
representative are used in some settings.  
Participant  Term used throughout the protocol to denote an 
individual who has be en contacted to participate or who 
participates in the clinical study as a recipient of the 
study intervention (vaccine(s)/product(s)/control).  
Synonym: subject  
Participant number  A unique identification number assigned to each 
participant who consents to  participate in the study.  
Primary Completion Date  The date on which the last participant in a clinical study 
was examined or received an intervention to collect final 
data for the  primary outcome measure.  
Whether the clinical study ended according to 
the protocol  or was terminated does not affect this date. 
CONFIDENTIAL  
222253  (RSV OA=ADJ -025) 
Protocol  Amendment 1  Final  
03 May 2024  22 Term  Definition  
For clinical studies with more than one primary outcome 
measure with different completion dates, this term refers 
to the date on which data collection i s completed for all 
the primary outcome measures.  
Randomization  Process of random attribution of intervention to 
participants to reduce selection bias.  
Remote visit  This term refers to the visit conducted in the place other 
than the study site.  
Screene d participant  All participants who were screened for eligibility.  
Self-contained study  Study with objectives not linked to the data of another 
study.  
Serious Adverse Reaction  All noxious and unintended responses to an IMP related 
to any dose administered  that result in death, are life -
threatening, require patient hospitalization or 
prolongation of existing hospitalization, result in 
persistent or significant disability or incapacity, or are a 
congenital anomaly or birth defect.  
Solicited adverse event  Events to be recorded as endpoints in the clinical study. 
The presence/occurrence/intensity of these events is 
actively solicited from the participant or an observer 
during a specified follow -up period following study 
intervention administration.  
Source data  All information in original records and certified copies 
of original records of clinical findings, observations, or 
other activities in a clinical study necessary for the 
reconstruction and evaluation of the study. Source data 
are contained in so urce documents (original records or 
certified copies).  
Source documents  Original legible documents, data, and records (e.g., 
hospital records, clinical and office charts, laboratory 
notes, memoranda, participants’ diaries or evaluation 
checklists, pharmac y dispensing records, recorded data 
from automated instruments, copies or transcriptions 
certified after verification as being accurate copies, 
microfiches, photographic negatives, microfilm or 
magnetic media, x -rays, participant files, and records 
kept at  the pharmacy, laboratories and at medico -
technical departments involved in the clinical study).  
CONFIDENTIAL  
222253  (RSV OA=ADJ -025) 
Protocol  Amendment 1  Final  
03 May 2024  23 Term  Definition  
Study completion date  The date on which the last participant in a clinical study 
was examined or received an intervention/treatment  to 
collect final data for the  primary outcome 
measures,  secondary outcome measures, and  AEs (that 
is, the last participant's last visit or LSLV).  
Study intervention  Term used throughout the clinical study to denote a set 
of inves tigational product(s) or marketed product(s) or 
placebo intended to be administered to a participant.  
Note: “Study intervention” and “study treatment” are 
used interchangeably unless otherwise specified.  
Study monitor  An individual assigned by the sponsor and responsible 
for assuring proper conduct of clinical studies at 1 or 
more investigational sites.  
SUSAR  Suspected Unexpected Serious Adverse Reaction; in a 
clinical trial, a serious adverse reaction that is 
considered unexpected, i.e., the natur e or severity of 
which is not consistent with the reference safety 
information (e.g., Investigator's Brochure for an 
unapproved investigational medicinal product). All 
adverse drug reactions (ADRs) that are both serious and 
unexpected are subject to expedi ted reporting.  
Unsolicited adverse event  Any AE reported in addition to those solicited during the 
clinical study. Also, any ‘solicited’ symptom with onset 
outside the specified period of follow -up for solicited 
symptoms will be reported as an unsolicited  adverse 
event.  
Virtual visit  This term refers to study visits conducted using 
multimedia or technological platforms.  
CONFIDENTIAL  
222253  (RSV OA=ADJ -025) 
Protocol  Amendment 1  Final  
03 May 2024  24 1. PROTOCOL SUMMARY  
1.1. Synopsis  
Protocol Title:  A Phase 3b, open -label study to evaluate the non -inferiority of the 
immune response and to evaluate the safety of the RSVPreF3 OA investigational vaccine 
in adults 18 -49 years of age at increased risk f or respiratory syncytial virus disease, 
compared to older adults ≥60 years of age.  
Brief  Title:  A study on the immun e response and safety  of vacc ine against respiratory 
syncytial virus given to adults 18 to 49 years of age at increased risk for respiratory 
syncytial virus  disease, compared to older adults 60 years of age and above.  
Rationale : Refer to Section 2.1. 
Objectives , Endpoint s, and Estimands : Refer to Section 3. 
Overall Design : Refer to Section 4.1. 
Number of Participants:  Refer to Section 9.5. 
Data Monitoring /Other  Committee:  Refer to Section 10.1.6 . 
1.2. Schema  
The study design overview  for Part A and Part B  is presented in Figure  1 and Figure 2, 
respectively . 
 
CONFIDENTIAL  
222253  (RSV OA=ADJ -025) 
Protocol  Amendment 1  Final  
03 May 2024  25 Figure  1 Study design overview  (Part A)  
 
A= Adults; AE=Adverse event; AESI=Adverse events of special interest; AIR=At increased risk; ; N=Number of participants; OA=Older adults ; 
pIMD=Potential immune -mediated disease; RSV=Respiratory syncytial virus; SAE=Serious adverse event; YOA=Years of age.  
*Participants with underlyi ng medical conditions such as chronic pulmonary and cardiovascular diseases, diabetes mellitus types 1 and 2, chronic liver a nd renal diseases, and 
neurologic or neuromuscular conditions . 
CCI
CCI
CCI
CCI
CCI
CCI
CONFIDENTIAL  
222253  (RSV OA=ADJ -025) 
Protocol  Amendment 1  Final  
03 May 2024  26 Figure 2 Study design overvi ew (Part B)  
 
A= Adults; AE=Adverse event; AESI=Adverse events of special interest; AIR=At increased risk; ; N=Number of participants; pIMD=Potential 
immune -mediated disease; RSV=Respiratory syncytial virus; SAE=Serious adverse eve nt; YOA=Years of age.  
*Participants with underlying medical conditions such as chronic pulmonary and cardiovascular diseases, diabetes mellitus typ es 1 and 2, chronic liver and renal diseases, and 
neurologic or neuromuscular conditions.  
CCI
CONFIDENTIAL  
222253  (RSV OA=ADJ -025) 
Protocol  Amendment 1  Final  
03 May 2024  27 1.3. Schedule of activities  (SoA)   
Table  1 Schedule of Activities  (Part A ) 
Type of contact  Visit 1  Visit 2  Visit 3  Notes  
Timepoint s Day 1  Day 31  Month 6  
Informed consent/Informed assent  ●   See Section  10.1.3  for details  
Inclusion and exclusion criteria  ●   See Sections 5.1 and 5.2 for 
details  
Distribution of ‘participant card’  ○   See Section 8.4.8  for more details  
Check with participants if he/she will appoint a caregiver, and distribute information letter to caregiver, when 
applicable  ○ ○ ○  
Baseline and demography assessments  
Collect demographic data  ●   See Section 8.1.1  for more 
information  
Measure height and weight  ●   See Section  8.1.3  for more 
information  
Record medical and vaccination history  ●   See Section 8.1.2  for more details  
Physical examination/vital signs  ● ○1 ○1 See Section 8.3.1.2  for more 
information .  
Record smoking status and smoking exposure history (including electronic smoking devices)  ●   See Section 8.1.4  for more details  
Screening conclusion  ●    
Clinical specimen for laboratory assessment   
Blood sampling for humoral immune response assessment  (~15 mL) ●2,a ●a ●a See Section 8.2.1  for more 
information  
Urine pregnancy test (only for women of childbearing potential in Cohort 1)3 ●   See Section 8.3.1.3  for more 
details  
CCI
CONFIDENTIAL  
222253  (RSV OA=ADJ -025) 
Protocol  Amendment 1  Final  
03 May 2024  28 Type of contact  Visit 1  Visit 2  Visit 3  Notes  
Timepoint s Day 1  Day 31  Month 6  
Study intervention  
Check contraindications, warnings and precautions to vaccination  ○   See Section 8.3.3  for details  
Check criteria for temporary delay for enrolment and/or study intervention administration  ○   See Section 5.5 for more 
information  
Record body temperature before study intervention administration  
●   The route for measuring 
temperature can be oral or 
axillary. Fever is defined as 
temperature  38.0°C/100.4°F, 
regardless of the location of 
measurement  
Study intervention number allocation  ●    
Study intervention administration (including 30 -minutes post -study intervention administration observation)  ●    
Record administered study intervention number  ●    
Safety assessments  
Set-up of eDiary and/o r distribute eDiary  device  ○   See Section 10.3.5.1  for more 
details  
Training on use of eDiary  ○   See Section 10.3.5.1  for more 
details  
Record solicited administration site and systemic events (Days 1 –4 post -dose)  ○a   See Section 8.4.1  for more 
information  
Review eDiary   ○4   
Collect eDiary or assist participant to delete application   ○   
Record unsolicited AEs (Days 1-30 post -study intervention administration)  ● ●  See Section 10.3.5  for more 
details  
Record concomitant medications/vaccinations  ● ● ● See Section 6.9 for more 
information  
Record any intercurrent medical conditions  ● ● ●  
Record all SAEs, AESI (including pIMDs and AF5) and pregnancy  ● ● ● See Section 10.3.5  for more 
details  
CONFIDENTIAL  
222253  (RSV OA=ADJ -025) 
Protocol  Amendment 1  Final  
03 May 2024  29 Type of contact  Visit 1  Visit 2  Visit 3  Notes  
Timepoint s Day 1  Day 31  Month 6  
Record AE/SAEs leading to withdrawal  from the study  ● ● ● See Section 10.3.5.1  for more 
details  
Record SAEs related to study participation, or to a concurrent GSK medication/vaccine6 ● ● ● See Section 10.3.5  for more 
details  
Study conclusion    ● See Section 4.4 for more details  
Note: The double -line border indicates the analyses which will be performed on all data (i.e. , data that are as clean as possible) obtained up to these timepoints.  See Section 9.4.1  for 
more details.  
AE=Adverse event; AESI=Adverse event of specific interest; AF=Atrial fibrillation;  eCRF =electronic case report form; pIMD=Potential i mmune -mediated diseases; SAE=Serious 
adverse event.  
● Is used to indicate a study procedure that requires documentation in the individual eCRF.  
○ Is used to indicate a study procedure that does not require documentation in the individual eCRF.  
○a Is used to indicate a study procedure recorded in eDiary by participants.  
●a Is used to indicate a study procedure that requires documentation in Site2Test  app 
1 If deemed necessary by the investigator.  
2 Blood sampling at Visit 1 should be performed prior to study intervention administration. If the study intervention administration is delayed by any reason, bloo d sampling needs to be 
repeated on the day of study intervention administration.  
3 The urine sample for pregnancy test must be take n on the same day, prior to study intervention administration. If the study intervention administration is delayed by any rea son, urine 
pregnancy test needs to be repeated on the day of study intervention administration. 
4 Designated site staff  must  review  the responses in the  eDiary frequently in the portal  during the active event collection period to assess participant compliance and monitor reported 
events  to ensure correct data is provided . 
5 AF will be considered as AESI in this study and will be addit ionally reported in the AF follow -up questionnaire (electronic or paper) in eCRF. AF reporting will follow the same reporting 
periods as for AEs and SAEs.  The reporting of non -serious AF will be performed according to the unsolicited AE reporting period. The reporting of AF meeting the SAE definition 
(serious AF) will be performed according to the SAE reporting period.  
6 SAEs related to study participation, or to a concurrent GSK medication/vaccine should be collected from the time of consent o btained (prior to study vaccine administration) up to 
study end.  
Return of the eDiary device is not applicable if the participant has a “Bring Your Own” e -device.  
Visit 3 should preferably be done on -site but  in case of exceptional cir cumstances where the part icipant cannot come to the site, this study visit can be replaced by a home visit 
conducted by authorized staff. Any information from the participant required according to study procedures and not collected during the home visit can be obtained by multiple  
formats (e.g., email, text, message, fax or  phone call ) conducted by the site staff.   
 
CCI
CONFIDENTIAL  
222253  (RSV OA=ADJ -025) 
Protocol  Amendment 1  Final  
03 May 2024  30 Table 2 Schedule of Activities ( Part B ) 
Type of contact  Visit 1  Visit 2  Contact  Notes  
Timepoints  Day 1  Day 31  Month 6  
Informed consent/Informed assent  ●   See Section 10.1.3  for details  
Inclusion and exclusion criteria  ●   See Sections 5.1 and 5.2 for 
details  
Distribution of ‘participant card’  ○   See Section 8.4.8  for more details  
Check with participants if he/she will appoint a caregiver, and distribute information letter to caregiver, when 
applicable  ○ ○ ○  
Baseline and demography assessments  
Collect demographic data  ●   See Section 8.1.1  for more 
information  
Measure height and weight  ●   See Section 8.1.3  for more 
information  
Record medical and vaccination history  ●   See Section 8.1.2  for more details  
Physical examination/vital signs  ● ○1  See Section 8.3.1.2  for more 
information.  
Record smoking status and smoking exposure history (including electronic smoking devices)  ●   See Section 8.1.4  for more details  
Screening conclusion  ●    
Clinical specimen for laboratory assessment   
Urine pregnancy test (only for women of childbearing potential)2 ●   See Section 8.3.1.3  for more 
details  
Study intervention  
Check contraindications, warnings and precautions to vaccination  ○   See Section 8.3.3  for details  
Check criteria for temporary delay for enrolment and/or study intervention administration  ○   See Section 5.5 for more 
information  
Record body temperature before study intervention administration  
●   The route for measuring 
temperature can be oral or 
axillary. Fever is defined as 
temperature  38.0°C/100.4°F, 
regardless of the location of 
measurement  
Study intervention number allocation  ●    
CONFIDENTIAL  
222253  (RSV OA=ADJ -025) 
Protocol  Amendment 1  Final  
03 May 2024  31 Type of contact  Visit 1  Visit 2  Contact  Notes  
Timepoints  Day 1  Day 31  Month 6  
Study intervention administration (including 30 -minutes post -study intervention administration observation)  ●    
Record administered study intervention number  ●    
Safety assessments  
Set-up of eDiary and/or distribute eDiary device  ○   See Section 10.3.5.1  for more 
details  
Training on use of eDiary  ○   See Section 10.3.5.1  for more 
details  
Record solicited administration site and systemic events (Days 1 –4 post -dose)  ○a   See Section 8.4.1  for more 
information  
Review eDiary   ○3   
Collect eDiary or assist participant to delete application   ○   
Record unsolicited AEs (Days 1-30 post -study intervention administration)  ● ●  See Section 10.3.5  for more 
details  
Record concomitant medications/vaccinations  ● ● ● See Section 6.9 for more 
information  
Record any intercurrent medical conditions  ● ● ●  
Record all SAEs, AESI (including pIMDs and AF4) and pregnancy  ● ● ● See Section 10.3.5  for more 
details  
Record AE/SAEs leading to withdrawal from the study  ● ● ● See Section 10.3.5.1  for more 
details  
Record SAEs related to study participation, or to a concurrent GSK medication/vaccine5 ● ● ● See Section 10.3.5  for more 
details  
Study conclusion    ● See Section 4.4 for more details  
Note: The double -line border indicates the analyses which will be performed on all data (i.e., data that are as clean as possible) obtained up  to these timepoints. See Section 9.4.1  for 
more details  
AE=Adverse event; AESI=Adverse event of specific interest; AF=Atrial fibrillation;  eCRF =electronic case report form; pIMD=Potential immune -mediated diseases; SAE=Serious 
adverse event.  
● Is used to indicate a study proce dure that requires documentation in the individual eCRF.  
○ Is used to indicate a study procedure that does not require documentation in the individual eCRF . 
○a Is used to indicate a study procedure recorded in eDiary by participants.  
1 If deemed necessary by the investigator.  
2 The urine sample for pregnancy test must be taken on the same day, prior to study intervention administration. If the study i ntervention administration is delayed by any reason, urine 
pregnancy test needs to be r epeated on the day of study intervention administration. 
CONFIDENTIAL  
222253  (RSV OA=ADJ -025) 
Protocol  Amendment 1  Final  
03 May 2024  32 3 Designated site staff must  review the response in the eDiary  in the portal  frequently during the active event collection period to assess participant compliance and monitor reported 
events  to ensur e correct data is provided . 
4 AF will be considered as AESI in this study and will be additionally reported in the AF follow -up questionnaire (electronic or paper) in eCRF. AF reporting will follow the same reporting 
periods as for AEs and SAEs. The report ing of non -serious AF will be performed according to the unsolicited AE reporting period. The reporting of AF meeting the SAE definition  
(serious AF) will be performed according to the SAE reporting period.  
5 SAEs related to study participation, or to a concurrent GSK medication/vaccine should be collected from the time of consent obtained (prior to stud y vaccine administration) up to 
study end.  
Return of the eDiary device is not applicable if the participant has a “Bring Your Own” e-device.  
Visit 2 should preferably be done on -site but in case of exceptional circumstances where the participant cannot come to the site, this study visit can be replaced  by a home visit 
conducted by authorized staff. Any information from the participant  required according to study procedures and not collected during the home visit can be obtained by multiple 
formats (e.g., email, text, message, fax or phone call) conducted by the site staff.  
CONFIDENTIAL  
222253  (RSV OA=ADJ -025) 
Protocol  Amendment 1  Final  
03 May 2024  33 Table  3 Intervals between study visits  (Part A ) 
Interval  Planned visit interval  Allowed interval range  
Visit 1→Visit 2 30 days  30-42 days  
Visit 1→Visit 3  180 days  180-210 days  
If the study intervention  date is different from the ICF signature date, the study intervention  date needs to be taken as a  
reference for calculating intervals relative to subsequent visits . 
Interval is computed as the difference between 2 dates . 
Table 4 Intervals between study visits  (Part B ) 
Interval  Planned visit interval  Allowed interval range  
Visit 1→Visit 2  30 days  30-42 days  
Visit 1→  Contact (Month 6)  180 days  180-210 days  
If the study intervention date is different from the ICF signature date, the study intervention date needs to be taken as a 
reference for calculating intervals relative to subsequent visits.  
Interval is computed as the difference between 2 dates.  
2. INTRODUCTION  
2.1. Study rationale  
GSK has develop ed an RSV PreFusion protein F3 O lder Adult  (referred to as RSVPreF3 
OA vaccine throughout this document ) which consists of 120 µg of  the RSVPreF3 
recombinant antigen and the AS01E adjuvant system administered as a single dose, to 
address the unmet medical need for prevention of RSV -LRTD  in older adults . The 
vaccine was approved for use in adults ≥60 Y OA in the US on 03 May 2023, under the 
tradename Arexvy.  To date,  the vaccine is also approved in the EU , UK, Canada, Japan  
Hongkong , Australia  and other countries. However, some younge r patient groups also 
have an increased risk f or RSV  disease . The aim of this open -label  study is to 
demonstrate the NI of the immune response and to evaluate safety of the RSVPreF3 OA 
investigational vaccine in adults 18-49 YOA, who are AIR for RSV  disease , versus adults 
≥60 YOA, where vaccine efficacy against RSV  disease  has been assessed in  another 
clinical study  (RSV OA =ADJ-006). 
2.2. Background  
RSV is a ribonucleic acid virus of which 2  antigenically distinct subtypes exist, referred 
to as RSV -A and RSV -B [Borchers , 2013 ]. RSV causes respiratory tract infections (RTI) 
in people of all ages. RSV can cause severe disease  in infants, OA and adults AIR due to 
presence of chronic diseases.  Currentl y, there are 2 vaccines available for prevention of 
RSV infection in  adults ≥60 Y OA; Arexvy (manufactured by GSK) and Abrysvo  
(manufactured by Pfizer Inc) . 
RSV is recognized as an important cause of hospitalization for severe respiratory illness 
in OA and those with underlying medical conditions [ Branche , 2022 a; Jain, 2015 ]. RSV 
CONFIDENTIAL  
222253  (RSV OA=ADJ -025) 
Protocol  Amendment 1  Final  
03 May 2024  34 infections are increasingly recognized as a cause of serious illness in high -risk, non-
immunocompromised adults, including those with chronic lung and heart disease, 
diabetes mellitus,  chronic renal and liver disease, and neurologic disease [ Melgar , 2023 ]. 
In a prospective cohort study over 4  RSV seasons in healthy elderly patients ( ≥65 YOA) 
and high-risk adults ( ≥21 YOA) with chronic heart or lung disease, RSV infection 
developed annually in 3% to 7% of healthy elderly patients and in 4% to 10% of high -
risk adults [ Falsey , 2005;  Shi, 2021 ]. 
In patient populations with chronic diseases, both the prevalence and incidence of RSV 
infections is increased, leading to an increased need for medical care and hospitalization 
in high income countries. In a major study in the United States (US), the incidence 
among chronic pulmonary disease patients ranged between 1.47 to 4.68 per 
10 000 patients aged 18 -49 years. Among patients with diabetes, th e incidence of RSV -
hospitalizations ranged between 6.54 to 8.34 per 10  000 patients aged 18 -49 years. For 
patients with  congestive heart failure ( CHF ), the incidence ranged between 11.5 to 29.52 
per 10  000 patients aged 20 -39 years and 23.16 to 48.59 per 1 0 000 patients aged 
40-59 years  [Branche , 2022b] . 
The RSVPreF3 OA vaccine induces humoral and cellular immune responses to both 
RSV -A and RSV -B at 1-month  post-vaccination in adults 50 -59 YOA, including adults 
AIR for RSV disease. Th e results observed in adults 50 -59 YOA are consistent with the 
robust immunogenicity data observed in the pivotal Phase 3 study RSV  OA=ADJ -004 
and study RSV OA=ADJ -006, where  overall vaccine efficacy of 82.6% (96.95% CI , 
57.9-94.1) against RSV -LRTD  up to 6  months post -vaccination  was demonstrated . Based 
on these results,  licensure of the RSV OA vaccine was received in different countries  
[Papi, 2023;  Leroux -Roels , 2023 ]. Currently, studies in participants ˂ 60 YOA who are 
more vu lnerable to severe disease as result of RSV infection  are ongoing , among which is 
the RSV OA=ADJ -018-NI study in patients with chronic diseases AIR for RSV -LRTD in 
50-59 YOA and RSV OA=ADJ -023- evaluating the immune response and safety of the 
vaccine in renal and lung SOT patients ≥ 18 YOA.  
The aim of this study is to demonstrate the NI of the immune response and evaluate 
safety of RSVPreF3 OA investigational  vaccine in non -immunocompromised adults 
18-49 YOA, who are AIR f or RSV  disease , versus adults ≥60 YOA, where vaccine 
efficacy against RSV  disease has been demonstrated.  
Please refer to the IB for information regarding pre -clinical studies, and clinical st udies of 
RSVPreF3 OA investigational vaccine.  
2.3. Benefit/ risk assessment  
2.3.1.  Risk assessment  
Detailed information about the known and expected benefits, potential risks, and 
reasonably expected AEs of RSVPreF3 OA investigational vaccine can be found in the 
IB/PI. 
CONFIDENTIAL  
222253  (RSV OA=ADJ -025) 
Protocol  Amendment 1  Final  
03 May 2024  35 Table 5 Risk Assessment  
Potential Risk 
of Clinical 
Significance  Rationale for Risk  Mitigation Strategy  
RSVPreF3 OA investigational vaccine  
pIMDs  pIMDs are considered a 
theoretical risk, as for all vaccines 
containing an adjuvant system.  Refer to Section 8.4.4  for details.  
Hypersensitivity 
reactions 
(including 
anaphylaxis)  Previous exposure to components 
of the vaccine might have induced 
an immune response that results 
in an exaggerated or inappropriate 
reaction.  All participants will remain under observation at the clinica l 
center for at least 30 minutes after study intervention 
administration or longer if deemed necessary by site 
personnel.  
Appropriate medical care must be readily available during 
this period.  
Participants with a history of hypersensitivity or severe 
allergic reaction to any component of the vaccine are 
excluded from study enrollment.  
Syncope 
(fainting)  Syncope (fainting) can occur 
following or even before study 
intervention administration as a 
psychogenic response to the 
needle insertion.  Participants who mention experiencing previous episodes 
of fainting or dizziness before, during or after vaccination, 
will be asked to lie down during the intervention and remain 
under observation at the clinical center for at least 30 
minutes after study intervention administration or longer if 
deemed necessary by site personnel.  
Appropriate medical care must be readily available during 
this period.  
Study procedures  
Local reactions 
at the injection 
site Intramuscular vaccination 
commonly precipitates a t ransient 
and self -limiting local inflammatory 
reaction. This may typically 
include pain at injection site, 
erythema/redness, and swelling.  Physician can implement the measures that they consider 
necessary.  
Solicited local AE will be collected and reviewed up to Day 
4 following vaccination.  
Local reactions 
at site of blood 
draw  Pain, redness /erythema , irritation, 
and bruising may occur at the site 
where blood is drawn.  Physician can implement the measures th at they consider 
necessary.  
Syncope 
(fainting)  Syncope (fainting) can occur 
following or even before any blood 
draw as a psychogenic response 
to the needle insertion.  Participants who mention experiencing previous episodes 
of fainting or dizziness before , during or after a blood draw, 
will be asked to lie down during the intervention and remain 
under observation at the clinical center for at least 30 
minutes after blood draw or longer if deemed necessary by 
site personnel.  
Appropriate medical care must be readily available during 
this period.  
pIMD: Potential immune -mediated disease; AE -Adverse event  
For details of study procedures, dose, and study design justification, refer to Section  1.3 
and Section  4.2. 
In parallel with the RSVPreF3 OA clinical development program, another RSV vaccine 
development program was initiat ed by GSK . GSK developed an investigational RSV 
vaccine for administration to pregnant women, with the aim of preventing medically 
assessed, RSV -associated LRTIs in their infants up to 6 months of age, by transfer of 
maternal antibodies.  
CONFIDENTIAL  
222253  (RSV OA=ADJ -025) 
Protocol  Amendment 1  Final  
03 May 2024  36 In 2020, GSK initiated a Phase 3, double -blind, 2:1 -randomized, placebo -controlled study 
(RSV MAT -009; [STUDY_ID_REMOVED]) in 24 countries to assess the safety and efficacy of the 
maternal vaccine candidate (RSVPreF3 Mat) administered to 18 –49-year-old women in 
the late secon d or third trimester of pregnancy.  
In February 2022, GSK decided to stop enrollment and vaccination in RSV maternal 
vaccine studies involving pregnant women. This decision was taken because of an 
observed imbalance in the proportions of both preterm births  and neonatal deaths (death 
of an infant within the first 28 days of life) in the treatment group vs. the placebo group 
in the RSV MAT -009 study. Subsequently, the enrollment and vaccination in all studies 
of the RSV maternal vaccine candidate involving wo men of childbearing potential were 
also stopped.  
Following the Day 43 post -birth interim analysis (DLP 04 October 2022) of the RSV 
MAT -009 study, GSK concluded that preterm birth is an identified risk for the pregnant 
women population, for the RSV maternal vaccine candidate. The observed numerical 
imbalance in neonatal deaths is not an independent safety signal but a consequence of the 
imbalance in preterm births. GSK has discontinued the further development of this RSV 
maternal vaccine candidate.  
The safety concern is specific to women who received the RSV maternal vaccine 
candidate during the late second or third trimester of pregnancy  [Dieussaert , 2024] . 
Analyses of the available safety data have not established what caused the observed 
imbalance in preterm births. The overall incidence of preterm birth in the study was low 
in both treatment groups and remained below the preterm birth background rates for th e 
majority of the participating countries. The imbalance in preterm births was observed 
more in low and middle -income countries (relative risk 1.57 [95% CI: 1.17 - 2.10) than 
high-income countries (relative risk 1.04 [95% CI: 0.68 - 1.58]).  
The vaccine can didate for OA (RSV PreF3 OA vaccine), contains the same RSV antigen 
as the RSV maternal vaccine candidate but the RSVPreF3 OA vaccine is  combined with 
GSK’s established AS01E adjuvant to boost the immune response in the OA population.  
After further conside ration of the preterm birth safety signal observed in the RSV 
Maternal study and recommendations by external experts, GSK has assessed that 
WOCBP can be included in this study. As a precautionary measure, no pregnant women 
will be included and all WOCBP wi ll be required to use adequate contraception and have 
a negative pregnancy test prior to each vaccination in this study  (see Section  5.1.1 ). Study 
participants will be adequately informed of the risks associated with pregnancy as the 
informed consent contains specific information regarding the RSV Maternal study.  
The RSVPreF3 OA vaccine clinical trials are closely monitored for safety with all 
availa ble safety data reviewed by the sponsor.  In addition, the Phase 3 RSV OA=ADJ -
006 clinical study is monitored by an IDMC on an ongoing basis. The IDMC has not 
raised any concern for safety in the OA population. The RSVPreF3 OA vaccine has not 
been studied i n pregnant women to date.  
CONFIDENTIAL  
222253  (RSV OA=ADJ -025) 
Protocol  Amendment 1  Final  
03 May 2024  37 2.3.2.  Benefit assessment  
The participants  may or  may not benefit directly from participating in this study. By 
receiving the RSVPreF3 OA vaccine, the participant may have the benefit of being 
protected against RSV -LRTD . In a pre -specifi ed efficacy interim analysis of an ongoing 
Phase 3 trial (RSV OA=ADJ -006) in participants  ≥ 60 YOA , for those receiving a single 
dose of the RSVPreF3 OA investigational vaccine,  the primary endpoint was met with 
82.6%  vaccine efficacy  (96.95% CI, 57 .9-94.1)  [Papi, 2023]  during the first RSV season 
and no unexpected safety concerns observed (refer to IB).  A study in adults 50 -59 YOA , 
in which half of the population was AIR for RSV disease, showed that the immune 
response was not lower in adults 50 -59 YOA -AIR for RSV compared to older adults 
≥ 60 YOA . 
An indirect benefit is that the information obtained in this study will further aid the 
development of the RSV OA vaccine, whi ch is intended to prevent disease associated 
with RSV infection in OA and adults at increased risk f or RSV  disease . 
Another benefit for all study participants may include gaining information about their 
general health status through the medical evaluations/assessments associated with this  
study (i.e., physical examination).  
2.3.3.  Overall benefit -risk conclusion  
The RSVPreF3 OA vaccine ’s marketing authorization has been initially granted for use 
in adults ≥  60 YOA . The clinical development  of the RSVPre F3 PA investigational 
vaccine in other populations is ongoing . Considering the measures taken to minimize the 
risk to participants in this study, the potential risks are justified by the potential benefits 
linked to the development of this vaccine.  
3. OBJECTI VES, ENDPOINTS AND ESTIMANDS  
Table 6 Objectives and Endpoints  
Objective  Endpoint  
Primary*  (Part A ) 
• To demonstrate the NI** of the humoral immune 
response in participants 18 -49 YOA at increased 
risk for RSV disease  compared to OA (≥60  YOA) 
for the RSV -A strain after RSVPreF3 OA 
investigational vaccine administration.  • RSV-A neutralizing titers expressed a s GMT ratio 
(RSV -OA over RSV -A-AIR) at 1 month (Day 31) 
after study intervention administration***.  
• Seroresponse in RSV -A neutralizing titers from Day 
1 to Day 31***.  
• To demonstrate the NI** of the humoral immune 
response in participants 18-49 YOA at increased 
risk f or RSV disease  compared to OA (≥60  YOA) 
for the RSV -B strain after RSVPreF3 OA 
investigational vaccine  administration.  • RSV-B neutralizing titers expressed as GMT ratio 
(RSV -OA over RS V-A-AID) at 1 month (Day 31) 
after study int ervention administration***.  
• Seroresponse in RSV -B neutralizing titers from Day 
1 to Day 31***.  
Secondary Safety  (Part A and Part B ) 
• To evaluate the safety and reactogenicity after the 
RSVPreF3 OA investigational vaccine 
administration.  • Occurrence of  each solicited administration site 
event with onset within 4  days after  dosing  (i.e., the 
day of study intervention administration and 
3 subsequent days).  
CONFIDENTIAL  
222253  (RSV OA=ADJ -025) 
Protocol  Amendment 1  Final  
03 May 2024  38 Objective  Endpoint  
• Occurrence of  each solicited systemic event with 
onset within 4  days after study intervention 
administration (i.e., the day of study intervention 
administration and 3  subsequent days).  
• Occurrence of  unsolicited AEs within 30  days after 
study intervention administration  (i.e., the day of 
study intervention administration and 
29 subsequent days).  
• Occurrence of all SAEs (including fatal and related 
SAEs) and AESIs after study intervention 
administration (Day  1) up to study end ( Month 6 ). 
Secondary Immunogenicity  (Part A ) 
• To evaluate the humoral immune response to the 
RSVPreF3 OA  investigational vaccine  until 6 
months  after study vaccination for both 
populations . • RSV-A and RSV -B neutraliz ing titers, at pre -study 
intervention administration and 1 month  and 6 
months  after st udy intervention administration.  
Tertiary Immunogenicity  (Part A ) 
AE=Adverse event; AESI=Adverse event of special interest; AIR= At increased risk;   
; ; GMT= Geometric mea n titer ; NI=Non-inferiority;  OA=Older 
adults;  RSV= Respiratory syncytial virus; SAE= Serious adverse event ; YOA= Years of age. 
* Refer to Section  9.3.1  for the testing sequence of primary objectives.  
** NI criteria are defined in Section  9.3.1.1. 
*** Co -primary endpoints. Refer to Section  9.1 for statistical hypotheses . 
Primary estimands  (for Part A ) 
The primary question of interest is to evaluate the NI of the humoral immune response after 
RSVPreF3 OA investigational study intervention  in RSV -A-AIR group (18 -49 YOA), 
vaccinated as per protocol when compared to RSV -OA (≥60  YOA ) group.  
CCI
CCI
CCI
CONFIDENTIAL  
222253  (RSV OA=ADJ -025) 
Protocol  Amendment 1  Final  
03 May 2024  39 Table 7 Primary estimands (Part A)  
Attributes  Summary measure  
Treatment  Population  Endpoint (variable)  Intercurrent events (ICEs)  
Description  Handling strategy  
RSVPreF3 OA 
investigational vaccine at 
Day 1. Non-
immunocompromised 
adults at increased risk 
for RSV disease  with 18 -
49 YOA . 
OA with ≥60 YOA . • RSV-A neutralizing titers (expressed in 
ED60) measured at 1 month (Day 31) 
after study intervention administration.  
• Serorespon se in RSV -A neutralizing titers 
(expressed in ED60) from Day 1 to 
Day 31. 
• RSV-B neutralizing titers (expressed in 
ED60) measured at 1 month (Day 31) 
after study intervention administration.  
• Seroresponse in RSV -B neutralizing titers 
(expressed in ED60) from  Day 1 to 
Day 31. Taking prohibited 
medication  
/vaccine or intercurrent 
medical condition prior to 
Day 31.  
 Data collected after 
ICEs will be 
excluded from the 
analysis at Day 31  
(Hypothetical 
strategy)  
Rationale: To 
evaluate the 
immunogenicity 
parameters in the 
absence of ICE  Ratio of GMTs with 
95% CI and 
difference in 
seroresponse rate 
(SRR) with 95% CI 
for RSV-A and RSV -
B neutralizing titers 
(ED60 ) at Day 31 
between the RSV -
OA group 
(≥60  YOA)  and the 
RSV-A-AIR group 
(18-49 YOA ) 
SRR is defined as the proportion of participants having a fold increase in neutralizing titers (1 -month post -study intervention administration over pre -study intervention administration) 
≥4. 
AIR= At increased risk;  CI=Confidence interval; ED60= Estimated d ilution 60;  GMT= Geometric mean titer ; OA=Older adults; YOA= Years of age 
Rationale for estimand:  
The primary estimands address the objective of demonstrating the NI of the humoral immune response in non-immunocompromised 
adults aged 18 -49 YOA  AIR for  RSV disease , when compared to older adults aged ≥ 60 YOA after administration of a single dose of 
RSVPreF3 OA investigational vaccine . This is done by  estimating the true effect of the vaccine without any confounding of other 
medications/vaccinations/medi cal condition(s) on the target population since the impact of developing medical condition(s) forbidden by 
protocol and use of forbidden medications and vaccinations is anticipated to modify the vaccine effect.  
CONFIDENTIAL  
222253  (RSV OA=ADJ -025) 
Protocol  Amendment 1  Final  
03 May 2024  40 Table 8 Secondary estimands for safety (Part A and Part B)  
Attributes  Summary measure  
Treatment  Population  Endpoint (Variable)  Intercurrent events (ICEs)  
Description  Handling strategy  
RSVPreF3 OA 
investigational vaccine 
at Day  1. Non-immunocompromis ed 
adults at increased risk for 
RSV disease  with 18 -49 
YOA . 
OA with ≥60 YOA . • Occurrence of each solicited 
administration site event with onset 
within 4  days after study intervention 
administration.  
• Occurrence of each solicited systemic 
event with onset within 4 days after 
study intervention administration.  
• Occurrence of unsolicited AEs within 
30 days after study intervention 
administration.  
• Occurrence of SAEs  (including fatal 
and related SAEs)  and AESIs after 
study intervention administration (Day 
1) up to study end (Month  6). Taking prohibited 
medication  
/vaccine or intercurrent 
medical condition 
during respective 
duration.  
 All the data collected for 
the variable of interest 
are used regardless of 
whether the inter current 
event occurs (treatment 
policy).  The percentage of 
participants by 
group who report 
each of the 
endpoints.  
AE=Adverse event; AESI=Adverse event of special interest; RSV= Respiratory syncytial virus; SAE= Serious adverse event;  YOA= Years of age. 
CONFIDENTIAL  
222253  (RSV OA=ADJ -025) 
Protocol  Amendment 1  Final  
03 May 2024  41 4. STUDY DESIGN  
4.1. Overall  design  
• Type of study:  Self-contained.  
• Experimental design:  Phase 3 b, open -label, uncontrolled  (as there is no 
comparative intervention) , non -randomized  study . The study will be conducted in 
2 Parts  - Part A and Part B. Part A will include  2 parallel cohorts  (Cohort 1 and 
Cohort 2)  (See Figure  1) and Part B will include 1 Cohort (Cohort 3) (see Figure 2) 
− Enrollment rules will be applied to ensure adequate representation by sex 
category within Part A ( Cohort 1  and 2) and Part B  (Cohort 3 ): 
o Approximately 35% of male participants per cohort.  
o Approximately 35% of female participants per cohort.  
o The remaining 30% can be distributed freely across the 2 categories.  
Part A:  
− Cohort 1: approximately 425 adults (A)18 -49 YOA AIR for RSV  disease  (RSV -
A-AIR Group)  will receive 1 dose of RSVPreF3 OA investigational vaccine at 
Visit 1 (Day 1) . 
− Enrollment rules for disease categories within Cohort 1:  
o At least ~25% of participants with cardiopulmonary conditions.  
o At least ~25% of participants with diabetes mellitus.  
o The remaining ~50% can be distributed freely across the above 2 disease 
categories as well as include participants with chronic renal or liver disease 
or neurological or neuromuscular disease.  
− Cohort 2: approximately 425 adults ≥60  YOA ( RSV -OA Group)  will receive 
1 dose of RSVPreF3 OA investigational vaccine at Visit 1 (Day 1) . 
− Enrollment rules will be applied to ensure adequate representation by age 
category within Cohort 2:  
o Approximately 40% of participants 60 -69 YOA.  
o Approximately 30% of participants 70 YOA or above.  
o The remaining 30% can be distributed freely across the 2 age categories.  
Part B:  
− Cohort 3 : Approximately 600  adults (A)18 -49 YOA AIR for RSV disease 
(RSV -A-AIR Group) will receive 1 dose of RSVPreF3 OA investigational 
vaccine at Visit 1 (Day 1).  
− Enrollment rules for disease categories within Cohort 3: 
o At least ~25% of participants with cardiopulmonary conditions . 
CONFIDENTIAL  
222253  (RSV OA=ADJ -025) 
Protocol  Amendment 1  Final  
03 May 2024  42 o At least ~25% of participants with diabetes mellitus.  
o The remaining ~50% can be distributed freely across the above 2 disease 
categories as well as include participants with chronic renal or liver disease 
or neurological or neuromuscular disease.  
• Duratio n of the study : Approximately 6 months for all participants.  
• Sampling schedule : Three blood samples (approximately 15 mL each)  will be 
collected from all participants in Part A ( Cohort 1 and Cohort 2 ) to evaluate humoral 
immune response  to the investigation al RSVPreF3 OA vaccine on Visit 1  (pre-
intervention), Visit 2 ( Day 31 , post-study intervention ) and Visit 3 ( Month 6 , post -
study intervention).   
 
. No blood samples will be collected 
from participants in Part B ( Cohort 3 ). 
• Primary completion date : Completion of last  Visit 2 at Day 31  after the study 
intervention  for participants in  Part A . 
• Blinding : Open -label, all participants will receive the RSVPreF3 OA investigational 
vaccine.  
• Data collection : A standardized electronic case report form (eCRF) will be used. 
Solicited events will be  collected by the participant using an eDiary. Unsolicited AEs 
and new concomitant medications/vaccinations will be collected in source 
documents by the PI or delegated study team member prior to entering them in the 
eCRF and this until study end.  
• Safety m onitoring : The study will be conducted with oversight by the project SRT.  
• Dosing  schedule : Participants will receive a single dose of the investigational study 
intervention (RSVPreF3 OA ) at Visit 1 (Day 1).  
Refer to the SoA in Section  1.3 for additional details.  
4.2. Scientific rationale  for study design  
RSV is a respiratory infection which may lead to an increased risk for RSV disease in OA 
and adults AIR for RSV disease . The efficacy of a single dose of the RSVPreF3 OA 
investigational vaccine in the prevention of RSV disease in OA ≥60 Y OA has been 
establ ished in the Phase 3 clinical study RSV OA=ADJ -006 ( refer to IB).  
The immune response of AIR patients has been shown to be non -inferior in patients aged 
50-59 compared to the OA population as of 60 YOA. Part A of t his study aims to 
continue exploring the i mmune response of patients considered AIR between the ages of 
18-49. By including a cohort of OA with the same inclusion and exclusion criteria as in 
the pivotal RSV OA=ADJ -006 efficacy study in this study, vaccine efficacy can 
potentially be inferred  based on NI of the immune response.  
CCI
CONFIDENTIAL  
222253  (RSV OA=ADJ -025) 
Protocol  Amendment 1  Final  
03 May 2024  43  
 
 
Lastly,  safety of the RSVPreF3 OA investigational vaccine will be evaluated in Part A 
and Part B of the study. By including Part B, safety will be evaluated in a large r sample 
size of adults AIR aged between 18 -49, which will allow better characteriz ation of  the 
safety  profile  of the RSVPreF3 OA investigational vaccine in this population.  
4.2.1.  Participant input into design  
Not applicable.  
4.3. Justification for dose 
A single dose (0.5 mL) of the licensed formulation (120 μg RSVPreF3/AS01E) will be 
used in this study.  
4.4. End-of-study definition  
A participant is considered to have completed the study if the participant  has completed 
visits of the stu dy including the last visit  or the last  scheduled procedure shown in the 
SoA. 
EOS: LSLV (Visit 3/contact ) or Date of the last testing/reading released of the Human 
Biological Samples, related to primary and secondary endpoints, whichever occurs later. 
EOS must be achieved no later than 8 months after LSLV. E OS cannot be before LSLV.  
5. STUDY POPULATION  
Prospective approval of protocol deviations to recruitment and enrollment criteria, also 
known as protocol waivers or exemptions, is not permitted.  
5.1. Inclusion criteria  
Participants are eligible to be included in the study only if all of the following criteria 
apply : 
• Participants and/or participant’s parent(s)/LAR who, in the opinion of the 
investigator, can and will comply with the requirements of the p rotocol (e.g., 
completion of the eDiary, attend study site visits, ability to access and utilize a phone 
or other electronic communications) . INC#1  
Note: for participants in case of physical incapacity that would preclude the 
self-completion of the eDiary,  either (i) site staff can assist the participant (for 
activities performed during site visits) (ii) or the participant may assign a caregiver 
to assist him/her with this activity (for activities performed at home). However, at no 
CCI
CONFIDENTIAL  
222253  (RSV OA=ADJ -025) 
Protocol  Amendment 1  Final  
03 May 2024  44 time will the site staff or caregiver evaluate the participant’s health status while 
completing eDiaries or make decisions on behalf of the participant.  
• Written or witnessed informed consent obtained from the participant/participant’s 
parent(s)/LAR(s) (participant must be able to understand the informed consent) prior 
to performance of any study -specific procedure.  INC#2  
Written informed assent obtained from the participant (participant must be able to 
understand the informed assent) if he/she is less than the legal age * prior to 
performance of any study -specific procedure.  
*The legal age is determined according to local regulations in each participating 
country. In case the legal age is achieved during the conduct of the study, an 
additional written informed consent from the participant should be obtained at the 
time of the legal age.  
5.1.1.  Specific inclusion criteria for all participants in Cohort 1  and 
Cohort 3  
• A male or female participant 18 -49 YOA at the time of the study intervention 
administration.  INC#3  
• Participants should be diagnosed with at least 1 of the following medical conditions 
if considered medically stable* by the investigator:  INC#4  
*A stable condition is defined as a disease not requiring significant change (based 
on the investigator’s opinion) in therapy or worsening during the 3 months before 
enrollment.  
- Chronic cardiopulmonary disease resulting in activity restricting symptoms or 
use of long‑term medica tion: 
o Chronic obstructive pulmonary disease ( COPD ) 
• Global Initiative for Chronic Obstructive Lung Disease ( GOLD ) 
Grade  2-4 
o Asthma  
• Patient on Maint enance and Reliever Therapy ( MART ) OR with at 
least one  rescue treatment per week (excluding exercise asthma)   
o Cystic fibrosis  
o Other chronic respiratory diseases: lung fibrosis, restrictive lung disease, 
interstitial lung disease, emphysema or bronchiectasis  
o Chronic  heart failure:  
• A minimum of class II symptoms according to New York Heart 
Association class ification of heart failure  
o Pre-existing CAD  (CAD not otherwise specified)  
CONFIDENTIAL  
222253  (RSV OA=ADJ -025) 
Protocol  Amendment 1  Final  
03 May 2024  45 • Physician diagnosis of CAD based on electrocardiogram, exercise 
stress test, nuclear stress test, cardiac computed tomography scan or 
cardiac angiogram (more than the presence of hyp ercholesterolemia)  
o Cardiac arrhythmia  
• Patient diagnosed with a cardiac arrythmia that require medical support 
either pharmacologically or with a medical device  
- Diabetes mellitus: types 1 or 2 with active treatment for the past 6 months  
- Other diseases at increased risk for RSV disease  
o Chronic kidney disease  
• G2-G3 disease (Glomerular Filtration Rate between 30 and 
90 ml/min/1.73 m2) 
o Chronic moderate to severe liver disease  
o Neurologic or neuromuscular conditions  (for specific exclusion criteria, see 
Section 5.2.1 ) 
• Female participants of non -childbearing potential may be enrolled in the study. 
Nonchildbearing potential is d efined as premenarche, hysterectomy, bilateral 
oophorectomy, bilateral salpingectomy or post -menopause. INC#5  
• Female participants of childbearing potential may be enrolled in the study, if the 
participant:  
- has practiced adequate contraception from 1 month prior to study intervention 
administration, and  
- has a negative pregnancy test on the day of study prior to intervention 
administration, and  
- has agreed to continue adequate contraception for at least 1 month after 
completion of the study intervention admini stration.  INC#6  
Refer to Section 10.4.1  for definitions of woman of childbearing potential  and non-
childbearing potentia l, and Section 10.4.2  on adequate contraception.  
5.1.2.  Specific inclusion criteria for all participants in Cohort 2  
• A male or female participant 60 YOA at the time of the study intervention 
administration.  INC#7  
• Participants with chronic stable medical conditions with or without specific 
treatment, such as diabetes, hypertension or cardiac disease are allowed to participate 
in this study if considered medically stable* by the inv estigator.  INC#8  
*A stable condition is defined as disease not requiring significant change (based on 
the Investigator's opinion) in therapy or worsening disease during the 3 months 
before enrollment.  
CONFIDENTIAL  
222253  (RSV OA=ADJ -025) 
Protocol  Amendment 1  Final  
03 May 2024  46 • Participants living in the general community or in an a ssisted -living facility that 
provides minimal assistance, such that the participant is primarily responsible for 
self-care and activities of daily living.  INC#9  
5.2. Exclusion criteria   
Participants are excluded from the study if any of the following criteria apply:  
5.2.1.  Medical conditions  
• Any confirmed or suspected immunosuppressive or immunodeficient condition 
resulting from disease (e.g., current malignancy, human immunodeficiency virus) or 
immunosuppressive/cytotoxic therapy (e.g., medication used durin g cancer 
chemotherapy, organ transplantation, or to treat autoimmune disorders), based on 
medical history and physical examination (no laboratory testing required ). EXC#1  
• History of any reaction or hypersensitivity likely to be exacerbated by any 
component  of the study intervention ( For details on components of study 
intervention administered, refer to Arexvy  SmPC/Prescribing Information [ Arexvy 
Summary of Product Characteristics , 2023 ; Arexvy Prescribing Information , 2023 ] 
and Table 9 in Section 6.1). EXC#2  
• Unstable* chronic illness.  EXC#3  
*Unstable condition is defined as a disease that does not fall under the definition of 
stable disease  in Section  5.1.1 . 
• Any history of dementia or any medical condition that  moderately or severely 
impairs cognition.  EXC#4  
Note: If deemed necessary for clinical evaluation, the investigator can use tools such 
as Mini -Mental State Exam, Mini -Cog or Montreal Cognitive Assessment (to 
determine cognition levels of the participant).  
• Recurrent or uncontrolled neurological disorders or seizures. Participants wit h 
medically controlled active or chronic neurological diseases can be enrolled in the 
study as per investigator assessment, provided that their condition will allow them to 
comply with the requirements of the protocol (e.g., completion of the diary cards, 
attend study site visits). Study participants may decide to assign a caregiver to help 
them complete the study procedures.  EXC#5  
• Significant underlying illness that in the opinion of the investigator would be 
expected to prevent completion of the study (e. g., life -threatening disease).  EXC#6  
• Any medical condition that in the judgment of the investigator would make 
intramuscular injection unsafe.  EXC#7  
• Any other clinical condition that, in the opinion of the investigator, might pose 
additional risk to the participant due to participation in the study.  EXC#8  
CONFIDENTIAL  
222253  (RSV OA=ADJ -025) 
Protocol  Amendment 1  Final  
03 May 2024  47 5.2.2.  Prior/Concomitant therapy  
• Use of any investigational or non -registered product (drug, vaccine, or medical 
device) other than the study intervention during the period beginning 30 days before 
the dose of study intervention (Day -29 to Day 1), or planned use during the study 
period (up to Visit 3 / contact , Month 6).  EXC#9  
• Planned or actual administration of a vaccine not foreseen by the study protocol in 
the period starting 30 days before and ending 30 days  after the dose of study 
intervention administration*, with the exception of  inactivated, subunit and split 
influenza vaccines or COVID -19 vaccines which can be administered up to 14 days 
before or from 14  days after the study intervention administration.  EXC#10  
Note: In case an emergency mass vaccination for an unforeseen public health threat 
(e.g., a pandemic) is recommended and/or organized by the public health authorities, 
outside the routine immunization program, the time period described above can be 
reduced if necessary for that vaccine provided it is used according to the local 
governmental recommendations and that the Sponsor is notified accordingly.  
• Previous vaccination with any RSV vaccine, including investigational RSV vaccines.  
EXC#11  
• Chronic administration of immune -modifying drugs (defined as more than 
14 consecutive days in total) and/or administration of long -acting immune -modifying 
treatments or planned administration at any time up to the EOS. EXC#12  
− Up to 3 months prior to the st udy intervention administration:  
o For corticosteroids, this will mean prednisone 20 mg/day, or equivalent. 
Inhaled, topical and intra -articular steroids are allowed . 
o Administration of immunoglobulins and/or any blood products or plasma 
derivatives  
− Up to 6 months prior to study intervention administration: long -acting immune -
modifying drugs including among others immunotherapy (e.g., TNF -inhibitors), 
monoclonal antibodies, antitumoral medication.  
5.2.3.  Prior/Concurrent clinical study experience  
• Concurrently partic ipating in another clinical study, at any time during the study 
period, in which the participant has been or will be exposed to an investigational or a 
non-investigational vaccine/product (drug or invasive medical device).  EXC#13  
5.2.4.  Other exclusions  
5.2.4.1.  Other exclusions for all participants  
• History of chronic alcohol consumption and/or drug abuse as deemed by the 
investigator to render the potential participant unable/unlikely to provide accurate 
safety reports or comply with study procedures.  EXC#14  
• Bedr idden participants.  EXC#15  
CONFIDENTIAL  
222253  (RSV OA=ADJ -025) 
Protocol  Amendment 1  Final  
03 May 2024  48 • Planned move during the study period that will prohibit participating in the study 
until study end.  EXC#16  
• Participation of any study personnel or their immediate dependents, family, or 
household members.  EXC#17  
5.2.4.2.  Other exclusions for Cohort 1  and Cohort 3  
• Pregnant or lactating female participant.  EXC#18  
• Female planning to become pregnant or planning to discontinue contraceptive 
precautions within 1 month after study intervention administration.  EXC#19  
5.3. Lifestyle considerations  
No restrictions are required . 
5.4. Screen failures  
A screen failure occurs when a participant who has consented to participate in the clinical 
study is not subsequently  entered in the study. A minimal set of screen failure 
information is required to ensure transparent reporting of screen failure participants to 
meet the CONSORT publishing requirements and to respond to queries from regulatory 
authorities. Minimal information includes demography, screen failure details, eligibility 
criteria, and any  SAE s related to study procedures/concurrent GSK medication . 
5.5. Criteria for temporarily delaying enrollment/ administration 
of study intervention  
Enrollment/study intervention administration  may be postponed until transient conditions 
cited below are resolved, and prior to the end of the study enrollment period:  
• Acute disease and/or fever  at the time of enrollment and/or study intervention 
administration. Refer to the SoA in Section 1.3 and Section 8.3.1.2  for definition of 
fever and preferred location for measuring temperature in this stud y. 
• Participants with a minor illness (such as mild diarrhea, mild upper respiratory 
infection) without fever may be enrolled and/or dosed at the discretion of the 
investigator.  
• Participants with symptoms suggestive of active COVID -19 infection (e.g., fever, 
cough, etc.). The return of the participant to the site will follow the specific guidance 
from local public health and other competent authorities (e.g., free of symptoms, 
COVID -19 negative testing, etc.).  
• Participants with known COVID -19 positive contacts  may be dosed at least 14  days 
after the exposure, provided that the participant remains symptom -free, and at the 
discretion of the investigator.  
• In case of administration of inactivated and subunit influenza vaccines and COVID -
19 vaccines: postponement of  study intervention administration within given 
protocol timelines and prior to the end of the study enrollment period, to allow 
CONFIDENTIAL  
222253  (RSV OA=ADJ -025) 
Protocol  Amendment 1  Final  
03 May 2024  49 respect of at least 14 days interval between flu/COVID -19 vaccination and study 
intervention administration.  
• In case of adminis tration of any other vaccines, postponement of study intervention 
administration within given protocol timelines and prior to the end of the study 
enrollment period, to allow respect of at least 30 days interval between other 
vaccination and study interven tion administration.  
All efforts should be made so that blood sample is taken on the same date as vaccination.  
The following procedures must be repeated prior to the delayed study intervention  
administration:  
• Blood sampling  (applicable for Part A  only)  
• Urine for pregnancy testing  
• Body temperature and vital signs  
• Physical examination  
• Re-check contradictions, warnings, and precautions to study intervention  
• Re-check inclusion/exclusion criteria  
Visit window for Visit 2 starts f rom day of first study administration.  
6. STUDY INTERVENTION AND CONCOMITANT THERAPY  
The definition of s tudy intervention is provided in the  Definition of Terms . 
6.1. Study intervention (s) administered  
Study intervention administered is mentioned in Table 9 below.  Refer to  Section  4.1 for 
study intervention administration schedule.  
Table 9 Study Intervention administered  
Study intervention name:  RSVPreF3 OA Investigational Vaccine  
Study intervention formulation:  RSVPreF3 (120  µg) AS01E: QS -21* (25 µg), MPL 
(25 µg), liposomes; Water for 
injections  
Presentation:  Powder for suspension for 
injection; Vial  Suspension for suspension for 
injection; Vial  
Type:  Investigational  
Product category:  Biologic  
Route of administration:  IM 
Administration site:  
• Location  Deltoid  
• Directionality  Upper  
• Laterality **  Non-Dominant  
Number of doses to be administered:  1 
Volume to be administered by dose ***:  0.5 mL 
Packaging and labeling:  Refer to the pharmacy manual for more details  
Manufacturer:  GSK  
 GSK=GlaxoSmithKline Biologicals SA; IM=Intramuscular; MPL=Monophosphoryl lipid A; OA=Older adults  
CONFIDENTIAL  
222253  (RSV OA=ADJ -025) 
Protocol  Amendment 1  Final  
03 May 2024  50 * QS-21: Quillaja saponaria Molina, fraction 21 (Licensed by GSK from Antigenics Inc, a wholly owned subsidiary of 
Agenus Inc., a Delaware, USA corporation)  
** The non -dominant arm is the preferred arm of injection. In case it is not possible to administer the study intervention 
in the non -dominant arm, an injection in the dominant arm may be performed.  
*** Refer to the pharmacy manual for the volume after re -constitution.  
Study participants must be observed closely for at least 30 minutes after the 
administration of the study intervention. Appropriate medical treatment and equipment 
must be readily available during the observation period in case of anaphylaxi s or 
syncope.  
6.1.1.  Medical devices  
• There are no GSK manufactured medical devices (or devices manufactured for GSK 
by a third party) provided for use in this study. Other medical devices (not  
manufactured by or for GSK) provided for use in this study are thermometer for 
body temperature measurement, ruler for skin reaction measurement, materials for 
study intervention administration, syringes, blood collection kits, and cup for urine 
collection.  
• Instructions for medical device use are provided  in Laborator y Manual and 
Pharmacy Manual . 
• Complaints related to medical devices should be reported to GSK as detailed in the 
Pharmacy Manual . 
6.2. Preparation , handling , storage , and accountability  
• The investigator or designee must confirm appropriate conditions (e.g., temperature) 
have been maintained during transit for all study intervention received , and any 
discrepancies are reported and resolved before use of the study intervention.  
• Only partici pants enrolled in the study may receive study intervention , and only 
authorized site staff may supply , prepare,  or administer study intervention.  
• All study intervention must be stored in a secure, environmentally controlled, and 
monitored (manual or automa ted) area in accordance with the labeled storage 
conditions with access limited to the investigator and authorized site staff.  
• The investigator, institution, the head of the medical institution (where applicable), 
or authorized site staff  is responsible fo r study intervention accountability, 
reconciliation, and record maintenance ( i.e., receipt, reconciliation, and final 
disposition records).  
• Further guidance and information for the final disposition of unused study 
interventions are provided in the pharmacy  manual.  
CONFIDENTIAL  
222253  (RSV OA=ADJ -025) 
Protocol  Amendment 1  Final  
03 May 2024  51 6.3. Assignment to study intervention  
6.3.1.  Participant identification  
Participant identification numbers will be assigned sequentially to the individuals who 
have consented to participate in the study. Each study center will be allocated a range of 
participant identification numbers.  
6.3.2.  Randomization to study intervention  
All participants will receive 1 dose of the RSVPreF3 OA investigational vaccine at 
Visit  1 (Day 1).  
The assignment of clinical trial supplies will be performed using a GSK RTSM system.  
6.3.3.  Intervention allocation to the participant  
The subject level study intervention assignment activity is conducted using a GSK RTSM 
system.  
Participants in Part A  will be enrolled into 2 different cohorts.  
• Participants 18-49 YOA at increased risk f or RSV  disease  will be enrolled into 
Cohort 1 in 3 disease categories (cardiopulmonary conditions, diabetes mellitus and 
other disease categories), with approximately 25% of participants with 
cardiopulmonary conditions and approxima tely 25% of participants with diabetes 
mellitus. The remaining approximately 50% can be distributed freely across the 
above 2 disease categories as well as include participants with chronic renal or liver 
disease or neurological or neuromuscular disease.  In terms of the sex as well 
approximately 35% of male participants, approximately 35% of female participants 
and remaining 30% can be distributed freely across the 2 categories will be enrolled 
to Cohort 1.  
• Participants in Cohort 2 will be enrolled in 2 age  categories (60 -69 YOA and 
≥ 70 YOA), with approximately 40% of participants 60 -69 YOA and approximately 
30% of participants ≥ 70 Y OA. The remaining 30% can be distributed freely across 
the 2 age categories.  In terms of the sex as well approximately 35% of  male 
participants, approximately 35% of female participants and remaining 30% can be 
distributed freely across the 2 categories will be enrolled to Cohort 2 . 
Participants in Part B will be enrolled into 1 cohort.  
• Participants 18 -49 YOA at increased risk f or RSV disease (Coh ort 3) will be enrolled 
in 3 disease categories (cardiopulmonary conditions, diabetes mellitus and other 
disease categories) , with approximately 25% of participants with cardiopulmonary 
conditions and approximately 25% of participants wi th diabetes mellitus. The 
remaining approximately 50% can be distributed freely across the above 2 disease 
categories as well as include participants with chronic renal or liver disease or 
neurological or neuromuscular disease . In terms of the sex approximately 35% of 
CONFIDENTIAL  
222253  (RSV OA=ADJ -025) 
Protocol  Amendment 1  Final  
03 May 2024  52 male participants, approximately 35% of female participants and remaining 30% can 
be distributed freely across the 2 categories.  
The RTSM system will assign the study intervention number . Recruitment caps are 
manag ed by the RTSM system.  
When RTSM system is not available, please refer to the Pharmacy Manual for 
instructions.  
Refer to the Pharmacy Manual for additional information about the study intervention 
number allocation.  
6.4. Blinding  
This is an open -label study.  
6.5. Study intervention compliance  
When participants are dosed at the site, they will receive study intervention directly from 
the investigator or designee, under medical supervision. The dat e of the dose as well as 
kit number  administered in the clinic will be recorded in the source documents.  
A record of the quantity  of RSVPreF3 OA investigational vaccine administered  to each 
participant must be maintained and reconciled with study intervention and compliance 
records.  
6.6. Dose modification  
Not applicable.  
6.7. Continued access  to study intervention  after the end of the 
study  
There is no plan to provide continued access to the study intervention following the end 
of study . 
CCI
CONFIDENTIAL  
222253  (RSV OA=ADJ -025) 
Protocol  Amendment 1  Final  
03 May 2024  53 During the study conclusion visit, the investigator will ask each participant/participant’s 
parent(s)/LAR(s) if they are interested in participating/allowing the participant to join  any 
potential  booster or long-term evaluation stud ies. If a participant/participant’s  
parent(s)/LAR(s) are  not interested in joining any potential booster or long-term 
evaluation stud ies the reason for refusal will be documented, when available, in the 
participant’s eCRF.  
6.8. Treatment of overdose  
Not applicable.  
6.9. Prior and concomitant therapy  
At each study visit, the investigator(s) or their delegate(s) should question the participant 
about all medications/products taken, and vaccinations received by the participant.  
The following concomitant medication(s)/product(s)/vaccine(s)  must be recorded in the 
eCRF:  
• All concomitant medication including vaccines/products, except vitamins and dietary 
supplements, administered during the 30 -day period after the dose of study 
intervention (Day 1 to Day 30).  
• All concomitant medication leading to elimination from the analysis, including 
products/vaccines. Please refer to the Section 5.2.2  for further det ails. 
• All concomitant medication which may explain/cause/be used to treat an 
SAE/pIMD /AESI  including vaccines/products, as defined in Section 8.4.1  and 
Section  10.3.5 . These must also be recorded in the Expedited A E Report  (as 
applicable) . 
− For all AF AESIs (including serious and non -serious), concomitant drugs which 
could be associated with development or worsening of AF must be reported in 
the AF follow -up questionnaire.  
• Any prophylactic medication (e.g., analgesics, antipyretics) administered in the 
absence of ANY symptom and in anticipation of a reaction to the study intervention 
administration.  
• Any medication or vaccine (including over -the-counter or prescription medicines, 
recreational drugs, vitamins, and/or herbal supplements) or other specific categories 
of interest that the participant is receiving at the time of enrolment or receives during 
the study must be recorded along with:  
− Reason for use  
− Dates of administration including start and end dates  
− Dosage information including dose and frequency  
• Any antipyretic administered in the period starting 6 hours before vaccination and 
ending 12 hours after vaccination needs to be recorded on the eCRF.  
CONFIDENTIAL  
222253  (RSV OA=ADJ -025) 
Protocol  Amendment 1  Final  
03 May 2024  54 The Medical monitor should be contacted if there are any questions regarding 
concomitant or prior therapy.  
Medications that are contraindicated for use in this study are stipulated in the exclusion 
criteria in Section  5.2.2 . 
Table 10 describes prohibited medications (that could impact evaluation of participants 
baseline status, safety  and efficacy assessments) and the required washout period prior to 
study intervention administration. Generally, these medications are prohibited until after 
study end ( Visit 3 /contact , Month 6 ), unless otherwise stated below.  
Medications that are not sti pulated in the exclusion criteria or listed in Table 10 may be 
used based on the discretion of the investigator (after careful evaluation whether or not 
the medication could impact evaluation of the clinical trial objective or the saf ety of the 
participant).  
Table 10 Prohibited medications and washout period  
Prohibited medications  Washout period  
Investigational or non -registered product  30 days prior to first dose until Visit 3 (Part A) and 
contact (Part B)  
Vaccine  30 days prior to first dose until 30 days after study 
administration (Visit 1)1 
Immune -modifying drugs >14 consecutive days in total  3 months prior to first dose until Visit 3 (Part 
A)/Contact  (Part B)2 
Long -acting immune -modifying treatments (e.g., 
immunotherapy (e.g., TNF -inhibitors), monoclonal 
antibodies, antitumoral medication)  6 months prior to first dose until Visit 3 (Part A)/ 
Contact (Part B)  
Immunoglobulins and/or any blood products or plasma 
derivatives2 3 months prior to first dose until Visit 3  (Part A)/ 
Contact (Part B)  
1 Any vaccine. However, for COVID -19 and inactivated/subunit/split influenza vaccines (fully licensed or with EUA) , this 
time window can be decreased to 14 days before and after each dose. If emergency mass vaccination for an 
unforeseen public health threat  (e.g., a pandemic) is recommended and/or organized by the public health 
authorities outside the routine immunization program, the time period of 30 days described above can be reduced, 
if necessary for that vaccine, provided it is used according to the lo cal governmental recommendations and that 
the Sponsor is notified.  
2For corticosteroids, this will mean prednisone equivalent ≥20 mg/day, or equivalent. Please note: Inhaled, topical and 
intra-articular steroids are allowed.  
Refer to  Table 11 for an overview of the timing for recording of concomitant medication 
during the study.  
Table 11 Timing of collection of concomitant medication to be recorded  
 Dose 1  Study conclusion  
(Visit 3/ contact  at 
Month 6)  Day 1  Day 30  
All concomitant medication including vaccines/products, except 
vitamins and dietary supplements     
All concomitant medication including products/vaccines leading 
to elimination from the analysis     
All concomitant medication including vaccines/products which 
may explain/cause/be used to treat an SAE /AESI (pIMD and 
AF*)   
 
Any prophylactic medication     
CONFIDENTIAL  
222253  (RSV OA=ADJ -025) 
Protocol  Amendment 1  Final  
03 May 2024  55 AESI: Adverse event of special interest ; AF=Atrial Fibrillation; pIMD=Potential immune -mediated disease; 
SAE=Serious adverse event.  
Note: The collection period for the concomitant medications to be recorded in eCRF is indicated in gray.  
* For all AF AESIs (inclu ding serious and non -serious), concomitant drugs which could be associated with development 
or worsening of AF must be reported in the AF follow -up questionnaire.  
7. DISCONTINUATION OF STUDY INTERVENTION AND 
PARTICIPANT DISCONTINUATION/WITHDRAWAL  
7.1. Discontinuat ion of study intervention  
Not applicable to this study.  
7.2. Participant discontinuation/withdrawal from the study  
A participant may withdraw from the study at any time at the participant’s own request 
for any reason (or without providing any reason).  
A participant may be withdrawn at any time at the discretion of the investigator for 
safety, behavioral, or compliance  reasons.  
Investigators will attempt to contact participants who do not return for scheduled visits or 
follow -up. 
All data and samples colle cted up to and including the date of withdrawal of/last contact 
with the participant will be included in the study analyses.  If the participant  withdraws 
consent  for disclos ure of future information, the s ponsor may retain and continue to use 
any data coll ected before such a withdrawal of consent . 
If a participant withdraws from the study, the participant may request  destruction of 
samples taken and not tested, and the investigator must document this in the site study 
record s. Local regulations may also require that any samples  taken and not yet tested at 
the time a participant withdraws from the study are destroyed.  
A participant can  also request for the destruction of their samples any time during the 
study. The investigator must document the request in the site study records.  
The primary reason for participant discontinuation/ withdrawal from the study will be 
docu mented in the eCRF  based on the list below:  
Reasons  Additional items/Sub -reasons  
AE Unsolicited AE  
Solicited event  
SAEs /AESI s 
Lost to follow -up Unknown  
Other, Specify  
Protocol deviation   
CONFIDENTIAL  
222253  (RSV OA=ADJ -025) 
Protocol  Amendment 1  Final  
03 May 2024  56 Reasons  Additional items/Sub -reasons  
Investigator  Decision  Specify  
Pregnancy    
Site Terminated by Sponsor    
Study Terminated by Sponsor    
Withdrawal by Participant  Burden of Procedure  
Participant Relocated  
Pandemic  
Other , Specify  
Death  
Other  Specify  
Participants who are withdrawn from the study because of AEs/SAEs must be clearly 
distinguished from participants who are withdrawn for other reasons. Investigator will 
follow participants who are withdrawn from the study due to an AE/SAE /AESI  until the 
event is resolved , stabilized, otherwise exaplained, or the participant is l ost to follow up  
(see Section 10.3.5.5 ). 
7.3. Lost to follow -up 
A participant  will be considered lost to follow -up if the participant  repeatedly fails to 
return for scheduled visits and is unable to be contacted by the study site.  
The following actions must be taken if a participant  fails to return to the clinic for a 
required study  visit:  
• The site must attempt to contact the participant and reschedule the missed visit as 
soon as possible, counsel the participant on the importance of maintaining the 
assigned visit schedule and  ascertain whether the participant wishes to and/or should  
continue in the study.  
• Before a participant is deemed lost to follow -up, the investigator or designee must 
make every effort to regain contact with the participant (where possible, 3  telephone 
calls, and if necessary, a certified letter to the participant ’s last known mailing 
address or local equivalent methods). These contact attempts should be documented 
in the participant’s medical record.  
• Should the participant continue to be unreachable, the participant will be considered 
to have withdrawn from the st udy.  
• Site personnel will attempt to collect the vital status of the participant within legal 
and ethical boundaries for all participants randomized, including those who did not 
get study intervention. Public sources may be searched for vital status inform ation. If 
vital status of the participant is determined as deceased, this will be documented,  and 
the participant will not be considered lost to follow -up. Sponsor personnel will not 
be involved in any attempts to collect vital status information.  
CONFIDENTIAL  
222253  (RSV OA=ADJ -025) 
Protocol  Amendment 1  Final  
03 May 2024  57 8. STUDY ASSESSMENTS AND PROCEDURES  
• Study procedures and their timing are summarized in the SoA in Section  1.3. 
Protocol  waiver s or exemptions are not allow ed. 
• Adherence to the study design requirements, including those specified in the SoA, is 
essential and required for study conduct.  
• Immediate safety concerns should be discussed with the sponsor as soon as they 
occur or when the study team becomes aware of them. In case of doubts of 
immediate safety concerns regarding the inclusion of a possible participant, inclusion 
should be postponed until a decision can be made.  
• All screening evaluations must be completed and reviewed to confirm that  potential 
participant s meet all eligibility criteria  prior to study intervention administration . The 
investigator  will maintain  a log of all participants screened.  All relevant information, 
such as confirmation of eligibility and reasons for screening  failure will be 
mentioned in this screening log.  Participant s who have signed informed consent but 
are not eligible to proceed should be recorded in the eCRF with a status of ‘screen 
failure’ . 
• If allowed by country regulation/ethics, study visits may be conducted remotely (by a 
HHS professional or site’s own staff) and/or virtually (secure video conferences, 
phone calls, or a web portal and/or mobile application), as per the SoA.  
• In the event of a significant study -continuity issue (e .g., caused by a pand emic), 
alternate strategies for participant visits, assessments, study intervention  distribution 
and monitoring may be implemented by the sponsor or the investigator, as per local 
health authority/ethics requirements.  
• The maximum amount of blood collected from each participant in Part A  (Cohort 1 
and 2) over the duration of the study, related to procedures in this study, will not 
exceed  45 mL and  
 Repeat or unscheduled samples may be taken once at eve ry 
timepoint for technical issues with the samples.  
• Study participants may decide to assign a caregiver to help them fulfill the study 
procedures.  
• It is preferred to have all visits on -site. However, during special circumstances (e.g.,  
pandemic , patients for whom  the transfer to the clinic has become very difficult ), the 
specific guidance from local public health, if applicable, and other competent 
authorities regarding the protection of individuals’ welfare must be applied and 
consulted with the sponsor. For the duration of such special circumstances, the 
following measures may be implemented for enrolled participants:  
− For Part A, Visit 3 may be conducted at the participant’s home (by the site 
staff), if appropriate. Biological sample at Visit 3 may be collected at 
participant’s home. Biological samples should not be collected if they cannot be 
processed in a timely manner or appropriately stored until the intended use.  
CCI
CCI
CONFIDENTIAL  
222253  (RSV OA=ADJ -025) 
Protocol  Amendment 1  Final  
03 May 2024  58  
 
− For Part s A and B, i f the eDiary device has been provided by GSK it may be 
transmitted from and to the site by courier service if allowed by local regulations 
and or collected at home.  
• Impact of visits performed outside of the site’s location on the PPS for 
immunogenicity  will be determined on a case -by-case basis.  
8.1. Administrative baseline procedures  
8.1.1.  Collection of demograph ic data  
Record demo graphic data such as year of birth,  sex, race *, and ethnicity  in the 
participant’s eCRF .  
Collection  of sex, race and ethnicity data is necessary to assess and monitor the diversity 
of the trial participants , and to determine if the trial participants  are truly representative  of 
the impacted population.  
*Differences in the safety and efficacy of certain medical products,  including vaccines 
[Haralambieva , 2013 ; Pérez -Losada , 2009 ; Kollmann , 2013 ] have been observed in 
racially and ethnically distinct subgroups. These differences may be attributable to 
intrinsic factors (e.g., genetics, metabolism, elimination), extrinsic factors (e.g., diet, 
environmental exposure , sociocultural issues), or interactions between these factors. 
Therefore, both geographic ancestry (race) and ethnicity will be collected for all study 
participants.  
Year of birth  is collected to stratify the population and determine the impact of the study 
intervention by age.  
8.1.2.  Medical/vaccination history  
Obtain the participant’s medical/vaccination history by interviewing the 
participant/parent(s)/LAR(s)  and/or review of the parti cipant’s medical records. Record 
any relevant  pre-existing conditions, signs and/or symptoms present prior to  the study 
intervention/study start  in the  eCRF.  
Any vaccine administered up to 1 year before study vaccine administration should be 
recorded in th e eCRF with date of vaccination. For history of influenza vaccination, 
information about the vaccine formulation (e.g., adjuvanted or non -adjuvanted or 
high-dose) should be recorded.  
Administration of Shingrix  and any COVID -19 vaccine /vaccines (if multiple  
doses/administrations)  at any timepoint (even if longer than 1 year before the study 
vaccine administration) should be recorded in the eCRF. The date of vaccinations should 
be collected and recorded in the eCRF.  
CCI
CONFIDENTIAL  
222253  (RSV OA=ADJ -025) 
Protocol  Amendment 1  Final  
03 May 2024  59 8.1.3.  Measure  height and weight  
Measure the participant’s height and weight and record the values in the eCRF .  
8.1.4.  Smoking status and smoking exposure history  
The smoking status will be collected in the eCRF, differentiating tobacco use (cigarettes, 
cigars, cigarillos, pipes, etc.) and use of electroni c smoking devices (e -cigarettes). Refer  
to Definition of Terms  for the definitions of current and former smoker.  
Smoking exposure history should be r ecorded as number of years for both current and 
former smokers. When applicable, the number of years of exposure should be collected 
separately for tobacco and electronic smoking devices.  
All data will be recorded in the participant’s eCRF.  
8.2. Immunogenicity assessments  
Planned timepoints for all  immunogenicity assessments are provided in the SoA.  
Immunogenicty assessments will be performed for participants in Part A only (Cohort 1 
and Cohort 2 ). 
Biological samples will be used for research planned in the protocol and for purposes 
related to the improvement, development and quality assurance of the laboratory tests 
described in this protocol.  
Findings in this or future studies may make it desirable to use samples acquired in this 
study for research not planned in this protocol. In this case, all participants in countries 
where this is allowed will be asked to give consent to allow GSK or a contracted partner, 
to use the samples for further research. The further research will be subjec t to prior 
IEC/IRB approval, if required by local legislation.  
Information on further research and its rationale can be obtained from GSK.  
Sample testing will be done in accordance with the recorded consent of the individual 
participant /participa nt’s paren t(s)/LAR (s). 
By default, collected samples will be stored for a maximum of 20 years. This storage 
period begins when the last participant performs the last study visit. This timeline can be 
adapted based on local laws, regulations or guidelines requiring d ifferent timeframes or 
procedures. In all cases, the storage period should be aligned with participant’s consent. 
These additional requirements must be formally communicated to, discussed and agreed 
with GSK.  
8.2.1.  Biological samples  
An overall volume of 45 mL ( approximately 1 5 mL at each visit) will be collected from 
all study participants in Part A ( Cohort 1 and Cohort 2 ) during the entire study period. 
CONFIDENTIAL  
222253  (RSV OA=ADJ -025) 
Protocol  Amendment 1  Final  
03 May 2024  60 Refer to SoA in Section 1.3 for information on volumes collected for different 
assessments.  
 
 
Table 12 Biological samples  (Part A)   
Sample type  Quantity  Unit Timepoint  Subset name*  
Blood for humoral 
response  ~15 mL Visit 1 (Day 1)  
Visit 2 (Day 31)  
Visit 3 (Month 6)  All participants  (Part A ) 
. 
* Refer to Section 6.3 for subset description.  
Blood sample at Visit 1 (Day 1) should be collected prior to study intervention administration.  
8.2.2.  Laboratory assays  
All clinical testing will be performed at GSK laborat ory or in a laboratory designated by 
GSK.  
Table 13 Laboratory assays  (Part A)  
Test Classification  System  Component  Challenge  Method  Laboratory  
Humoral immunity 
(antibody determination)  Serum  RSV-A 
neutraliz ing 
titer  
Neutralization  GSK*  
 Serum  RSV-B 
neutraliz ing 
titer  
Neutralization  GSK*  
GSK*  
; GSK=GlaxoSmithKline Biologicals 
SA; ICS=Intracellular cytokine staining;  
RSV=Respiratory syncytial virus; ; . 
 
 
 
Please refer to Section 10.2 for a brief description of the assa ys performed in the study.  
The addresses of clinical laboratories used for sample analysis are provided in a separate 
document accompanying this study protocol.  
GSK clinical laboratories have established a Quality System supported by procedures. 
The activities of GSK clinical laboratories are audited regularly for quality assessment by 
an internal (sponsor -dependent) but laboratory -independent Quality Department.  
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CONFIDENTIAL  
222253  (RSV OA=ADJ -025) 
Protocol  Amendment 1  Final  
03 May 2024  61 8.2.3.  Immunological read -outs  
Immunological read -outs are described in  Table 14. 
Table 14 Immunological read -outs (Part A)  
Blood sampling time point  
Subset name  No. of 
participants  Component  Type of contact and 
time point  Sampling time 
point  
Humoral immunity (on serum samples)  
Visit 1 (Day 1)  Pre-Adm All 
participants  ~850 RSV-A neutraliz ing titer 
RSV-B neutraliz ing titer 
Visit 2 (Day 31)  Day 31  All 
participants  ~850 RSV-A neutraliz ing titer 
RSV-B neutraliz ing titer 
Visit 3 (Month 6)  Month 6  All 
participants  ~850 RSV-A neutraliz ing titer 
RSV-B neutraliz ing titer 
 
 
Pre-Adm=Pre -study intervention administration; RSV=Respiratory syncytial virus;  
 
 
 
 
8.2.4.  Immunological correlates of protection  
No generally accepted immunological correlate of protection has been demonstrated so 
far for the antigen used in the RSVPreF3 OA investigational vaccine . 
8.3. Safety assessments  
Planned  timepoints for all safety assessments are provided in the  SoA. 
8.3.1.  Pre-study  intervention administration procedures  
8.3.1.1.  Physical examination  
History directed physical examination will be performed for each participant.  
If the investigator determines that the participant’s health on the day of study intervention 
administration temporarily precludes dosing, the visit will be rescheduled. Refer to the 
Section  5.5 for the list of criteria for temporary delay of study intervention 
administration. Treatment of any abnormality observed during this examination has to be 
CCI
CCI
CCI
CCI
CCI
CONFIDENTIAL  
222253  (RSV OA=ADJ -025) 
Protocol  Amendment 1  Final  
03 May 2024  62 performed according to local medical practice outside this study or by referral to an 
appropriate he alth care provider.  
8.3.1.2.  Vital signs 
At a minimum, o ral or axillary temperature, pulse rate, respiratory rate, and blood 
pressure will be recorded.  
The body temperature of each participant needs to be measured prior to study 
intervention administration and reco rded in the eCRF. The location for measuring 
temperature will be oral or axillary. If the participant has fever (defined as temperature 
≥38.0°C/100.4°F regardless of the location of measurement) on the day of study 
intervention administration, the visit wi ll be rescheduled  (refer to Section 5.5 for details).  
Vital signs are to be taken after at least 10 minutes of rest and before  blood collection for 
laboratory tests and will consist of systolic/diastolic blood pressure, heart rate and 
respiratory rate by counting the number of breaths for 1 minute.  
Blood pressure and pulse measurements will be assessed with a completely automated  
device. Manual techniques will be used only if an automated device is not available.  
Collected information needs to be recorderd in the eCRF.  
8.3.1.3.  Pregnancy testing  
Female participants of childbearing potential must perform a urine pregnancy test before 
the ad ministration of any dose of study intervention. Pregnancy testing must be done 
even if the participant is menstruating at the time of the study visit. The study 
intervention may only be administered if the pregnancy test is negative.  
Refer to Section 8.4.6  for the information o n study continuation for participants who 
become pregnant during the study.   
8.3.2.  Post -study intervention administration procedures  
8.3.2.1.  Physical examination  
Physical examination a t each study visit after the study intervention administration will 
be performed only if the participant/participant’s parent/LAR(s) indicates during 
questioning that there might be some underlying pathology(ies) or if deemed necessary 
by the investigator or delegate. Should there be an underlying condition or illness that is 
diagnosed in any of these visits, this will be adequatly recorded in eCRF.  
8.3.3.  Warnings and precautions to administration of study intervention  
Refer to Arexvy  SmPC/Prescribing Information  [Arexvy Summary of Product 
Characteristics , 2023; Arexvy Prescribing Information , 2023] . 
CONFIDENTIAL  
222253  (RSV OA=ADJ -025) 
Protocol  Amendment 1  Final  
03 May 2024  63 Warnings and precautions to administration of study intervention must be checked at 
Visit 1 (Day 1)  as specified in SoA.  
8.3.4.  Safety monitoring and Committee  
• Participant safety will be continuously monitored by the Medical Monitor, 
designated Safety Lead (or delegate) and SRT, throughout the study. Pertinent 
findings and conclusions are shared with the product’s SRT for review of the overall 
benefit -risk profil e of the product.  
8.4. Adverse Events (AEs) , serious adverse events (SAEs), and 
other safety reporting  
For definitions relating to safety information see Section 10.3 
The investigator and any qualified designees are responsible for detecting, documenting, 
and recording events that meet the definition of an AE or SAE or pIMD and other safety 
information  and remain responsible for following up all AEs  (see Section  7). This 
includes events reported by the participant (or, when appropriate, by a caregiver, or the 
participant’s legally authorized representative).  
Investigator safety reports must be prepared for SUSARs according to local regulatory 
requirements and sponsor policy and forwarded to investigators as necessary.  
The method of recording, evaluating, and assessing causality of AEs and SAEs and the 
procedures for completing and transmitting SAE reports are provided in Section 10.3. 
8.4.1.  Time period and frequency for colle cting AE , SAE, and other 
safety information  
All AEs and SAEs will be collected at time points specified in the SoA (Section  1.3). 
AF reporting will follow the same reporting periods as for AEs and SAEs. Non -serious 
AF with an onset during the 30 -day period following each study vaccine administration 
will be collected.  The reporting of AF meeting the SAE definition (serious AF) will be 
performed according to the SAE reporting period.  
SAEs assessed as related to study participation (e.g.,  protocol -mandated pr ocedures, 
invasive tests, or change in existing therapy) or related to a GSK product (non -IMP) will 
be recorded from the time a participant consents to participate in the study.  
Medical occurrences that begin before the start of study intervention but afte r obtaining 
informed consent will be recorded as medical history/current medical conditions, not as 
AEs.  
CONFIDENTIAL  
222253  (RSV OA=ADJ -025) 
Protocol  Amendment 1  Final  
03 May 2024  64 Table 15 Collection and reporting of safety information  
Event  Pre-adm*  
Day 1  Adm  6 months post -
intervention and  
study conclusion  
Day 1  Day 4 # Day 30  Month 6  
Solicited administration 
site and systemic solicited 
AEs      
     
     
Unsolicited AEs†      
     
     
All SAEs  and AESIs 
(including pIMDs and AF†) 
and fatal SAEs†      
     
     
SAEs related to study 
participation**  
or concurrent GSK 
medication/ vaccine       
     
     
Pregnancy       
     
     
AEs/SAEs leading to 
withdrawal from the study       
     
     
Intercurrent medical 
conditions***       
     
     
AF=Atrial fibrillation; Pre -adm=pre -study intervention administration; Adm=study intervention administration; 
AE=Adverse event; SAE=Serious adverse event; pIMD=Potential immune -mediated disease.  
* Corresponds to the day when informed consent/informed assen t is obtained (Day 1, prior to study intervention 
administration).  
** Any SAE assessed as related to study participation (e.g., protocol -mandated procedures, invasive tests) or related to 
a GSK product will be recorded from the time a participant consents to participate in the study.  
*** A condition that has the capability of altering the immune response to the study vaccine or is confirmed to have an 
alteration of the participant’s initial immune status.  
†Atrial fibrillation will be considered as AESI in t his study and will be additionally reported in the AF follow -up 
questionnaire in (electronic or paper) in eCRF. The collection of AF will be performed following the AE/SAE 
reporting periods. The reporting of non -serious AF will be performed according to th e unsolicited AE reporting 
period. The reporting of AF meeting the SAE definition (serious AF) will be performed according to the SAE 
reporting period.  
# Day 4 is not a visit/contact at site.  
The shaded region in the table indicates time period of data col lection.  
All SAEs will be recorded and reported to the s ponsor or designee immediately and under 
no circumstance should this exceed 24 hours, as indicated in Section 10.3. The 
investigator will submit any updated SAE data to the sponsor within 24 hours of it being 
available.  
A poststudy AE/SAE is defined as any event that occurs outside of the AE/SAE reporting  
period defined in Section  8.4.1 . 
CONFIDENTIAL  
222253  (RSV OA=ADJ -025) 
Protocol  Amendment 1  Final  
03 May 2024  65 Investigators are not obligated to actively seek information on AEs or SAEs after 
conclusion of the study participation . However, if the investigator learns of any SAE, 
including a death, af ter a participant has been discharged from the study, the investigator 
must record it in the medical records. If the investigator  considers the event to be 
reasonably related to the study intervention or study participation, the investigator must 
promptly notify the sponsor . 
8.4.2.  Method of detecting AEs and SAEs   
Care will be taken not to introduce bias when detecting AEs and SAEs. Open -ended and 
nonleading verbal questioning  of the participant /participants’ parent(s)/LAR(s)  is the 
preferred method to inquire about AE occurrences.  
8.4.3.  Follow -up of AEs and SAEs  
After the initial AE/SAE report, the investigator is required to proactively follow each 
participant at subsequent visits/contacts. All SAEs  and AESIs [and AEs of special 
interest (as defined in Secti on 8.4.4 )] will be followed until resolution, stabilization, the 
event is otherwise explained, or the participant is lost to follow -up (as defined i n Section  
7.3). For AF cases, the investigator will provide any new or updated relevant information 
on previously reported AF during the study to GSK using a paper/electronic Expedited 
AEs Report and the A F follow -up questionnaire as applicable. Further information on 
follow -up procedures is provided in Section 10.3.5.5 . 
8.4.4.  AESIs  
pIMDs and AF are the AESIs collected during the study.  
Collecting and reporting timeframes for AESIs:  
• pIMDs: To be reported from Day 1 (after administration of study intervention) up to 
study end (6 months after administration of study intervention).  
• Atrial fibrillation:  
− AF No n-serious AEs: to be reported from Day 1 (after administration of study 
intervention) up to Day 30.  
− AF SAEs: to be reported from Day 1 (after administration of study intervention) 
up to study end (6 months after administration of study intervention).  
8.4.4.1.  Poten tial immune -mediated diseases  
pIMDs are a subset of AESIs that include autoimmune diseases and other inflammatory 
and/or neurologic disorders of interest which may or may not have an autoimmune 
etiology. AEs that need to be recorded and reported as pIMDs i nclude those listed in the  
Table 16. 
CONFIDENTIAL  
222253  (RSV OA=ADJ -025) 
Protocol  Amendment 1  Final  
03 May 2024  66 In order to facilitate the documentation of pIMDs in the eCRF, a pIMD standard 
questionnaire and a list of preferred terms (PTs) and PT codes corresponding to the below  
diagnoses will be ava ilable to investigators at study start.  
The investigator(s) must exercise their medical/scientific judgment to determine whether 
other diseases have an autoimmune origin (i.e., pathophysiology involving systemic or 
organ -specific pathogenic autoantibodies)  and should also be recorded as a pIMD. In 
addition, the investigator should categorize each pIMD either as a new onset condition (if 
it started following vaccination) or as an exacerbation of a preexisting chronic condition 
(if it exacerbated following va ccination) in the eCRF . 
Table 16 List of potential immune -mediated diseases (pIMDs)  
Blood disorders and 
coagulopathies  Cardio -pulmonary inflammatory 
disorders  Endocrine disorders  
• Antiphospholipid syndrome  
• Autoimmune aplastic anemia  
• Autoimmune hemolytic 
anemia, including:  
− Warm antibody 
hemolytic anemia  
− Cold antibody hemolytic 
anemia  
• Autoimmune 
lymphoproliferative syndrome 
(ALPS)  
• Autoimmune neutropenia  
• Autoimmune pancytopenia  
• Autoimmune 
thrombocytopenia  
− Frequently used related 
terms include: 
“autoimmune 
thrombocytopenic 
purpura”, “idiopathic 
thrombocytopenic 
purpura (ITP)”, 
“idiopathic immune 
thrombocytopenia”, 
“primary immune 
thrombocytopenia”.  
• Evans syndrome  
• Pernicious anemia  
• Thrombosis with 
thrombocytopenia syndrome 
(TTS)  
• Thrombotic thrombocytopenic 
purpura  
− Also known as 
“Moschcowitz -
syndrome” or 
“microangiopathic 
hemolytic anemia”  • Idiopathic Myocarditis/Pericarditis, 
including:  
− Autoimmune / 
Immune -mediated myocarditis  
− Autoimmune / Immune -
mediated pericarditis  
− Giant cell myocarditis  
• Idiopathic pulmonary fibrosis, 
including:  
− Idiopathic interstitial pneumonia 
(Interstitial lung disease, 
Pulmonary fibrosis, 
Immune -mediated pneumonitis)  
− Pleuroparenchymal 
fibroelastosis (PPFE)  
• Pulmonary alveolar pr oteinosis (PAP)  
− Frequently used related terms 
include: “pulmonary alveolar 
lipoproteinosis”, 
“phospholipidosis”  • Addison’s disease  
• Autoimmune / Immune -
mediated thyroiditis, 
including:  
− Hashimoto 
thyroiditis 
(autoimmune 
hypothyroidism, 
lymphocytic 
thyroiditis ) 
− Atrophic thyroiditis  
− Silent thyroiditis  
− Thyrotoxicosis  
• Autoimmune diseases of 
the testis and ovary, 
including:  
− Autoimmune 
oophoritis  
− Autoimmune 
ovarian failure  
− Autoimmune orchitis  
• Autoimmune 
hyperlipidemia  
• Autoimmune hypophysitis  
• Diabetes mellitus type  I 
• Graves’ or Basedow’s 
disease, including:  
− Marine Lenhart 
syndrome  
− Graves' 
ophthalmopathy, 
also known as 
thyroid eye disease 
(TED) or endocrine 
ophthalmopathy  
• Insulin autoimmune 
syndrome  
CONFIDENTIAL  
222253  (RSV OA=ADJ -025) 
Protocol  Amendment 1  Final  
03 May 2024  67 • Polyglandular 
autoimmune syndrome, 
including:  
− Polygland ular 
autoimmune 
syndrome type  I, 
II and III 
Eye disorders  Gastrointestinal disorders  Hepatobiliary disorders  
• Ocular Autoimmune / 
Immune -mediated disorders, 
including:  
− Acute macular 
neuroretinopathy (also 
known as acute macular 
outer retinopathy)  
− Autoimmune/Immune -m
ediated retinopathy  
− Autoimmune/Immune -m
ediated uveitis, 
including idiopathic 
uveitis and sympathetic 
ophthalmia  
− Cogan's syndrome: an 
oculo -audiovestibular 
disease  
− Ocular pemphigoid  
− Ulcerative keratitis  
− Vogt-Koyanagi -Harada  
disease  • Autoimmune / Immune -mediated 
pancreatitis  
• Celiac disease  
• Inflammatory Bowel disease, 
including:  
− Crohn’s disease  
− Microscopic colitis  
− Terminal ileitis  
− Ulcerative colitis  
− Ulcerative proctitis  • Autoimmune cholangitis  
• Autoimmune hepatitis  
• Primary bil iary cirrhosis  
• Primary sclerosing 
cholangitis  
Musculoskeletal and connective 
tissue disorders  Neuroinflammatory/neuromuscular 
disorders  Renal disorders  
• Gout, including:  
− Gouty arthritis  
• Idiopathic inflammatory 
myopathies, including:  
− Dermatomyositis  
− Inclusion body myositis  
− Immune -mediated 
necrotizing myopathy  
− Polymyositis  
• Mixed connective tissue 
disorder  
• Polymyalgia rheumatica 
(PMR)  
• Psoriatic arthritis (PsA)  
• Relapsing polychondritis  
• Rheumatoid arthritis, 
including:  
− Rheumatoid arthritis  
associated conditions  
− Juvenile idiopathic 
arthritis  
− Palindromic rheumatism  
− Still's disease  
− Felty’s syndrome  • Acute disseminated 
encephalomyelitis (ADEM) and other 
inflammatory -demyel inating variants, 
including:  
− Acute necrotising myelitis  
− Bickerstaff's brainstem 
encephalitis  
− Disseminated necrotizing 
leukoencephalopathy (also 
known as Weston -Hurst 
syndrome, acute hemorrhagic 
leuko -encephalitis, or acute 
necrotizing hemorrhagic 
encepha lomyelitis)  
− Myelin oligodendrocyte 
glycoprotein 
antibody -associated disease  
− Neuromyelitis optica (also 
known as Devic’s disease)  
− Noninfective encephalitis/ 
encephalomyelitis / myelitis  
− Postimmunization 
encephalomyelitis  
• Guillain -Barré syndrome (GBS)*, 
including:  • Autoimmune/Immune -me
diated glomerulonephritis, 
including:  
− IgA nephropathy  
− IgM nephropathy  
− C1q nephropathy  
− Fibrillary 
glomerulonephritis  
− Glomerulonephritis 
rapidly progressive  
− Membranoproliferati
ve 
glomerulonephritis  
− Membranous 
glomerulonephritis  
− Mesangioproliferativ
e glomerulonephritis  
− Tubulointerstitial 
nephritis and uveitis 
syndrome  
CONFIDENTIAL  
222253  (RSV OA=ADJ -025) 
Protocol  Amendment 1  Final  
03 May 2024  68 • Sjogren’s syndrome  
• Spondyloarthritis, including:  
− Ankylosing spondylitis  
− Juvenile 
spondyloarthritis  
− Keratoderma 
blenorrhagica  
− Psoriatic spondylitis  
− Reactive Arthritis  
− Undifferentiated 
spondyloarthritis  
• Systemic Lupus 
Erythematosus, including:  
− Lupus associated 
conditions (e.g., 
Cutaneous lupus 
erythematosus, Lupus 
nephritis, etc.)  
− Complications such as 
shrinking lung syndrome 
(SLS)  
• Systemic Scleroderma 
(Systemic Sclerosis), 
including:  
− Raynaud’s syndrome  
− Systemic sclerosis with 
diffuse scleroderma  
− Systemic sclerosis with 
limited scleroderma 
(also known as CREST 
syndrome)  − Variants such as Miller Fisher 
syndrome and the acute motor 
and sensory axonal neuropathy 
(AMSAN)  
• Idiopathic cranial nerve 
palsies/paresis and inflammations 
(neuritis), including:  
− Cranial nerve neuritis (e.g., 
Optic neuritis)  
− Idiopathic nerve palsies/paresis 
(e.g., Bell’s palsy)  
− Melkersson -Rosenthal 
syndrome  
− Multiple cranial nerve 
palsies/paresis  
• Multiple Sclerosis (MS), including:  
− Clinically isolated syndrome 
(CIS)  
− Malignant MS (the Marburg 
type of MS)  
− Primary -progressive MS 
(PPMS)  
− Radiologi cally isolated 
syndrome (RIS)  
− Relapsing -remitting MS 
(RRMS)  
− Secondary -progressive MS 
(SPMS)  
− Uhthoff's phenomenon  
• Myasthenia gravis, including:  
− Ocular myasthenia  
− Lambert -Eaton myasthenic 
syndrome  
• Narcolepsy (with or without presence 
of unambiguous cataplexy ) 
• Peripheral inflammatory 
demyelinating neuropathies and 
plexopathies, including  
− Acute Brachial Radiculitis (also 
known as Parsonage -Turner 
Syndrome or neuralgic 
amyotrophy)  
− Antibody -mediated 
demyelinating neuropathy  
− Chronic idiopathic axonal 
polyneuropath y (CIAP)  
− Chronic Inflammatory 
Demyelinating 
Polyradiculoneuropathy (CIDP), 
including atypical CIDP variants 
(e.g., multifocal acquired 
demyelinating sensory and 
motor neuropathy also known 
as Lewis -Sumner syndrome)  
− Multifocal motor neuropathy 
(MMN)  
CONFIDENTIAL  
222253  (RSV OA=ADJ -025) 
Protocol  Amendment 1  Final  
03 May 2024  69 • Transverse myelitis (TM), including:  
− Acute partial transverse myelitis 
(APTM)  
− Acute complete transverse 
myelitis (ACTM)  
Skin and subcutaneous tissue 
disorders  Vasculitis  Other (including 
multisystemic)  
• Alopecia areata  
• Autoimmune / Immune -
mediated blistering 
dermatoses, including:  
− Bullous Dermatitis  
− Bullous Pemphigoid  
− Dermatitis herpetiformis  
− Epidermolysis bullosa 
acquisita (EBA)  
− Linear IgA -mediated 
bullous dermatosis 
(LABD), also known as 
Linear IgA disease  
− Pemphigus  
• Erythema multiforme  
• Erythema nodosum  
• Lichen planus, including:  
− Liquen planopilaris  
• Localised Scleroderma 
(Morphoea)  
− Eosinophili c fasciitis 
(also called Shulman 
syndrome)  
• Psoriasis  
• Pyoderma gangrenosum  
• Reactive granulomatous 
dermatitis, including:  
− Interstitial 
granulomatous 
dermatitis  
− Palisaded neutrophilic 
granulomatous 
dermatitis  
• Stevens -Johnson Syndrome 
(SJS), including:  
− Toxic Epidermal 
Necrolysis (TEN)  
− SJS-TEN overlap  
• Sweet’s syndrome, including:  
− Acute febrile 
neutrophilic dermatosis  
• Vitiligo  • Large vessels vasculitis*, including:  
− Arteritic anterior ischemic optic 
neuropathy (AAION or arteritic 
AION)  
− Giant cell  arteritis (also called 
temporal arteritis)  
− Takayasu's arteritis  
• Medium sized and/or small vessels 
vasculitis*, including:  
− Anti-neutrophil cytoplasmic 
antibody (ANCA) positive 
vasculitis (type unspecified)  
− Behcet's syndrome  
− Buerger’s disease 
(thromboang iitis obliterans)  
− Churg –Strauss syndrome 
(allergic granulomatous angiitis)  
− Erythema induratum (also 
known as nodular vasculitis)  
− Henoch -Schonlein purpura 
(also known as IgA vasculitis)  
− Microscopic polyangiitis  
− Necrotizing vasculitis  
− Polyarteritis nodosa  
− Single organ cutaneous 
vasculitis, including 
leukocytoclastic vasculitis, 
hypersensitivity vasculitis and 
acute hemorrhagic edema of 
infancy (AHEI)  
− Granulomatosis with 
polyangiitis  • Anti-synthetase syndrome  
• Capillary leak syndrome  
− Frequently used 
related terms 
include: “systemic 
capillary leak 
syndrome (SCLS)” 
or “Clarkson's 
Syndrome”  
• Goodpasture syndrome  
− Frequently used 
related terms 
include: “pulmonary 
renal syndrome” 
and 
“anti-Glomerular 
Basement 
Membrane disease 
(anti-GBM disease)”  
• Immune -media ted 
enhancement of disease, 
including:  
− Vaccine associated 
enhanced disease 
(VAED and 
VAERD). Frequently 
used related terms 
include “vaccine -
mediated enhanced 
disease (VMED)”, 
“enhanced 
respiratory disease 
(ERD)”, “vaccine -
induced 
enhancement of 
infection”,  “disease 
enhancement”, 
“immune 
enhancement”, and 
“antibody -
dependent 
enhancement (ADE)  
• Immunoglobulin G4 
related disease  
• Langerhans' cell 
histiocytosis  
CONFIDENTIAL  
222253  (RSV OA=ADJ -025) 
Protocol  Amendment 1  Final  
03 May 2024  70 • Multisystem inflammatory 
syndromes, including:  
− Kawasaki’s disease  
− Multisystem 
inflammatory 
syndrome in adults 
(MIS -A) 
− Multisystem 
inflammatory 
syndrome in 
children (MIS -C) 
• Overlap syndrome  
• Raynaud’s phenomenon  
• Sarcoidosis, including:  
− Loefgren syndrome  
• Susac's syndrome  
8.4.4.2.  Atrial fibrillation (AF)  
AEs of AF are considered as AESI in this study.  
In the efficacy study (RSV OA=ADJ -006), at the time of safety analysis DLP of 30 April 
2022, a numerical imbalance in events of AF was observed within 30  days post -
vaccination, with 10 events of AF (among which 7 [0.1%] were serious) in the RSVPreF3 
group versus 4 (among which 1 [<0.1%] was serious) in the placebo group. No imbalance 
was observed for serious events of AF reported within 6 months post -vaccination. To 
further characterize events of AF, AF will be considered as an AESI.  
When there is enough evidence to make the above diagnosis, the AE must be reported as 
AESI. Symptoms, signs or conditions which might (or might not) represent AF, should be 
recorded and reported as AEs but not as AESI until the final or definitive diagnosis has 
been determined, and alt ernative diagnoses have been eliminated or shown to be less 
likely.  
For each case of AF reported as AE or SAE in the eCRF, additional information will be 
collected in a specific ‘AF follow -up questionnaire’ eCRF screen.  
8.4.5.  Regulatory reporting requirements  for SAEs /pregnancies/ AESI s  
• Prompt notification by the investigator to the sponsor of an SAE /pregnancy/ AESI  is 
essential so that legal obligations and ethical responsibilities toward  the safety of 
participants and the safety of a study intervention under clinical investigation are 
met. See Section  8.4.1  for reporting timeframes.  
• For SAEs/AESIs , the investigator must always provide an assessment of causality at 
the time of the initial report, as defined in the Section  10.3.5.3 . 
• An investigator who receives an investigator safety report describing an SAE or 
other specific safety information ( e.g., summary or listing of SAEs) from the sponsor 
will review and then file it along with the IB and will notify the IRB/IEC, if 
appropriate according to local requirements.  
CONFIDENTIAL  
222253  (RSV OA=ADJ -025) 
Protocol  Amendment 1  Final  
03 May 2024  71 Table 17 Timeframes for submitting SAE, pregnan cy and pIMDs to GSK   
Type of event  Initial reports  Follow -up of relevant information on a 
previous report  
Timeframe  Documents  Timeframe  Documents  
SAEs  24 hours*  electronic A Es Report  24 hours*  electronic  AEs Report  
Pregnancies  24 hours*  electronic pregnancy report  24 hours *  electronic pregnancy report  
pIMDs  24 hours**  electronic  AEs Report  24 hours*  electronic  AEs Report  
Serious AF***  24 hours ** Electronic AEs Report + AF 
follow -up questionnaire   24 hours * Electronic AEs Report + AF 
follow -up questionnaire  
* Timeframe allowed after receipt or awareness of the information by the investigator/site staff.  
** Timeframe allowed once the investigator determines that the event meets the protocol definition of an AESI . 
*** Only A F meeting SAE definition will be reported in electronic Expedited AEs Report and in the specific AF follow -up 
questionnaire. Non -serious AF will be reported as non-serious adverse event eCRF screen and in the AF follow -
up questionnaire.  
8.4.6.  Pregnancy  
Female participants who become pregnant after administration of the study intervention 
may continue the study at the discretion of the investigator.  
• Details of all pregnancies in female participants will be collected after the start of 
study intervention and until EOS. 
• If a pregnancy is reported, the investigator will record pregnancy information on the 
appropriate form and submit it to  the sponsor within 24 hours of learning of the 
female participant pregnancy.  
• Any pregnancy  complication or elective termi nation of a pregnancy for medical 
reasons will be reported as an AE or SAE.  
• Abnormal pregnancy outcomes ( e.g., spontaneous abortion, fetal death, stillbirth, 
congenital anomalies, ectopic pregnancy) are considered SAEs and will be reported 
as such.  
• The participant  will be followed to determine the outcome of the pregnancy. The 
investigator will collect follow -up information on the participant/pregnant female 
partner  and the neonate and the information will be forwarded to the sponsor.  See 
Table 17 for reporting timeframes.  
• Any poststudy pregnancy -related SAE considered reasonably related to the study 
intervention by the investigator will be reported to the sponsor as described in 
Section  8.4.5 . While the investigator is not obligated to actively seek this information 
in former study participants/pregnant female partner , he or she may learn of an SAE 
through spontaneous reporting.  
• Any female participant who becomes pregnant while participating in the study will 
continue to be monitored after study intervention.   
CONFIDENTIAL  
222253  (RSV OA=ADJ -025) 
Protocol  Amendment 1  Final  
03 May 2024  72 8.4.7.  Contact information for reporting SAEs, AESIs  and pregnancies.  
Study contact for questions regarding SAEs, AESIs, pregnancies and SAEs linked 
to device deficiencies  
Contact GSK’s local and/or medical contacts  
Contacts for reporting SAEs, AESIs, pregnancies and SAEs linked to device 
deficiencies  
Available 24/24 hours and 7/7 days  
ogm28723@gsk.com   
8.4.8.  Participant card  
The investigator (or designee) must provide the participant/participant’s parent(s)/LAR(s) 
with a “participant card” containing information about the clinical study. The 
participant/participant’s parent(s)/LAR(s) must be instructed to always keep the 
participant card in their possession for the duration of the study. In an emergency, this 
card serves to inform the responsible attending physician/LAR/caregiver/family member 
that the participant is in a clinical study and that relevant information may be obta ined by  
contacting the investigator(s) or their back up.  
8.5. Pharmacokinetics  
Not applicable to  this study.  
8.6. Pharmacodynamics  
Pharmacodynamics are not evaluated in this study.  
8.7. Genetics  
Genetics are not evaluated in this study.  
8.8. Biomarkers  
Biomarkers are not evaluated in this study.  
8.9. Immunogenicity assessments  
Immunogenicity is described in Section 8.2. 
8.10.  Health economics or medical resource utilization and health 
economic s 
Not applicable in this study.  
CONFIDENTIAL  
222253  (RSV OA=ADJ -025) 
Protocol  Amendment 1  Final  
03 May 2024  73 9. STATISTICAL CONSIDERATIONS  
9.1. Statistical hypotheses  
Statistical hypotheses are associated to the confirmatory primary NI objectives, which 
will be tested according to the hierarchical testing procedure described in Section  9.3.1 . 
Global type I error is controlled at 2.5% (1 -sided).  
Table 18 Study objectives and null hypothesis  
Objectives  Null hypothesis  
Primary  (Part A)  
• To demonstrate the NI of the humoral immune 
response in participants 18-49 YOA  at increased 
risk for RSV  disease  compared to OA ( 60 YOA) for 
the RSV -A strain after RSVPreF3 OA investigational 
vaccine administration.  • Null hypothesis 1 (H1):  
The anti -RSV-A GMT ratio RSV-OA (60 YOA)  over 
RSV-A-AIR (18-49 YOA ) is >1.5 or the SRR 
difference ( RSV-OA [60 YOA ] minus RSV-A-AIR 
[18-49 YOA ]) is >10% at 1  month post RSVPreF3 
OA vaccine administration. This must be rejected in 
favor of the alternative hypothesis that the GMT ratio 
is ≤1.5 and the SRR difference is ≤10%.  
• To demonstrate the NI  of the humoral immune 
response in participants 18-49 YOA  at increased 
risk for RSV  disease  compared to OA ( 60 YOA) for 
the RSV -B strain after RSVPreF3 OA investigational 
vaccine administration.  • Null hypothesis 2 (H2):  
The anti -RSV-B GMT ratio RSV-OA (60 YOA) over 
RSV-A-AIR (18-49 YOA ) is >1.5 or the SRR 
difference ( RSV-OA [60 YO]) minus RSV-A-AIR 
[18-49 YOA ]) is >10% at 1 month post RSVPreF3 
OA vaccine administration. This must be rejected in 
favor of the alternative hypothesis that the GMT ratio 
is ≤1.5 and the SRR difference is ≤10%.  
A=Adults; AIR=At increased risk; GMT=Geometric mean titer; H1=Null hypothesis 1; H2=Null hypothesis 2; NI=Non -
inferiority; OA=Older adults; RSV=Respiratory syncytial virus; SRR=Seroresponse rate; YOA=Years of age.  
9.2. Analysis sets  
Table 19 Analysis sets  
Analysis Set  Definition / Criteri a Analyses Evaluated  
Screened Set  All participants who were screened for eligibility.   Study Population   
Enrolled Set  All participants who entered the study (who were allocated a 
treatment number or received study intervention or 
underwent a post screening study procedure).  
Note : screening failures (who never passed screening) and 
participants screened  (met eligibility)  but never enrolled into 
the study are excluded from the Enrolled analysis set as they 
did not enter the study.  Study Population   
Exposed Set (ES)  All participants who received the study intervention. Analysis 
per group is based on the administered intervention.  Study population, 
Reactogenicity, Safety   
Per-Protocol Set 
(PPS)*  All eligible participants who received the study intervention as 
per protocol, had immunogenicity results pre - and post -dose, 
complied with blood draw intervals, without intercurrent 
conditions that may interfere with immunogenicity and without 
prohibited concomitant medication/vaccination. Analysis per 
group is based on the administered intervention.  Immunogenicity  
*Contribution of participants to PPS will be defined by timepoint  
CONFIDENTIAL  
222253  (RSV OA=ADJ -025) 
Protocol  Amendment 1  Final  
03 May 2024  74 9.2.1.  Criteria for elimination from analyses  
If a participant meets one of the criteria mentioned in the Section 5.2.1  (medical 
conditions) or Section 5.2.2  (concomitant therapy), they may be eliminated from per -
protocol analysis.  
Participants may be eliminated from the PPS for immunogenicity if, during the study, 
they incur a condition t hat has the capability of altering their immune response 
(intercurrent medical condition) or are confirmed to have an alteration of their initial 
immune status. Refer to  Definition of Terms  for the definition of intercurrent medical 
conditions.  
9.3. Statistical analyses  
SAP will include a more technical and detailed description of the statistical analyses 
described in this section. This section is a summary of the planned statistical analyses of 
the primary and secondary endpoints. Supportive analyses and demography summaries 
will be described in the SAP.  
9.3.1.  Primary endpoints/estimands analysis  (Part A)  
Primary estimand analysis will be performed on the Per -Protocol Set (PPS)  for 
participants in Part A . 
RSV -A and RSV -B neutralizing group GMT ratio at 1 month after the RSVPreF3 OA 
vaccine administration will be computed for RSV -OA (60 YOA) cohort over RSV -A-
AIR (18 -49 YOA ) cohort, with 95 % CI, using an  on log10 -transformed 
titers for each neutralization assay. The model will include the group RSV -OA 
(60 YOA)  and RSV -A-AIR (18 -49 YOA ) and the baseline log10 -transformed titer as 
covariate.  
RSV -A and RSV -B neutralizing group SRR differences at 1 month after the RSVPreF3 
OA vaccine administration will be computed for RSV -OA (60 YOA) cohort minus 
RSV -A-AIR (18 -49 YOA ) cohort , with 95% CI. The 95% CI will be derived using the 
method of 1985. SRR is defined as the proportion of participants having a fold 
increase in neutralizing titers (post -study intervention administration over pre -study 
intervention administration) 4. 
Missing data will not be imputed.  
9.3.1.1.  Success criteria for non -infer iority and testing sequence  
In order to control the global type I error at 2.5% (1 -sided), the primary objective will be 
assessed using a hierarchical testing. NI will be first tested for RSV -A strain and, only if 
NI has been demonstrated, will the NI be t ested for RSV -B strain.  
CCI
CCI
CONFIDENTIAL  
222253  (RSV OA=ADJ -025) 
Protocol  Amendment 1  Final  
03 May 2024  75 NI for RSV -A strain will be claimed to be successful if the upper limit of the 95% CI for 
the RSV -A neutralizing group GMT ratio will be ≤1.5 and the upper limit of 95% CI for 
the RSV -A neutralizing group SRR difference will be ≤10% . 
NI for RSV -B strain will be claimed to be successful if NI has been demonstrated for 
RSV -A strain and if the upper limit of the 95% CI for the RSV -B neutralizing group 
GMT ratio will be ≤1.5 and the upper limit of 95% CI for the RSV -B neutralizing group 
SRR difference will be ≤10%.  
9.3.2.  Secondary endpoints/estimands analyses  
The estimand analysis for immunogenicity will be performed on the PPS , for participants 
in Part A .  
For each timepoint with blood sample collection for humoral immune response and for 
RSV -A/B neutralizing titers, the following analysis will be performed by group:  
• Percentage of participants with neutralizing titers equal to or above the technical 
assay cut -off and their exact 95% CI will be tabulated.  
• GMTs and their 95% CI will be tabulated and represented graphically.  
• Distribution of neutralizing titers will be displayed using reverse cumulative curves.  
• MGI, i.e., geometric mean of ratios of neutralizing titers of post vaccination time 
point over pre -vaccination (Day  1), will be tabulated with 95% CI.  
• SRR and 95% CI will be tabulated.  
The estimand analysis for safety will be performed on the  ES, for participants in Parts A 
and Part B. Descriptive analysis by group will be summarized as follows:  
• Perce ntage of participants reporting each solicited administration site event (any 
grade, Grade 3 and resulting in medically attended visit) with onset within 4 days 
after study intervention administration (i.e., the day of study intervention 
administration and  3 subsequent days).  
• Percentage of participants reporting each solicited systemic event (any grade, 
Grade  3 and resulting in medically attended visit) with onset within 4 days after 
study intervention administration (i.e., the day of study intervention adm inistration 
and 3  subsequent days).  
• Percentage of participants reporting unsolicited AEs within 30 days after study 
intervention administration (i.e., the day of study intervention administration and 
29 subsequent days) by MedDRA Primary System Organ Class  (SOC), High Level 
Term (HLT) and Preferred Term (PT). Similar tabulation will be done for Grade 3 
unsolicited AEs, for any causally related unsolicited AEs, for Grade 3 causally 
related unsolicited AEs and for unsolicited AEs resulting in a medically atte nded 
visit.  
CONFIDENTIAL  
222253  (RSV OA=ADJ -025) 
Protocol  Amendment 1  Final  
03 May 2024  76 • Percentage of participants reporting SAEs and AESIs (including pIMDs and AF) 
after study intervention administration (Day  1) up to study end (6 months after study 
intervention administration) by MedDRA Primary SOC, HLT and PT.  
• Percentage of participants reporting SAEs and AESIs (including pIMDs and AF) 
related to study intervention administration after study intervention administration 
(Day  1) up to study end (6 months after study intervention administration) by 
MedDRA Primary S OC, HLT and PT.  
• Percentage of participants reporting any fatal SAEs after study intervention 
administration (Day 1) up to study end (6 months after study intervention 
administration).  
9.4. Interim analyses  
9.4.1.  Sequence of analys is 
The analyses will be performed  stepwise : 
• Day 31  (Part A) : A first analysis will be performed on all immunogenicity, 
reactogenicity and safety data available and as clean as possible, when data for at 
least primary and secondary endpoints up to Visit 2 (Day 31) are available fo r all 
participants  in Part A . This analysis will be considered as final for the primary 
endpoints.  
• Month 6  (Part A) : If required, a safety analysis can be performed when safety data 
up to Month 6 are available  and as clean as possible,  for all participants in Part A.   
• Day 31  (Part B) : If required, a safety analysis can be performed when safety data up  
to Visit 2 (Day 31) are available  and as clean as possible,  for all participants in Part 
B. This analysis may be combined with Month 6 sa fety analysis for Part A.  
Month 6  (Part A) : If required an immunogenicity analysis can be performed when 
all data for secondary endpoints up  to study conclusion ( Visit 3 , Month 6) are 
available  and as clean as possible,  for all participants in Part A.  
• An EOS  analysis will be performed when all immunogenicity and safety data up to 
study conclusion (Visit 3/ Contact, Month 6)  will be available  for all part icipants in 
Part A and Part B.  
• If the data of different analys es become available around the same timepoint, these 
analyses can be combined  into one analysis.   
9.5. Pre-dose  sample size determination  
The target sample size for the study is approximately 850 participants  for Part A : 
425 participants in Cohort 1 (RSV -A-AIR [18-49 YOA group ]) and 425 participants in 
Cohort 2 (RSV -OA [60 YOA group ]), to obtain at least 722 evaluable participants 
(361 participants in the RSV -A-AIR [18 -49 YOA] cohort and 361  participants in the 
RSV -OA [60 YOA]  cohort) for the evaluation of the primary objectives, assuming that 
approximately 15% of the enrolled participants will not be evaluable.  
CONFIDENTIAL  
222253  (RSV OA=ADJ -025) 
Protocol  Amendment 1  Final  
03 May 2024  77 Participants who withdraw from the study will not be replaced.  
The power to demonstrate the primary NI objectives following the hierar chical testing 
procedure described in Section 9.3.1  is presented in  Table 20. 
Table 20 Power for primary objectives of non -inferiority of the humoral 
immune response after RSVPreF3 OA vaccine between the RSV -A-
AIR (18 -49 YOA) Cohort 1 to RSV -OA ( ≥ 60 YOA) Cohort 2 for 
361 evaluable participants per group  
Objective  Standard deviation (SD) of 
log10 titers / SRR (%)  Non-
inferiority 
margin  Type II Error  Power1 
NI for RSV -A strain      
GMT RSV -A  SD=0.45  
 1.5 0.05 99.95%  
SRR RSV -A  SRR=81.6%2 
 10% 6.92 93.08%  
Global power for 
RSV-A strain     93% 
NI for RSV -B strain      
GMT RSV -B SD=0.45  1.5 0.05 99.95%  
SRR RSV -B SRR=78.7%2 10% 9.56 90.44%  
If non -inferiority 
is demonstrated 
for RSV -A, global 
power for RSV -B 
strain     90% 
NI=Non -inferiority; SRR=Seroresponse rate; GMT=Geometric mean titer; RSV=Respiratory syncytial virus  
1Pass 2019 1 -sided alpha=2.5% for each endpoint (GMT ratio and SRR difference), two -Sample T -Tests for Non -
Inferiority assuming equal variance for group GMT ratios and  for Non -Inferiority tests for 
group SRR difference, Non -inferiority limit=0.176 (=log10(1.5)) for group GMT ratios  
2Reference from RSV OA=ADJ -006 
For the evaluation of reactogenicity and safety, the sample size of 1025 participants in 
combined Cohorts 1 and 3 (RS V-A-AIR group) has 64% and 87% probability of 
observing at least one vaccinated participant with AE if the true AE incidence rate is 
0.1% and 0.2% respectively. This probability increases to at least 95% for true AE 
incidence rates ≥0.3%.  
10. SUPPORTING DOCUME NTATION AND OPERATIONAL 
CONSIDERATIONS  
10.1.  Appendix 1: Regulatory, ethical , and study oversight 
considerations  
10.1.1.  Regulatory and ethical considerations  
• This study will be conducted in accordance with the protocol and with the following:  
− Consensus ethical principles derived from international guidelines including the 
Declaration of Helsinki and CIOMS international ethical guidelines  
CCI
CONFIDENTIAL  
222253  (RSV OA=ADJ -025) 
Protocol  Amendment 1  Final  
03 May 2024  78 − Applicable ICH GCP guidelines  
− Applicable laws and regulations  
• The protocol, protocol amendments, ICF ,  IB,  and other relevant documents ( e.g., 
advertisements) must be submitted to an IRB/IEC by the investigator and reviewed 
and approved by the IRB/IEC before the study is initiated.   
• Any amendments to the protocol will require IRB/IEC approval before 
implementa tion of changes made to the study design, except for changes necessary to 
eliminate an immediate hazard to study participants.  
• Protocols and any substantial amendments  to the protocol will require health 
authority approval prior to initiation except for c hanges necessary to eliminate an 
immediate hazard to study participants.  
• The investigator will be responsible for the following , as applicable : 
− Providing written summaries of the status of the study to the IRB/IEC annually 
or more frequently in accordance with the requirements, policies, and 
procedures established by the IRB/IEC  
− Notifying the IRB/IEC of SAEs or other significant safety findings as required 
by IRB/IEC procedures  
− Providing oversight of the conduct of the study at the site and adher ence to 
requirements of 21 CFR, ICH guidelines, the IRB/IEC, European regulation 
536/2014 for clinical studies  (if applicable) , and all other applicable local 
regulations  
10.1.2.  Financial disclosure  
Investigators and sub -investigators will provide the sponsor wit h sufficient, accurate 
financial information as requested to allow the sponsor to submit complete and accurate 
financial certification or disclosure statements to the appropriate regulatory authorities. 
Investigators are responsible for providing informati on on financial interests during the 
course of the study and for 1 year after completion of the study.  
10.1.3.  Informed consent process  
• The investigator or the investigator’s representative will explain the nature of the 
study, including the risks and benefits, to  the participants/participants’ 
parent(s)/LAR(s)  and answer all questions regarding the study.  
• Potential participants/participants’ parent(s)/LAR(s)  must be informed that their 
participation is voluntary. They or their LARs  will be required to physically sign a 
statement of informed consent that meets the requirements of 21 CFR 50 , local 
regulations, ICH guidelines, HIPAA requirements , privacy and data protection 
requirements, where applicable, and the IRB/IEC or study center . 
• The investigator must obtain assent from the minor participant in addition to the 
consent provided by the participants’ parent(s)/LAR(s) when a minor can assent to 
participate in a study. The investigator is also accountable for determining a minor's 
CONFIDENTIAL  
222253  (RSV OA=ADJ -025) 
Protocol  Amendment 1  Final  
03 May 2024  79 capacity to assent to participation in a research study according to the local laws and 
regulations.  
• In accordance with local laws and regulations, participants who become legally 
emancipated during the study, i.e., reach the legal age of consent, must be 
reconsented.  
• The medical record must include a statement that physical  informed consent was 
obtained before the participant was enrolled in the study and the date the  physical  
consent was obtained. The authorized person obtaining the informed consent must 
also sign the ICF.  
• Participants /participant ’s parent(s)/LAR(s)  must be reconsented to the most current 
version of the ICF(s) /IAF  during their participation in the study.  
• A physical  copy of the ICF(s) /IAF  must be provided to the participant /participant’s 
parent(s)  or their LAR . 
• In accordance with local laws and regulations, participants who become legally 
emancipated during the study, i.e. , reach the legal age of consent, must be 
reconsented.  
• The particip ant/participant’s parent(s)/LAR(s)  must provide consent by signing an 
ICF/IAF , which summari zes the study , includes a consent statement and provides 
document ation  that the participant agrees to continue participating in the study.   
The ICF will contain a separate section that addresses the use of remaining mandatory 
samples for optional exploratory research. The investigator or authorized designee will 
explain to e ach participant the objectives of the exploratory research. Participants will be 
told that they are free to refuse to participate and may withdraw their consent at any time 
and for any reason during the storage period  
In case of unexpected pregnancy, parti cipant must be informed that PI such as date of 
birth, sex of the baby will be collected as part of safety follow -up. Consent for the baby 
may be obtained from the participant and/or their partner as per local regulations.  
10.1.4.  Recruitment strategy  
• The study is  planned to be conducted at sites in multiple countries. The recruitment 
plan will be defined by each participating site. Recruitment will be tracked using 
RTSM system.  
• The recruitment plan may be adapted based on the actual number of participants 
enrolled  in each country. In case a site would fall behind in participant recruitment, a 
redistribution of the enrollment target in the participating sites across  participant 
countries may be made. This would allow the other participating sites to enroll 
additional participants to ensure full and timely enrollment of the overall targeted 
number of participants specified in this protocol.  
• When the target number of participants is reached in each cohort, further enrollment 
of participants in that cohort will be stopped. If needed, the maximum number of 
participants in a particular cohort may  be adapted during the study.  
CONFIDENTIAL  
222253  (RSV OA=ADJ -025) 
Protocol  Amendment 1  Final  
03 May 2024  80 • The procedures for participants identification/recruitment (e.g., referral letters, 
advertisements etc.) must be approved by the I RB/IEC together with the material 
intended for participants identification/recruitment and participants use.  
10.1.5.  Data protection  
• Participants will be assigned a unique identifier by the investigator . Any participant 
records or datasets that are transferred to the sponsor will contain the identifier only; 
participant names or any information which would make the participant identi fiable 
will not be transferred.  
• GSK will ensure protection of the personal data of the investigator and site staff 
which is collected within the framework of and for the purpose of the study.  
• The participant /participants’ parent(s)/LAR(s) must be informed that their/the minor 
participants’s personal  study -related data will be used by the sponsor in accordance 
with local data protection law. The level of disclosure must also b e explained to the 
participant/participants’ parent(s)/LAR(s) , that their/the minor partcipant’s data will 
be used as described in the informed consent /assent . 
• The participant/participants’ parent(s)/LAR(s) must be informed that their/the  minor 
participant’s  medical records may be examined by Clinical Quality Assurance 
auditors or other authorized personnel appointed by the sponsor, by appropriate 
IRB/IEC members, and  by inspectors from regulatory authorities.  
• The contract between sponsor and study sites specifies responsibilities of the parties 
related data protection, including handling of data security breaches and respective 
communication and cooperation of the par ties. 
• Information technology systems used to collect, process, and store study -related data 
are secured by technical and organizational security measures designed to protect 
such data against accidental or unlawful loss, alteration, or unauthorized disclos ure 
or access.   GSK and/or  trusted third parties working on behalf of GSK and/or 
institutions working with GSK for the purposes of this study are contractually bound 
to protect participant  coded data. GSK will protect participant  coded data and will 
only s hare it as described in th e ICF. 
10.1.6.  Committees structure  
A SRT is in place for each GSK product. It comprises of a global cross -functional team 
responsible for the ongoing assessment of benefit -risk for a product. The SRT contribute 
to the continual assessment of incoming new efficacy and safety information.  
10.1.7.  Dissemination of Clinical Study Data  
• The key design elements of this protocol and results summaries will be posted on 
www.ClinicalTrials.gov  and/or GSK Clinical Study Register in compliance with 
applicable regulations/GSK policy. GSK  will aim to register protocols summaries 
prior to study start and target results summaries submission within 12 months of 
CONFIDENTIAL  
222253  (RSV OA=ADJ -025) 
Protocol  Amendment 1  Final  
03 May 2024  81 primary/ study completion date. Where external regulations require earlier 
disclosure, GSK will follow those timelines.  
• Where required by regulation, summaries will also be posted on applicable national 
or regional clinical study registers.  
• Where required by applicable regulatory requirements, an investigator signatory will 
be identified for the appr oval of the study report, and provided reasonable access to 
statistical tables, figures, and relevant reports. GSK will also provide the investigator 
with the full summary of the study results , including a summary of trial results 
understandable to laypers ons. The investigator is encouraged to share the plain 
language summary  with the study participants, as appropriate.  The full study report 
will be made available upon request, after decision on marketing authorization by 
regulatory authorities.    
• GSK will provide the investigator with the Treatment Code  and participant -level line 
listings for their site only after completion of the full statistical analysis.  
• GSK  intends to make anonymi zed participant -level data from this study available to 
external  researchers for scientific analyses or to conduct further research that can 
help advance medical science or improve patient care. This helps ensure the data 
provided by study participants are used to maximum effect in the creation of 
knowledge and underst anding.  
10.1.8.  Data quality assurance  
• All participant data relating to the study will be recorded on eCRFs unless 
transmitted to the sponsor or designee electronically ( e.g., laboratory data). The 
investigator is responsible for verifying that data entries are accurate and correct by 
lectronically signing the CRF.  
• Guidance on completion of eCRFs  will be provided in eCRF completion guidelines . 
• The investigator must permit study -related monitoring, audits, IRB/IEC review, and 
regulatory agency inspections and provide direct access to source documents.  
• QTLs will be predefined in the quality plan  to identify systematic issues that can 
impact participant right,  safety and/or reliabi lity of study results. These predefined 
parameters will be monitored during the study, and important deviations from the 
QTLs and remedial actions taken will be summarized in the CSR . 
• Monitoring details describing strategy, including definition of study cr itical data 
items and processes ( e.g., risk -based initiatives in operations and quality such as risk 
management and mitigation strategies and analytical risk -based monitoring , 
involvement of central reading mechanism ) methods, responsibilities, and 
require ments, including handling of noncompliance issues and monitoring 
techniques (central, remote, or on -site monitoring) are provided in the monitoring 
plan. 
• The sponsor or designee is responsible for the data management of this study , 
including quality checking of the data.  
CONFIDENTIAL  
222253  (RSV OA=ADJ -025) 
Protocol  Amendment 1  Final  
03 May 2024  82 • The sponsor assumes accountability for actions delegated to other individuals ( e.g., 
contract research organizations).  
• Records and documents, including signed ICF, pertaining to the conduct of this study 
must be retained by the investigator for 25 years  rom the issue of the final CSR/ 
equivalent summary  unless local regulations or institutional policies require a 
different  retention period. No records may be destroyed during the retention period 
without the written approval of the sponsor. No records may be transferred to 
another location or party without written notification to the sponsor.  
• When copies of source documents  are shared externally for review by a central 
reader mechanism (e.g. , endpoint adjudication committee; expert reader), documents 
are stored by the external body for 25 years . 
10.1.9.  Source documents  
• Source documents provide evidence for the existence of the participant and 
substantiate the integrity of the data collected. Source documents are filed at the 
investigator’s site.  
• Data reported on the eCRF  or entered in the eCRF  that are transcribed from source 
documents must be consistent with the source document s or the discrepancies must 
be explained. The investigator may need to request previous medical records or 
transfer records, depending on the study. Also, current medical records must be 
available.  
• Definition of what constitutes source data and its origin can be found in  the 
Definition of Terms . 
• The investigator must maintain accurate documentation (source data) that supports 
the information entered in the eCRF.  
• The sponsor or designee will perform monitoring to confirm that data entered into 
the eCRF by authorized site personnel are accurate, com plete, and verifiable from 
source documents; that the safety and rights of participants are being protected; and 
that the study is being conducted in accordance with the currently approved protocol 
and any other study agreements, ICH GCP, and all applicabl e regulatory 
requirements.  
• Copies of documents are shared with external third parties contracted by GSK  for 
review by a central reader mechanism ( e.g., endpoint adjudication committee; expert 
reader ). The non -exhaustive list of documents shared to inform the central reader 
may include, discharge summaries, imaging reports, ECG reports etc . Participant 
names or any information which would make the participant identifiable or is not 
essential for the c entral reader mechanism will be redacted by the investigator sites 
prior to transfer.   Detail s of the  list of documents and the redaction procedure are 
provided in the site manual or equivalent.  These documents will be used by the third 
party solely for th e purpose indicated within this protocol.  
CONFIDENTIAL  
222253  (RSV OA=ADJ -025) 
Protocol  Amendment 1  Final  
03 May 2024  83 10.1.10.  Study and site start and closure  
Start of study and first act of recruitment  
The start of study and the first act of recruitment are defined as FSFV at a country -level . 
Study/Site Termination  
GSK  or designee reserves the right to close the study site or terminate the study at any 
time for any reason at the sole discretion of GSK . Study sites will be closed upon study 
completion. A study site is considered closed when all required documents and study 
supplies have been collected and a study -site closure visit has been performed.  
The investigator may initiate study -site closure at any time, provided there is reasonable 
cause and sufficient notice is given in advance of the intended termination.  
Reasons f or the early closure of a study site by the sponsor or investigator may include 
but are not limited to:  
For study termination:  
• Discontinuation of further study intervention development  
For site termination:  
• Failure of the investigator to comply with the protocol, the requirements of the 
IRB/IEC or local health authorities, the sponsor ’s procedures, or GCP guidelines  
• Inadequate or no recruitment (evaluated after a reasonable amount of time) of 
participants by the investigator  
• Total number of participants i ncluded earlier than expected  
If the study is prematurely terminated or temporarily suspended, the sponsor shall 
promptly inform the investigators, the IECs/IRBs, the regulatory authorities, and any 
contract research organization(s) used in the study of the reason for termination or 
temporary suspension, as specified by the applicable regulatory requirements. The 
investigator shall promp tly inform the participant and should assure appropriate 
participant therapy and/or follow -up. 
10.1.11.  Publication policy  
The results of this study may be published in peer reviewed scientific literature and/or 
presented at scientific meetings. The sponsor will co mply with the requirements for 
publication of study results in accordance with standard editorial and ethical practice and 
as per the sponsor’s internal policy. Authorship will be determined by mutual agreement 
and in line with ICMJE authorship requirement s. 
CONFIDENTIAL  
222253  (RSV OA=ADJ -025) 
Protocol  Amendment 1  Final  
03 May 2024  84 10.2.  Appendix 2: Clinical laboratory tests 
10.2.1.  RSV-A and RSV -B neutralization assays  
The serum neutralization assay is a functional assay that measures the ability of serum 
antibodies to neutralize RSV entry and replication in a host cell line.  
Virus neutralization is performed by incubating a fixed amount of RSV -A strain (Long, 
ATCC No. VR -26) or RSV -B strain (18537, ATCC No. VR -1580) with serial dilutions of 
the test serum. The serum -virus mixture is then transferred onto a layer of Vero cells 
(African Green Monkey, kidney, Cercopitheus aethiops , ATCC CCL 81) and incubated 
for 2 days to allow infection of the Vero cells by non -neutralized virus and the formation 
of plaques in the cell layer. Following a fixation step, RSV -infected cells are dete cted 
using a primary antibody directed against RSV (Polyclonal anti -RSV -A/B IgG) and a 
secondary antibody conjugated to horse -radish peroxidase, allowing the visualization of 
plaques after coloration with TrueBlue  peroxidase substrate. Viral plaques are co unted 
using an automated microscope coupled to an image analyzer (Scanlab system with a 
Reading software or equivalent). For each serum dilution, a ratio, expressed as a 
percentage, is calculated between the number of plaques at each serum dilution and the  
number of plaques in the virus control wells (no serum added). The serum neutralizing 
titer is expressed in Estimated Dilution 60 and corresponds to the inverse of the 
interpolated serum dilution that yields a 60% reduction in the number of plaques 
compar ed to the virus control wells, as described by others [ Barbas , 1992;  Bates , 
2014 ]. Seconda ry standards calibrated against the international reference (NIBSC 16/284) 
[McDonald , 2018;  McDonald , 2020 ] are included in every run to allow conversion into 
international units per milliliter.  
CCI
CONFIDENTIAL  
222253  (RSV OA=ADJ -025) 
Protocol  Amendment 1  Final  
03 May 2024  85 10.3.  Appendix 3: AEs  and SAEs : Definitions and procedures for 
recording, evaluating, follow -up, and reporting  
10.3.1.  Definition of AE  
AE definition  
• An AE is any untoward medical occurrence in a clinical study participant, 
temporally associated with the use of a study intervention, whether or not 
considered related to the study intervention.  
• NOTE: An AE can therefore be any unfavorable and unintended sign (including an 
abnormal laboratory finding), symptom, or disease (new or exacerbated) 
temporally associated with the use of a study intervention.  
 
Events Meeting the AE Definition  
• Any abnormal laboratory test results (hematology, clinical chemistry, or 
urinalysis) or other safety assessments (e.g., ECG, radiological scans, vital signs 
measurements), including those that worsen from baseline, considered clinically 
significant in the medical and scientific judgment of the investigator (i.e., not 
related to progression of underlying d isease).  
• Exacerbation of a chronic or intermittent pre -existing condition including either an 
increase in frequency and/or intensity of the condition.  
• New condition detected or diagnosed after study intervention administration even 
though it may have been present before the start of the study.  
• Signs, symptoms, or the clinical sequelae of a suspected intervention - intervention 
interaction.  
• Signs, symptoms, or the clinical sequelae of a suspected overdose of either study 
intervention or a concomitant medicati on. Overdose per se will not be reported as 
CCI
CONFIDENTIAL  
222253  (RSV OA=ADJ -025) 
Protocol  Amendment 1  Final  
03 May 2024  86 an AE/SAE unless it is an intentional overdose taken with possible suicidal/self -
harming intent. Such overdoses should be reported regardless of sequelae.  
• Events that occur as a result of protocol -mandated proced ures (i.e. invasive 
procedures, modification of participant’s previous therapeutic regimen).  
 
Events NOT  Meeting the AE Definition  
• Any clinically significant abnormal laboratory findings or other abnormal safety 
assessments that are associated with the underlying disease, unless judged by the 
investigator to be more severe than expected for the participant’s condition.  
• Medical or surgical procedure (e.g., endoscopy, appendectomy): the condition that 
leads to the procedure is the AE.  
• Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospital , admission for routine examination. ). 
• Anticipated day -to-day fluctuations of pre -existing disease(s) or condition(s) 
present or detected at the start of the study that do not worsen.  Pre-existing 
diseases will be recorded in the medical history section of the eCRF.  
• Hospitalization  for elective treatment of a pre -existing condition (known or 
diagnosed before signing the informed consent) that d id not worsen from baseline.  
10.3.2.  Definition of SAE  
An SAE is defined as any untoward medical occurrence that, at any dose, meets one or 
more of the criteria listed:  
• Results in death  
• Is life threatening  
The term 'life -threatening' in the definition of 'serious' refers to an event in which the 
participant was at risk of death at the time of the event. It does not refer to an event, 
which hypothetically might have caused death, if it were more severe.  
• Requires inpatient hospitalization or prolongation of existing hospitalization  
• In general, hospitalization signifies that the participant has been admitted (usually 
involving at least an overnight stay) at the hospital or emergency ward for 
observation and/or treatment that would not have been  appropriate in the 
physician’s office or outpatient setting. Complications that occur during 
hospitalization are AE. If a complication prolongs hospitalization or fulfills any 
other serious criteria, the event is serious. When in doubt as to whether 
“hosp italization” occurred or was necessary, the AE should be considered serious.  
• Hospitalization for elective treatment of a pre -existing condition that did not 
worsen from baseline is not considered an AE.  
• Results in persistent or significant disability/incapacity  
CONFIDENTIAL  
222253  (RSV OA=ADJ -025) 
Protocol  Amendment 1  Final  
03 May 2024  87 • The term disability means a substantial disruption of a person’s ability to conduct 
normal life functions.  
• This definition is not intended to include experiences of relatively minor medical 
significance such as uncomplicated headache,  nausea, vomiting, diarrhea, 
influenza, and accidental trauma ( e.g., sprained ankle) that may interfere with or 
prevent everyday life functions but do not constitute a substantial disruption.  
• Is a congenital anomaly/birth defect  in the offspring of a stud y participant  
• Abnormal pregnancy outcomes ( e.g., spontaneous abortion, f etal death, stillbirth, 
congenital anomalies, ectopic pregnancy)  
• Is a suspected transmission of any infectious agent via an authorized medicinal 
product  
• Other situations : 
• Medical or scientific judgment should be exercised by the investigator in deciding 
whether SAE reporting is appropriate in other situations such as significant 
medical events that may jeopardize the participant or may require medical or 
surgical interventi on to prevent one of the other outcomes listed in the above 
definition. These events should usually be considered serious.  
− Examples of such events include invasive or malignant cancers, intensive 
treatment for allergic bronchospasm, blood dyscrasias, convu lsions, or 
development of intervention dependency or intervention abuse.  
10.3.3.  Solicited events  
• Definition of solicited event 
• Solicited events  are predefined events  administration site events and systemic 
events  for which the participant/ participant’s parent(s) /LAR(s) is specifically 
questioned, and which are noted by the participant/ participant’s parent(s) /LAR(s) 
in their eDiary. 
Table 21 Solicited administration site  
Pain at adminis tration site  
Redness (Erythema)  at administration site  
Swelling at administration site  
Table 22 Solicited systemic events  
Fever  
Myalgia (muscle pain)  
Arthralgia (joint pain)  
Headache  
Fatigue (tiredness)  
Note: Participants/participants’ parent(s)/LAR(s)  will be instructed to measure and 
record the oral/axillary temperature in the evening. If additional temperature 
CONFIDENTIAL  
222253  (RSV OA=ADJ -025) 
Protocol  Amendment 1  Final  
03 May 2024  88 measurements are taken at other times of the day, participants/participants’ 
parent(s)/LAR(s)  will be instructed to record the highest temperature in the eDiary.  
10.3.4.  Unsolicited AE   
• Definition of unsolicited AE  
• An unsolicited AE is an AE that was either not included in the list of solicited 
events or could be included in the list of solicited events but with an onset outside 
the specified period of follow -up for solicited events. Unsolicited AEs must have 
been communicated by participants / participant’s parent(s)/LAR(s) who has 
signed the informed consent. Unsolicited AEs include both serious and non serious  
AEs.  
• Potential unsolicited AEs may be medically attended (i.e., symptoms or illnesses 
requiring a hospitalization, emergency room visi t, or visit to/by a healthcare 
provider). The participants/ participant’s parent(s)/LAR(s ) will be instructed to 
contact the site as soon as possible to report medically attended event(s), as well as 
any events that, though not medically attended, are of p articipant/ participant’s 
parent(s) /LAR(s) concern. Detailed information about reported unsolicited AEs 
will be collected by qualified site personnel and documented in the participant’s 
records.  
• Unsolicited AEs that are not medically attended nor perceive d as a concern by the 
participant/participant’s parent(s)/LAR(s) will be collected during an interview 
with the participants/participant’s parent(s)/LAR(s) and by review of available 
medical records at the next visit.  
10.3.5.  Recording , assessment  and follow -up of AE, SAE, AESIs and 
pregnancies  
10.3.5.1.  AE and SAE recording  
• When an AE/SAE occurs, it is the responsibility of the investigator to review all 
documentation ( e.g., hospital progress notes, laboratory reports, and diagnostics 
reports) related to the event.  
• The investigator will then record all relevant AE/SAE information.  
• It is not acceptable for the investigator to send photocopies of the participant’s 
medical recor ds to GSK  in lieu of completion of the eCRF  /required form.  
• There may be instances when copies of medical records for certain cases are 
requested by GSK . In this case, all participant identifiers, with the exception of the 
participant number, will be redacted on the copies of the medical records before 
submission to GSK . 
• The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information. Whenever possible, the diagnosis (not 
the individual signs/symptoms) will be documented as the AE/SAE.  
CONFIDENTIAL  
222253  (RSV OA=ADJ -025) 
Protocol  Amendment 1  Final  
03 May 2024  89 • An eDiary will be used in this study to capture solicited administration site or 
systemic events. The partici pant/participant’s parent(s)/LAR(s)  should be trained on 
how and when to complete the eDiary.  
• Anyone who measures administration site or systemic events and who will record the 
event in the eDiary , e.g., the study caregiver,  should  have received a caregiver 
information letter explaining the role of the caregiver prior to completing the eDiary.  
This training must be documented in the participant’s source record.  
• For each solicited and unsolicited AE the participant experiences, the p articipant/  
participant’s parent(s)/LAR(s)  will be asked if they/their child received medical 
attention (defined as unscheduled visit to or from medical personnel for any reason, 
including emergency room visits). This information will be recorded in the 
participant’s eDiary and in the participant’s eCRF as part of normal AE reporting 
(for solicited and unsolicited AEs). If the collection of solicited AEs was not possible 
for any reasons via the eDiary and solicited AEs were reported to the investigator by 
the participant, then it would be possible for it to be reported directly to the site staff 
and submitted (e.g. , via the eCRF). Medical attention received for SAEs/AESIs will 
have to be reported using the normal AE reporting process in the eCRF.  
• If any indi vidual other than the participant/participant’s parent(s)/LAR(s) is making 
entries in the eDiary, their identity must be documented in the participant’s source 
record.  
• The completed eDiary will be collected and verified during discussions with the 
particip ant/participant’s caregiver(s) on Visit 2.  
• All solicited events that occur during the four days following administration of the 
dose of the study intervention (Day 1 to Day 4) must be recorded into the eDiary, 
irrespective of intensity. An automatic remin der to complete the eDiary will be sent 
to the participants during this time frame. Daily eDiary compliance will be checked 
by the investigator or delegate on the eDiary portal. In case of non -compliance, the 
investigator should contact the participant to remind the importance of daily entries. 
All other AEs occurring within this time frame should be recorded into the 
appropriate section of the eCRF, irrespective of their intensity or whether or not they 
are considered related to the study intervention.  
• After review and verbal discussion of the eDiary entries with the 
participant/participant’s parent(s)/LAR(s), if there are clear eDiary errors the 
investigator will complete his/her own assessment in the relevant sections of the 
eCRF.  
• Note: eDiary may be comp leted by a minor participant under the supervision of the 
participant’s parent(s)/LAR(s) provided the minor is capable of assessing and 
reporting the information to be recorded on eDiary. The ultimate accountability for 
completion of the eDiary remains wit h the participant’s parent(s)/LAR(s). The 
investigator should discuss this accountability with the participant’s 
parent(s)/LAR(s).  
• The investigator or delegate should verify the reported information during a 
discussion with the minor participant preferably  in the presence of their 
parent(s)/LAR(s).  
CONFIDENTIAL  
222253  (RSV OA=ADJ -025) 
Protocol  Amendment 1  Final  
03 May 2024  90 • Return of the eDiary device is not applicable if the participant has BYOD but 
verification of the recorded data should always take place.  
• Any unreturned eDiary will be sought from the participant/participant’s 
parent(s)/LAR(s) through telephone call(s) or any other convenient procedure.  
• Data on solicited events reported in the eDiary will be electronically transferred to 
the eDiary vendor, where it can be monitored by appropriately qual ified site staff and 
sponsor staff through a web -based portal.  
• Refer to the eDiary Manual for more information regarding the use of eDiary . 
10.3.5.2.  Assessment of intensity  
The investigator will make an assessment of intensity for each AE, AESI,  SAE reported 
durin g the study and assign it to one of the following categories:  
• Mild:  
A type of AE that is usually transient and may require only minimal treatment or 
therapeutic intervention. The event does not generally interfere with usual activities 
of daily living.  
• Moderate:  
A type of AE that is usually alleviated with additional specific therapeutic 
intervention. The event interferes with usual activities of daily living, causing 
discomfort but poses no significant or permanent risk of harm to the research 
particip ant. 
• Severe:  
A type of AE that interrupts usual activities of daily living, or significantly affects 
clinical status, or may require intensive therapeutic intervention.   
The intensity of the following solicited AEs will be assessed as described:  
Table 23 Intensity scale for solicited events  
Event  Intensity grade  Parameter  
Pain at administration site  0 None  
1 Mild: Any pain neither interfering with nor preventing normal 
everyday activities  
2 Moderate: Painful when limb is moved and interferes with 
everyday activities  
3 Severe: Significant pain at rest. Prevents normal everyday 
activities  
Redness (Erythema ) at 
administration site  See Table  Greatest surface diameter in mm  
Swelling at administration site  See Table  Greatest surface diameter in mm  
Temperature*  See Table  Temperature in °C/°F  
Headache  0 None /Normal ** 
1 Mild: Headache that is easily tolerated  
2 Moderate: Headache that interferes with normal activity  
3 Severe: Headache that prevents normal activity  
Fatigue (tiredness)  0 None /Normal ** 
CONFIDENTIAL  
222253  (RSV OA=ADJ -025) 
Protocol  Amendment 1  Final  
03 May 2024  91 Event  Intensity grade  Parameter  
1 Mild: Fatigue that is easily tolerated  
2 Moderate: Fatigue that interferes with normal activity  
3 Severe: Fatigue that prevents normal activity  
Myalgia (muscle pain)  0 None /Normal ** 
1 Mild: Myalgia present but does not interfere with activity  
2 Moderate: Myalgia that interferes with normal activity  
3 Severe: Myalgia that prevents normal activity  
Arthralgia (joint pain)  0 None /Normal ** 
1 Mild: Arthralgia present but does not interfere with activity  
2 Moderate: Arthralgia that interferes with normal activity  
3 Severe: Arthralgia that prevents normal activity  
* Refer to the SoA (Section 1.3) for the definition of fever and the preferred location for temperature measurement.  
**For participants already experiencing some of the solicited systemic events  prior to vaccine administrat ion, 
‘None /Normal ’ corresponds to ‘similar to baseline’ and only discomfort above baseline is to be reported as ≥1.  
The maximum intensity of administration site redness  (Erythema) /swelling, and fever 
will be scored at GSK as follows:  
Table 24 Intensity scale of administration site redness  (Erythema )/swelling, 
and fever  
Intensity 
grade  Redness  (Erythema )/Swelling  Fever  
0 ≤20 mm  <38.0°C (100.4°F)  
1 >20 - ≤50 mm  ≥38.0°C (100.4°F) - ≤38.5°C (101.3°F)  
2 >50 - ≤100 mm  >38.5°C (101.3°F) - ≤39.0°C (102.2°F)  
3 >100 mm  >39.0°C (102.2°F)  
The investigator will assess the maximum intensity that occurred over the duration of the 
event for all unsolicited AEs (including SAEs) recorded during the study. The assessment 
will be based on the investigator’s clinical judgment.  
An AE that is assessed as Grade 3 (severe) should not be confused with an SAE. Grade 3 
is a category used for rating the intensity of an event; and both AEs and SAEs can be 
assess ed as Grade 3. An event is defined as ‘serious’ when it meets 1 of the predefined 
outcomes as described in the Section 10.3.2 . 
10.3.5.3.  Assessment of causality  
• The investigator is obligated to assess the relationship between study intervention 
and each occurrence of each AE/SAE . The investigator will use clinical judgment to 
determine the relationship.  
• A reasonable possibility  of a relationship conveys that there  are facts, evidence, 
and/or arguments to suggest a causal relationship, rather than a relationship cannot 
be ruled out.  
• Alternative causes, such as underlying disease(s), concomitant therapy, and other 
risk factors, as well as the temporal relationship of  the event to study intervention 
administration, will be considered and investigated.  
CONFIDENTIAL  
222253  (RSV OA=ADJ -025) 
Protocol  Amendment 1  Final  
03 May 2024  92 • For causality assessment, the investigator will also consult the IB and/or product 
information, for marketed products.  
• The investigator must review and provide an assessment of causality for each 
AE/SAE and document this in the medical notes There may be situations in which an 
SAE has occurred and the investigator has minimal information to include in the 
initial report to  GSK . However, it is very important that the investigator always make 
an assessment of causality for every event before the initial transmission of the SAE 
data to GSK . 
• The investigator may change their opinion of causality in light of follow -up 
informatio n and send an SAE follow -up report with the updated causality 
assessment.  
• The causality assessment is one of the criteria used when determining regulatory 
reporting requirements.  
10.3.5.4.  Assessment of outcomes  
The investigator will assess the outcome of all seriou s and non serious  unsolicited AEs 
recorded during the study as:  
• Recovered/resolved  
• Recovering/resolving  
• Not recovered/not resolved  
• Recovered with sequelae/resolved with sequelae  
• Fatal (SAEs only).  
10.3.5.5.  Follow -up of AEs, SAEs, AESIs, pregnancies or any other events of 
interest  
• The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically indicated or as requested by GSK  to 
elucidate the nature and/or causality of the AE or SAE as fully as possi ble. This may 
include additional laboratory tests or investigations, histopathological examinations, 
or consultation with other health care professionals.  
• New or updated information will be recorded in the originally submitted documents.  
• The investigator w ill submit any updated SAE data to GSK  within 24 hours of 
receipt of the information.  
• After the initial AE/SAE/AESI/pregnancy or any other event of interest, the 
investigator is required to proactively follow each participant at subsequent 
visits/contacts. All SAEs, and non serious  AESI (as defined in the Section 8.4.4 ), will 
be followed until the event is resolved, stabili zed, otherwise explained, or the 
participant is lost to follow -up. 
• Other non serious  AEs must be followed until EOS  or until the participant is lost to 
follow -up. 
CONFIDENTIAL  
222253  (RSV OA=ADJ -025) 
Protocol  Amendment 1  Final  
03 May 2024  93 Follow -up during the study  
AEs/AESIs  documented at a previous visit/contact and defined as not recovered/not 
resolved or recovering/resolving will be reviewed at subsequent visits/contacts until EOS . 
If a participant dies during their participation in the study or during a recogni zed follow -
up period, GSK will be provided with any available postmortem  findings, including 
histopathology.  
Follow -up of pregnancies  
Pregnant participants will be followed to determine the outcome of the pregnancy. At the 
end of the pregnancy, whether full -term or premature, information on the status of the 
mother and child w ill be forwarded to GSK using the paper pregnancy follow -up 
report/ electronic pregnancy report  and the AE Report if applicable. Generally, the follow -
up period does not need to be longer than 6 to 8 weeks after the estimated date of 
delivery.  
Regardless of  the reporting period for SAEs in this study, if the pregnancy outcome is an 
SAE, it should always be reported as such.  
Furthermore, the investigator must report any SAE occurring as a result of a post study  
pregnancy that is considered by the investigator to be reasonably related to the study 
intervention, to GSK as described in the Section 10.3.5.7 . 
10.3.5.6.  Updating of SAE, AESI and pregnancy information af ter removal of 
write access to the participant ’s eCRF  
When additional SAE, AESI or pregnancy  information is received after write access to 
the participant’s eCRF is removed, new or updated information should be recorded on the 
appropriate paper report, with all changes signed and dated by the investigator. The 
updated report should be sent to the Study contact for reporting SAEs (refer to Section  
8.4.7 ). 
10.3.5.7.  Reporting of SAEs , AESI s and pregnancies  
SAE Reporting to GSK  via an Electronic Data Collection Tool  
• The primary mechanism for reporting an SAE to GSK  will be the electronic data 
collection tool.  
• If the electronic system is unavailable, then the site will use the paper SAE data 
collection tool (see next section) to report the event within 24 hours.  
• The site will enter the SAE data into the electronic system as soon as it becomes 
available.  
• After the study is completed at a gi ven site, the electronic data collection tool will be 
taken offline to prevent the entry of new data or changes to existing data.  
CONFIDENTIAL  
222253  (RSV OA=ADJ -025) 
Protocol  Amendment 1  Final  
03 May 2024  94 • If a site receives a report of a new SAE from a study participant or receives updated 
data on a previously reported SAE after the electronic data collection tool has been 
taken offline, then the site can report this information on a paper SAE form (see next 
section) or to the GSK /medical monitor  by telephone.  
• If the site during the course of the study or poststudy becomes aware o f any serious, 
nonserious  AEs, pregnancy exposure, related to any GSK non -IMP they will report 
these events to GSK or to the concerned competent authority via the national 
spontaneous reporting system.   These will be classified as spontaneous ICSRs.  
• Contacts for SAE reporting can be found in Section  8.4.7 .  
SAE Reporting to GSK  via Paper Data Collection Tool  
• Email/f acsimile transmission of the SAE paper data collection tool is the preferred 
method to transmit this information to the GSK /medica l monitor.  
• In rare circumstances and in the absence of email/ facsimile equipment, notification 
by telephone is acceptable with a copy of the SAE data collection tool sent by 
overnight mail or courier service.  
• Initial notification via telephone does not rep lace the need for the investigator to 
complete and sign the SAE data collection tool within the designated reporting 
timeframes.  
• Contacts for SAE reporting can be found in Section  8.4.7 . 
10.4.  Appendix 4: Contraceptive and barrier guidance  
10.4.1.  Definitions  
10.4.1.1.  WOCBP Definition  
Women in the following categories are considered WOCBP (fertile) : 
• Adolescents of childbearing potential: Tanner stage ≥2 (post -thelarche) irrespective 
of the occurrence of menarche or following menarche.  
• From the time of menarche until becoming post menopausal  unless permanently 
sterile (see below)  
• Note: Menarche is the first onset of menses in a young female. Menarche is normally 
preceded by several changes associated with puberty including breast development 
and pubic hair growth.  
CONFIDENTIAL  
222253  (RSV OA=ADJ -025) 
Protocol  Amendment 1  Final  
03 May 2024  95 10.4.1.2.  Woman of Nonchildbearing Po tential (WONCBP)  
Women in the following categories are considered WONCBP:  
• Premenarchal : Tanner stage 1 (prepubertal)  
Permanently sterile due to one of the following procedures : 
• Documented hysterectomy  
• Documented bilateral salpingectomy  
• Documented bilateral oophorectomy  
For permanently sterile individuals due to an alternate medical cause other than the 
above, (e.g., Mullerian agenesis, androgen insensitivity, gonadal dysgenesis), 
investigator discretion should be applied to determining study entry.  If reproductive 
status is questionable, additional evaluation should be considered . 
Note: Documentation can come from the site personnel’s review of the participant’s 
medical records, medical examination, or medical history interview.  
Postmenopausal female  
A postmenopausal state is defined as no menses for 12 months without an alternative 
medical cause.  
• A high follicle stimulating hormone (FSH) level in the postmenopausal range may be 
used to confirm a postmenopausal state in  women not using hormonal contraception 
or hormonal replacement therapy (HRT). However, in the absence of 12 months of 
amenorrhea, confirmation with more than one FSH measurement is required.  
• Females on HRT and whose menopausal status is in doubt must discontinue HRT  to 
allow confirmation of postmenopausal status before study enrol lment . 
10.4.2.  Contraception guidance  
• Female participants of childbearing potential are eligible to participate if they agree 
to use a highly effective contraceptive method consistently and correctl y according 
to the methods listed in GSK’s list of highly effective contraceptive methods ( Table 
25). 
Table 25 Highly effective contraceptive methods  
Highly Effective Contraceptive Methods That Are User Dependenta 
Failure rate of <1% per year when used consistently and correctly  
Combined (estrogen - and progestogen -containing) hormonal contraception associated with 
inhibition of ovulation  
• Oralb 
• Intravaginal  
• Transdermal  
Progestogen -only hormonal contraception associated with inhibition of ovulation  
CONFIDENTIAL  
222253  (RSV OA=ADJ -025) 
Protocol  Amendment 1  Final  
03 May 2024  96 • Injectable  
• Oralb  
Highly Effective Methods That Are User Independent  
• Implantable progestogen -only hormonal contraception associated with inhibition of 
ovulation  
• Intrauterine device (IUD)  
• Intrauterine hormone -releasing system (IUS)  
• Bilateral tubal occlusion/ligation  
Vasectomized partner  
(A vasectomized partner is a highly effective contraception method provided that the partner 
is the sole male sexual partner of the WOCBP and the absence of sperm has been 
confirmed. If not, an additional highly ef fective method of contraception should be used.)  
Male partner sterilization prior to the female participant’s entry into the study, and this male is the 
sole partner for that participant,  
(The information on the male sterility can come from the site pers onnel’s review of the 
participant’s medical records; medical examination and/or semen analysis, or medical history 
interview provided by her or her partner)  
Sexual abstinence  
(Sexual abstinence is considered a highly effective method only if defined as refraining from 
heterosexual intercourse during the entire period of risk associated with the study drug. The 
reliability of sexual abstinence needs to be evaluated in relation to the duration of the study 
and the preferred and usual lifestyle o f the participant.)   
a Typical use failure rates may differ from those when used consistently and correctly. Use should be consistent with 
local regulations regarding the use of contraceptive methods for subjects in clinical studies.  
b For WOCBP taking hormonal contraception, an additional barrier contraception method is recommended if they are 
concomitantly taking drugs that interact and reduce effectiveness of hormonal contraception. The investigator 
should check the list of drugs tha t could reduce hormonal contraceptive effectiveness (Potent drug enzyme 
inducers).  
CONFIDENTIAL  
222253  (RSV OA=ADJ -025) 
Protocol  Amendment 1  Final  
03 May 2024  97 10.5.  Appendix  5: Country -specific requirements  
10.5.1.  Germany  
Explanatory statement concerning Gender Distribution (Article 7, paragraph 2 (12) 
of the German GCP ORDER).  
For this study, there is no intention to conduct specific analyses investigating the 
relationship between gender and the safety, immunogenicity and efficacy of the 
investigational RSVPreF3 OA vaccine. Recruitment will include both males and females. 
To not  expose pregnant women and their fetuses/children to an investigational vaccine, 
females enrolled in this study will either be of nonchildbearing potential (i.e., 
hysterectomy, bilateral oophorectomy, bilateral salpingectomy or post -menopause), or if 
she is of childbearing potential, she must have a negative pregnancy test and use 
appropriate methods of contraception for the study duration (refer to the study protocol, 
Section 5.1  “Inclusion criteria” and Section  5.2 “Exclusion criteria”). Women who are 
pregnant, planning to become pregnant or breastfeeding are excluded from t his study.  
10.5.2.  Japan  
Regulatory and ethical considerations  
The study will be conducted in accordance with “the Ministerial Ordinance on the 
Standards for the Conduct of Clinical Trials of Medicinal Products (MHW Notification 
No.28 dated 27 March 1997)” and Pha rmaceuticals and Medical Devices Act.  
The statement “To assume responsibility for the proper conduct of the study at this site.” 
on the Protocol Investigator Agreement  Page means the investigator’s responsibility 
defined by Japanese GCP.  
GSK will submit the clinical trial notification to the regulatory authorities in accordance 
with Pharmaceuticals and Medical Devices Act before conclusion of any contract for the 
conduct of the study with study sites.  
Study period  
Study Period is included in Exhibit.  
Study administrative structure  
Sponsor information , List of Medical Institutions and Investigators are included in 
Exhibit.  
10.5.3.  South Africa  
As per regulatory requirement and due to high prevalence of HIV infection, all 
participants from South Africa with unknown HIV status (unknown or previously tested 
negative) will be counselled and tested for HIV infection, using the South African Health 
CONFIDENTIAL  
222253  (RSV OA=ADJ -025) 
Protocol  Amendment 1  Final  
03 May 2024  98 Products Regulatory Authority (SAHPRA) approved test kits prior to enrolment. If HIV 
result is positive, these participants will be excluded as per Section 5.2.1  Medical 
Conditions exclusion criterion 1. 
10.6.  Appendix 6: Grading scales for chronic diseases in scope of 
the AIR population  
10.6.1.  GOLD classification  
Stages of COPD quantify the severity of the disease. COPD is classified into 4 classes 
[GOLD , 2020].  
GOLD Class  Intensity  Definition  
GOLD 1  Mild FEV 1 ≥ 80% predicted  
GOLD 2  Moderate  50% ≤ FEV 1 <80%  
GOLD 3  Severe  30% ≤ FEV 1 <50%  
GOLD 4  Very severe  FEV 1 < 30% predicted  
10.6.2.  New York Heart Association Classification of heart failure  
Stages of chronic heart failure quantify the severity of the disease. CHF is classified into 
4 classes [ NYHA ]. 
NYHA Class  Definition  Limitation  Example  
I Ordinary physical activity does 
not cause undue fatigue, 
dyspnoea, or palpitations.  None  Can complete any activity requiring  ≤7 MET:  
• Carry 11 kg up 8 steps  
• Carry objects weighing 36 kg  
• Shovel snow  
• Spade soil  
• Ski 
• Play squash, handball, or basketball  
• Jog or walk 8 km/hour.  
II Ordinary physical activity 
causes fatigue, dyspnoea, 
palpitations, or angina.  Mild Can complete any activity requiring  ≤5 MET:  
• Sexual intercourse without stopping  
• Garden  
• Roller skate  
• Walk 7 km/hour on level ground  
• Climb one flight of stairs at a normal pace 
without symptoms.  
III Comfortable at rest; less than 
ordinary physical activity 
causes fatigue, dyspnoea, 
palpitations, or a ngina.  Moderate  Can complete any activity requiring  ≤2 MET:  
• Shower or dress without stopping  
• Strip and make a bed  
• Clean windows  
• Play golf  
• Walk 4 km/hour.  
IV Symptoms occur at rest; any 
physical activity increases 
discomfort.  Severe  Cannot do or cannot complete any activity 
requiring  ≥2 MET; cannot do any of the above 
activities.  
MET = Metabolic equivalent of task, a measure of how much energy is expended compared to remaining at rest.  
CONFIDENTIAL  
222253  (RSV OA=ADJ -025) 
Protocol  Amendment 1  Final  
03 May 2024  99 10.6.3.  Chronic kidney disease classification  
Stages of CKD quantify the severity of the disease. CKD is classified into 5 stages 
[CKD , 2021].  
• Stage 1  (G1) : Normal GFR (≥90 mL/min/1.73 m2) plus either persistent albuminuria 
or known structural or hereditary renal disease.  
• Stage 2  (G2) : GFR 60 to 89 mL/min/1.73 m2 
• Stage 3a  (G3a) : 45 to 59 mL/min/1.73 m2 
• Stage 3b  (G3b) : 30 to 44 mL/min/1.73 m2 
• Stage 4  (G4) : GFR 15 to 29 mL/min/1.73 m2 
• Stage 5  (G5) : GFR < 15 mL/min/1.73 m2 
GFR (in mL/min /1.73 m2) in CKD can be estimated by the CKD -EPI creatinine equation: 
141 × (serum creatinine) -1.209× 0.993 age. The result is multiplied by 1.018 if the 
patient is female, and by 1.159 if the patient is African American. For female African 
Americans, the  result is multiplied by 1.018 × 1.159 (1.1799). Alternatively, GFR can be 
estimated using timed (most commonly 24 hours) urine creatinine clearance using 
measured serum and urine creatinine; this equation tends to overestimate GFR by 10 to 
20%. It is used  when serum creatinine assessment may not be as accurate (e.g., in patients 
who are sedentary, very obese, or very thin). Serum cystatin C is an alternative 
endogenous GFR marker used as a confirmatory test in people with nonrenal factors 
affecting serum c reatinine level (e.g., extremely high, or low muscle mass, exogenous 
creatine intake, amputations or neuromuscular diseases, and high protein or exclusively 
plant -based diets). GFR is calculated using CKD -EPI cystatin C equation.  
The CKD -EPI formula is more accurate than the MDRD and Cockcroft -Gault formulas, 
particularly for patients with a GFR near normal values. The CKD -EPI equation yields 
fewer falsely positive results indicating chronic kidney disease and predicts outcome 
better than the other formu las. 
CONFIDENTIAL  
222253  (RSV OA=ADJ -025) 
Protocol  Amendment 1  Final  
03 May 2024  100 11. REFERENCES  
Arexvy Prescribing Information.  AREXVY (Respiratory Syncytial Virus Vaccine, 
Adjuvanted) suspension for intramuscular injection, 2023. Accessed in October 2023 at 
https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information /Arexvy
/pdf/AREXVY.PDF  
Arexvy Summary of Product Characteristics.  Arexvy powder and suspension for 
suspension for injection, Respiratory Syncytial Virus (RSV) vaccine (recombinant, 
adjuvanted), 2023. Accessed in October 2023 at 
https://www.ema.europa.eu/en /documents/overview/arexvy -epar-medicine -
overview_en.pdf  
Bao K, Reinhardt RL. The differential expression of IL -4 and IL -13 and its impact on 
type-2 immunity. Cytokine.  2015;75(1):25 -37. doi: 10.1016/j.cyto.2015.05.008.  
Barbas  CF, Crowe JE, Cababa D, et al. Human monoclonal Fab fragments derived from a 
combinatorial library bind to respiratory syncytial virus F glycoprotein and neutralize 
infectivity. Proc Natl Acad Sci USA . 1992;89(21):10164 -8. 
Bates JT, Keefer CJ, Slaughter J C, et al. Escape from neutralization by the respiratory 
syncytial virus -specific neutralizing monoclonal antibody palivizumab is driven by 
changes in on -rate of binding to the fusion protein. Virology . 2014;454 -455:139 -44. doi: 
10.1016/j.virol.2014.02.010.  
Borchers AT, Chang C, Gershwin ME, et al. Respiratory syncytial virus – a 
comprehensive review. Clin Rev Allergy Immunol . 2013;45(3):331 -79. 
Boyman O, Sprent J. The role of interleukin -2 during homeostasis and activation of the 
immune system. Nat Rev Immu nol. 2012;12(3):180 -90. 
Branche AR, Saiman L, Walsh EE, et al. Change in functional status associated with 
respiratory syncytial virus infection in hospitalized older adults. Influenza Other Respir 
Viruses . 2022a;16(6):1151 -60. 
Branche AR, Saiman L, Walsh EE, et al. Incidence of Respiratory Syncytial Virus 
Infection Among Hospitalized Adults, 2017 -2020. Clin Infect Dis . 2022 b;74(6):1004 -
1011.  
Chattopadhyay PK, Yu J, Roederer M. A live -cell assay to detect antigen -specific CD4+ 
T cells with diverse cytokine profiles. Nat Med.  2005;11(10):1113 -7. 
Dieussaert I, et al. RSV prefusion F protein -based maternal vaccine -preterm birth and 
other outcomes. N.Eng J Med . 2024;390(11):1009 -1021 . 
Falsey  AR, Hennessey PA, Formica MA, et al. Respiratory syncytial virus infection in 
elderly and high -risk adults. N Engl J Med . 2005;352(17):1749 -59. 
CONFIDENTIAL  
222253  (RSV OA=ADJ -025) 
Protocol  Amendment 1  Final  
03 May 2024  101 Frentsch M, Arbach O, Kirchhoff D, et al. Direct access to CD4+ T cells specific for 
defined antigens according  to CD154 expression. Nat Med.  2005;11(10):1118 -24. 
GOLD COPD. Pocket guide to COPD diagnosis, management, and prevention. A guide 
for health care professionals. 2020 Edition. Accessed 14 June 2022. 
https://goldcopd.org/wp -content/uploads/2020/03/GOLD -2020 -POCKET -GUIDE -
ver1.0_FINAL -WMV.pdf  
Haralambieva IH, Ovsyannikova IG, Pankratz VS, et al. The genetic basis for 
interindividual immune response variation to measles vaccine: new understanding and 
new vaccine approaches. Expert Rev Vaccines . 2013;12(1):57 –70. 
Jain S, Self WH, Wunderink RG, Fakhran S, Balk R, Bramley AM, Reed C, Grijalva CG, 
Anderson EJ, Courtney DM et al: Community -Acquired Pneumonia Requiring 
Hospitalization among U.S. Adults. N Engl J Med . 2015, 373(5):415 -427. 
Kollmann TR. Variation between populations in the innate immune response to vaccine 
adjuvants. Front Immunol . 2013;4:81. doi: 10.3389/fimmu.2013.00081.  
Korn T, Bettelli E, Oukka M, et al. IL-17 and Th17 Cells. Annu Rev Immunol.  
2009;27:485 -517. 
Leroux -Roels I, Davis MG , Steenackers K, et al. Safety and Immunogenicity of a 
Respiratory Syncytial Virus Prefusion F (RSVPreF3) Candidate Vaccine in Older Adults: 
Phase 1/2 Randomized Clinical Trial. J Infect Dis . 2023;227(6):761 -772. 
McDonald JU, Rigsby P, Dougall T, et al. Establishment of the first WHO International 
Standard for antiserum to Respiratory Syncytical Virus: Report of an International 
collaborative study. Vaccine . 2018;36(50):7641 -7649. doi: 
10.1016/j.vaccine.2018.10.087.  
McDonald  JU, Rigsby P, Dougall T, et al. Expansion of the 1st WHO international 
standard for antiserum to respiratory syncytial virus to include neutralisation titres against 
RSV subtype B: An international collaborative study. Vaccine . 2020;38(4):800 -807. doi: 
10.1016/j.vaccine.2019.10.095.  
Melgar M, Britton A, Roper LE, et al. Use of Respiratory Syncytial Virus Vaccines in 
Older Adults: Recommendations of the Advisory Committee on Immunization Practices 
— United States, 2023. MMWR Morb Mortal Wkly Rep  2023;72:793 –801. 
Moris P, Van Der Most R, Leroux -Roels I, et al. H5N1 influenza vaccine formulated with 
AS03 A induces strong cross -reactive and polyfunctional CD4 T -cell responses. J Clin 
Immunol.  2011; 31(3):443 -54. 
MSD Manual. Chronic Kidney Disease (CKD). Updated  October 2021. Accessed 14 June 
2022. https://www.msdmanuals.com/professional/genitourinary -disorders/chronic -
kidney -disease/chronic -kidney -disease?query=chronic%20kidney%20disease%20stages  
CONFIDENTIAL  
222253  (RSV OA=ADJ -025) 
Protocol  Amendment 1  Final  
03 May 2024  102 MSD Manual. New York Heart Association (NYHA) Classification of He art Failure. 
Accessed 14 June 2022. 
https://www.msdmanuals.com/professional/multimedia/table/new -york-heart -association -
nyha -classification -of-heart -failure  
Papi A, Ison MG, Langley JM, et al. Respiratory Syncytial Virus Prefusion F Protein 
Vaccine in Older Adults. N Engl J Med . 2023;388(7):595 -608. 
doi:10.1056/NEJMoa2209604 . 
Pérez -Losada M, Posada D, Arenas M, et al. Ethnic differences in the adaptation rate of 
HIV gp120 from a vaccine trial. Retrovirology . 2009;6:67.  
Samten B, Thomas EK, Gong J, Barnes PF. Depressed CD40 ligand expression 
contributes to reduced gamma interferon production in human tuberculosis. Infect  Immun.  
2000;68(5):3002 -6. 
Schoenborn  JR, Wilson CB. Regulation of interferon -gamma during innate and adaptive 
immune responses. Adv Immunol.  2007;96:41 -101. 
Sedger  LM, McDermott MF. TNF and TNF -receptors: From mediators of cell death and 
inflammation to t herapeutic giants - past, present and future. Cytokine Growth Factor 
Rev. 2014;25(4):453 -72. 
Shi T, Vennard S, Jasiewicz F, et al. Disease burden estimates of respiratory syncytial 
virus related acute respiratory infections in adults with comorbidity: A sy stematic review 
and meta -analysis. J Infect Dis . 2021;15;jiab040. doi: 10.1093/infdis/jiab040.  
Stubbe M, Vanderheyde N, Goldman M, et al. Antigen -specific central memory CD4+ T 
lymphocytes produce multiple cytokines and proliferate in vivo in humans. J Immunol.  
2006;177(11):8185 -90. 
Wölfl M, Kuball J, Eyrich M, et al. Use of CD137 to study the full repertoire of CD8+ T 
cells without the need  to know epitope specificities. Cytometry  A. 2008;73(11):1043 -9. 
Signature Page for  222253 TMF-19110695 v1.0
Signature Page for TMF-19110695 v1.0Reason for signing: Approved Name:
Role: Approver
Date of signature: 03-May-2024 07:45:19 GMT+0000
PPD